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Cancer is a leading cause of death in the world and there is a continual 
search for new anti cancer drugs. Today, more than half of the clinically 
available drugs are either natural products or derived from natural products. 
This is not surprising as natural products have been used for centuries as 
medicine and it is clear that Nature will continue to be a source for many new 
drug leads. The use of natural product scaffolds to synthesize analogs has 
already produced many new drugs for cancer chemotherapy. Here the aim of 
this thesis is to develop different classes of natural product analogs as potential 
new chemotherapeutic agents. 
In Chapter 2, we described the first reported synthesis of a class of 
polyenylpyrrole natural products and their analogs. The compounds were 
evaluated for the cell cytotoxicity against human lung cancer cells A549 and 
structure-activity studies showed that the 3-chloropyrrole moiety is essential as 
replacement of the group with other 2 or 3-chloro aromatic rings led to a 
complete loss of activity. 2 of these compounds displayed excellent 
cytotoxicity with IC50 of 0.6 µM and 0.01 µM respectively. In addition, these 2 
compounds proved to be non-toxic to normal human lung cells Beas-2b at up 
to 80 µM. These results indicated that these 2 compounds have the potential to 
be developed as anticancer agents due to their high selectivity against A549 
cells. 
In Chapter 3, the synthesis of lignan natural products as potential anti-tumor 
agents was described. After the synthesis of racemic isochaihulactone and 
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nemerosin was achieved, asymmetric synthetic technique was introduced to 
afford all 4 lignan isomers: isochaihulactone, slyvestrin, nemerosin and its 
enantiomer. Of these 4 compounds synthesized, isochaihulactone and 
slyvestrin are natural products which had been isolated previously but never 
synthesized. Nemerosin is a natural product which had previously been 
synthesized while there are no reports on the isolation or synthesis of the 
enantiomer of nemerosin. Both isochaihulactone and slyvestrin displayed 
cytotoxicity against various cancer cells. 
Chapter 4 described the microwave assisted synthesis of 5-unsubstituted 
3,4-dihydropyrimidin-2-ones and thiones through a modified Biginelli 
procedure. Under microwave irradiation, the reaction time was shortened from 
12 h to 15 min. These results further demonstrate the value of microwave-
assisted synthesis in increasing yield, shortening reaction time and streamlining 
high throughput synthesis. This also represents the first reported synthesis of 
such a class of 5-unsubstituted 3,4-dihydropyrimidin-2-thiones. 
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Chapter 1: Introduction 
1.1.1 Overview of Cancer 
Cancer is a leading cause of death in the world and in the United States, 
about 23% of all human deaths can be attributed to it (Table 1.1)1. Cancer 
affects people of all age groups though the risk of most types of cancer 
increases with age. Although the many stages of carcinogenesis depend on 
environmental and other non-genetic factors, it is generally accepted that 
cancer arises from mutation in genes.2-5 Cancer cells are defined by two 
heritable characteristics:6 
1. They and their offspring reproduce with disregard for the normal restraints 
on cell division. 
2. They invade and occupy areas normally meant for other cells. 
The combination of these two traits makes cancer especially dangerous. A 
cell, regardless of how destructive it may be, cannot cause significant damage 
if it is isolated and does not proliferate faster than its normal neighbor. 
However when the cell proliferation is uncontrollable, it will lead to the 
formation of a tumor or neoplasm. A neoplasm is essentially a persisting 
growing mass of abnormal cell. If the cells are unable to invade other tissue, 
the tumor is said to be benign. Here, a complete cure can typically be achieved 
by removing the tumor surgically.7 A tumor is only considered cancerous or 
malignant if the cells acquire the ability to invade surrounding tissue. This 
invasion and formation of secondary tumors at other sites of the body by the 
original cancer cells is known as metastasis. 
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Table 1.1. Leading causes of death in the United States, 2007 (thousands)1 
 Deaths % 
Heart diseases 616 25.4 
Malignant neoplasms 563 23.2 
Cerebrovascular diseases 136 5.6 
Lower respiratory infections 128 5.3 
Accidents 124 5.1 
Alzheimer’s disease 75 3.1 
Diabetes mellitus 71 2.9 
Influenza and pneumonia 53 2.2 
Nephritis, nephrotic syndrome  46 1.9 
Septicemia 35 1.4 
Sucide 35 1.4 
Liver diease and cirrhosis 29 1.2 
Hypertension and hypertensive renal disease 24 1.0 
Parkinson’s disease 20 0.8 
 
Cancers are classified based on the tissue and cell type they originated from. 
Cancers arising from muscle cells or connective tissues are known as sarcomas 
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while those arising from epithelial cells are called carcinomas. There are also 
cancers that do not belong to these two categories and these include leukemia 
and cancer of the nervous system.6 
1.1.2 Cancer as an Evolutionary Process 
From an evolutionary perspective, a neoplasm can be viewed as a large 
population of genetically and epigenetically heterogeneous cells.8 Via natural 
selection, neoplastic cells will undergo genetic and epigenetic modifications 
that are beneficial to them. Evolution of neoplastic cells is determined by their 
interaction with its environment and other cells. This interaction includes 
attempts at treating or preventing cancer. Evolution of the cancer cell generally 
leads to faster proliferation and metastasis as well as greater drug resistance. 
Evidence of this can be observed by the resistance of mutant lung cancer cells 
to anilinoquinazoline EGFR inhibitors.9 Chronic myeloid leukemia and 
colorectal cancer have also been found to develop resistance to imatinib and 5-
fluorouracil respectively.10,11 
1.1.3 Molecular Causes of Cancer 
At the molecular level, cancer results from the mutation of cancer-
susceptible genes. These genes belong to one of 3 classes:12,13 gatekeepers, 
caretakers and landscapers. Gatekeepers consist of oncogenes and tumor-
supressor genes and they control the growth and differentiation pathways of the 
cell. The function of the caretakers is to maintain the genomic integrity of the 
cell.14,15 A mutation of the caretakers can result in genetic instability which in 
turn can lead to rapid mutation of the genes that directly control cell birth and 
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death. Landscapers are named as such because they create an abnormal stromal 
environment that leads to the neoplastic transformation of cells.16 
Despite cancer being a result of gene mutation, a single mutation is not 
sufficient to give rise to cancer. For full-blown cancer to develop several 
independent and rare mutations would have to occur.17,18 As such, the risk of 
cancer development depends not only on the initial mutation but also on 
successive mutations driving cancer progression. One indication of this comes 
from the study of the incidence of cancer as a function of age. If cancer is 
caused by a single mutation occurring with a fixed possibility per year, the 
incidence of cancer should be independent of age. However the development of 
cancer rises steeply with age (Figure 1.1).19 This is in line with the fact that 
cancer is caused by an accumulation of numerous random mutations in the cell 
line. 
 
Figure 1.1. All malignant neoplasms incidence rate by age group. 
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1.1.4 Environment Causes of Cancer 
Due to the inherent limitations in the accuracy of DNA replication, gene 
mutations and consequently cancer can never be completely avoided. If a 
person is to live long enough, the cell would eventually undergo sufficient 
mutations for cancer to develop. That said, evidence indicates that 
environmental factors play a role in the development of most types of cancer. 
This can be most clearly seen by comparing the cancer incidence rates in 
different countries. Many types of cancer vary in incidence between different 
countries and a cancer that is common in one country might be rare in 
another.20 The convergence of cancer incidence among immigrants toward that 
of the local population also points to the influence of the environment rather 
than genetic factors. By the 1960s, the World Health Organization concluded 
that most cancers should be avoidable or at least delayed based on environment 
or lifestyle choices (Table 1.2).21 
The most significant environmental cause of cancer in the world today is 
tobacco. The risk of lung cancer is the highest among those who smoke at a 
young age and continue to do so thereafter (Figure 1.2).22 This is because lung 
cancer incidence increases rapidly for continuing smokers. In Britain, the large 
increase in male smokers during the First World War led to an unprecedented 
rise in lung cancer incidence some forty years later.23 This pattern was repeated 
in the United States during the Second World War.20 Since then, after tobacco 
was proven to be a carcinogen, smoking has been declining steadily especially 
in Britain and as such, lung cancer incidence has fallen as well.21,24 In China, 
however, the rise in the number of smokers over the past two decades has led 
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to an increase in mortality from lung cancer.25 The carcinogenic effects of 
tobacco extend beyond the lung and include the stomach, liver, mouth, 
esophagus, pharynx, pancreas, bladder and kidney.25,26 
Table 1.2. US cancer deaths that would be avoided by removing known risks.21 
Cause Deaths avoided (%) after removing preceding 
cause 
 Smokers Non-smokers 
Smoking 60 - 
Known infection 2 5 
Alcohol 0.4 1 
Sunlight 0.4 1 
Air pollution 0.4 1 
Occupation 0.4 1 
Lack of exercise 0.4 1 
BMI > 25 kg m-2 4 10 
Dietary factors 4~12 10~30 




Another important environment cause of cancer would be diet. However it 
is exceedingly difficult to identify how a diet affects the incidence of cancer 
due to the vast variety of food and the patterns of consumption. Only the data 
collected from the consumption of excessive alcohol and food contaminated 
with aflatoxin B1 are sufficient to establish these two as significant 
carcinogens.27 Aflatoxin B1 is a fungus that grows on food such as peanut and 
is an important cause of cancer in Africa and Asia. The only way to determine 
if a particular food item is deemed cancer-preventive and cancer-causing is to 
conduct large randomized trials that continue for many years. However the 
following example highlights the difficulties in obtaining conclusive results 
even with such a trial. There had been substantial evidence suggesting that 
food rich in beta-carotene can reduce the risk of lung cancer.28 However a large 
randomized trial showed no benefits after 12 years of treatment.29 Moreover 
two shorter trials showed that lung cancer risk was higher among those who 
received beta-carotene supplements.30 Despite these conflicting data, one result 
that most cancer epidemiologist would agree upon is that obesity can lead to an 




Figure 1.2. Probability of death from lung cancer in the United States, 1984-
1991.1 
About 15% of cancers in the world could be due to bacteria, viruses and 
parasites.32 Chronic infection with bacteria or parasites may lead to the 
development of cancer. Helicobater pylori, which can cause chronic bacterial 
infection, is known to be a major cause of stomach cancer.33 Liver cancer is 
common in Africa and Southeast Asia and this coincides with the higher 
incidence of hepatitis-B infection.34 In fact in these areas, liver cancer occurs 
almost exclusively in patients who had been diagnosed with hepatitis-B 
infection.21 
Another small proportion of cancer today can be due to environmental 
pollutants and occupational exposure to certain hazards. In the past, the lack of 
knowledge of certain chemicals carcinogenic effects led to workers developing 
cancer as a result of overexposure to such carcinogens. A classic example 
occurred in the early 1900s when all the male workers who were distilling 2-
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napthylamine in a British factory eventually developed bladder cancer.35 A 
more recent example was the mesothelioma epidemic in the 1990s. This arose 
from the widespread use of asbestos from the 1950s to 1970s but due to the 
long latency of the disease, the patients showed symptoms of the disease only 
decades later. Even today incidence of mesothelioma is still rising due to 
exposure to asbestos in the 1970s and 1980s.36 By late 1970s, exposure limits 
for several industrial hazards have been reduced in many Western countries 
and it is believed that current occupational exposure levels would have a 
minimum impact on cancer incidence.20  
1.1.5 Cancer Treatment: Chemotherapy Past & Present 
One of the oldest descriptions of cancer is in the Ebers papyrus which dates 
back to about 1600 B.C. and it suggests cauterization for the treatment of 
tumor.37 Since then mankind has come a long way in the understanding and 
treatment of cancer.  Still, of the diseases that have plagued mankind, none 
have been more hard-fought than that against cancer.  The treatment of a 
cancer has been likened to the removal of weeds in a garden. The cancer cells 
can be removed surgically or destroyed using radiation or chemicals but it is 
difficult to eliminate every one of them. The few cells that remain can 
proliferate again resulting in a relapse.6 Moreover they may evolve resistance 
to the chemicals or radiation that was used previously. Before 1950, treatment 
of cancer mainly involved the removal of the tumor surgically. Radiation 
oncology proved to be effective for the control of localized tumor after 1960s 
but the drawback back then was radiation therapy, like surgery, could not treat 
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metastatic cancer.37 Chemotherapy has thus become the focus for the treatment 
of cancer. 
The beginning of effective chemotherapy dates back to World War I when 
autopsy findings of soldiers who died from sulphur mustard poisoning revealed 
that these victims had severe lymphoid hypoplasia and myelosuppression.38 
This led to the development of nitrogen mustard which was tested on a mouse 
with Gardner lymphosarcoma. The drug was surprisingly effective and the 
tumor began to regress after two injections. Although the tumor recurred, the 
mouse lived for 84 days when three weeks was the average survival period for 
a mouse with this tumor.39 This eventually resulted in the trial on a man who 
was suffering from terminal stages of lymphosarcoma which radiation therapy 
failed to treat.40 Treatment with nitrogen mustard caused the tumor to regress 
and although the remission lasted only a few weeks, it was the first concrete 
evidence that chemicals could be used to induce tumor suppression. 
In 1956, Gordon Zubrod was appointed the head of the Division of Cancer 
Treatment in the United States. He had a strong interest in natural products and 
spearheaded a program for the collection and testing of plants and marine 
sources.40 This led to the discovery of taxanes and camptothecins. Both classes 
of compounds encountered significant difficulties during development but 
eventually, paclitaxel was marketed by Bristol Myers Squibb as Taxol in 1991 
and it became the first billion dollar per year drug (Figure 1.4).41 As for 
camptothecin, its semi-synthetic analogue, irinotecan, finally won approval 
from the Food and Drug Administration (FDA) in 1996.42 Today, paclitaxel is 
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used primarily to treat lung and ovarian cancer while irinotecan is used for 

























Figure 1.3. Number of approval of new drugs for cancer by FDA.40 
Despite the development of new cancer drugs such as cisplatin and 
fludarabine, by the 1980s, cancer chemotherapy appeared to have slow down 
(Figure 1.3).44,45 One of the main reasons is the failure of animal models to 
accurately predict the pharmacokinetics of cancer drugs in human.40 Moreover 
cancer drug discovery requires long-term trials which often yield marginal 
gains. These gave cancer drug discovery a reputation for having high risks with 
minimal rewards.  All of these changed with the advancement of cell biology at 
the molecular and genetic levels. New signaling networks that regulate cell 
survival and proliferation were discovered and many of these were 
significantly different in cancer cells. Small biotechnology firms sprang up as 
researchers attempted to fix these molecular defects in cancer cells. This 
heralded the beginning of the targeted-therapy era. One of the most significant 
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landmarks of this period was the development of imatinib. Unlike paclitaxel 
and irinotecan which were derived from natural products, imatinib was 
developed by rational drug design. Imatinib inhibits the kinase BCR-ABL as 
well as the KIT tyrosine kinase and platelet derived growth factor receptor-β 
tyrosine kinase. These effects led to the use of imatinib for the treatment of 
gastrointestinal stromal tumors and the hypereosinophilic syndrome.46 When 
patients with chronic myeloid leukemia were treated with imatanib, 90% of 
them achieved total haematological remission.47,48 
 
Figure 1.4. Selected drugs used in cancer chemotherapy. 
Along with the many success stories of drug discovery for cancer, there 
have been several failures as well.  Nevertheless, our growing understanding of 
the molecular biology of cancer cell should eventually lead to better ways of 




1.2.1 Natural Products as Medicine 
Throughout the ages, man has looked to Nature for the provision of 
medicine for the treatment of a wide range of diseases. Ancient civilizations 
such as the Egyptian, Chinese and Indian had extensive records of the use of 
plants in particular as medicine and some of these documentations date as far 
back as 2900 B.C.49 Even today, the World Health Organization estimated that 
about 65% of the world’s population depends on traditional medicine derived 
from plants as their primary health care. In developed countries, of the top 50 
selling drugs sold in pharmacies, half of them are based on or derived from 
natural products.50,51  Since the 1950s, natural products have attracted the 
interests of numerous scientists as many possess unique compounds which are 
biologically active. 
1.2.2 Anticancer Drugs from Plants 
The first plant-derived anticancer drugs to be used clinically were 
vinblastine and vincristine (Figure 1.5).52 These compounds were derived from 
the rosey periwinkle and the plant was used in many parts of Asia to treat 
diabetes. It was the serendipitous discovery that the plant extract caused a 
reduction in white blood cell counts and bone marrow depression in rats which 
eventually led to the isolation of vinblastine and vincristine.  
Another modern anticancer drug that has its roots in traditional medicine is 
etoposide.49 The Native Americans had used extracts from podophyllum 
peltatum to treat warts and skin cancer. This eventually led to the isolation of 
podophyllotoxin as the active agent and after extensive research, etoposide was 
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developed for clininal use.49 Other examples of anticancer agents derived from 
plants include paclitaxel and irinotecan which was discussed in earlier sections. 
Flavopiridol differs from the other examples mentioned in that it is totally 
synthetic. However its structure is based on a natural product rohitukine. 
Rohitukine was isolated for its immunomodulatory and anti-inflammatory 
activity and flavopiridol was the result of a synthetic campaign carried out for 
structure-activity studies. Flavopiridol was the only compound out of more 
than 100 analogs synthesized to possess tyrosine kinase activity and 



























































Figure 1.5. Chemotherapeutic drugs developed from plant sources. 
1.2.3 Microbes as Sources of Antitumor Agents 
To date, the study of natural microorganisms has been very limited and it 
has been estimated that less than 1% of microorganisms seen microscopically 
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have been cultivated.54 Despite this small number, there have been many drugs 
that are derived from microbial organism. Microorganisms have traditionally 
been the main source of antibacterial agents but they have also led to the 
discovery of several anticancer drugs such as dactinomycin, mitomycin C and 
doxorubicin (Figure 1.6).52 
 
Figure 1.6. Anticancer agents from microbial organisms. 
Another example of a class of microbial-derived drug is the epothilones. 
They were first isolated in 1993 and had a similar mode of action as 
paclitaxel.55 Epothilones possessed 2 advantages in that they have greater water 
solubility and they can be obtained in large quantities via fermentation. The 
natural products epothilone A and B might be too considered too toxic for 
clinical use but combinatorial synthesis has allowed the production of a large 
number of analogs with the basic template.56 Epothilone D has shown to be at 
least as cytotoxic as paclitaxel against a range of cancer cell lines and one of 
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the analogs has recently entered Phase I clinical trials.57 Given that the severely 
limited studies of natural microorganisms have already yielded significant 
benefits, it is clear that the microbial universe presents a vast untapped 
resource for drug discovery. 
1.2.4 Anticancer Drugs from Marine Sources 
The study of natural products from marine organisms was nearly non-
existent before the 1960s.52 This can be due to the extreme difficulties in 
collecting materials from the marine environment. For example, marine 
sponges which are the sources for developmental drugs such as discodermolide 
are largely unculturable.58 Therefore many natural products have to be 
extracted and purified from the specimens collected by scuba-diving from 
shallow to deep waters. This is an expensive and foreign process to most 
pharmaceutical industries. Nevertheless research on natural products from 
marine environment has yielded several potential anticancer agents which are 
now on Phase I and Phase II clinical trials.59 
Bryostatin 1 is a potential anticancer drug that highlights the difficulty in 
obtaining sufficient materials from marine sources and the possible solution to 
it (Figure 1.7). Bryostatin 1 was first isolated from B. neritina in 1968 and was 
later found to possess potent in vitro activity against various cancer cell lines.60 
However the low abundance of compound (~10 parts per billion) prevented the 
clinical studies of bryostatin 1. The supply of bryostatin 1 via synthesis was 
also unfeasible due to the complexity of its structure. In 1991, a novel process 
of large scale collection and purification of 10,000 gallons of B. neritina 
afforded 18 g of bryostatin 1.61 At the same time, the aquaculture of B. nertina 
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was explored in order to obtain a renewable source of the marine organism.62 


























Figure 1.7. Marine sources derived anticancer drugs. 
(+)‑Discodermolide, like byrostatin 1, is a potential antitumor agent isolated 
from the marine environment and has entered clinical trials.58 Unlike bryostatin 
1, however, the supply of (+)‑discodermolide could not be obtained from 
harvesting and purification of the rare deep-water sponge Discodermia 
dissolute. Attempts at aquaculture or biosynthesis were also unsuccessful but 
fortunately the supply of (+)‑discodermolide could be obtained through total 
synthesis.64,65 
1.2.5 Synthesis of Natural Products 
The main problems of developing drugs from natural products are the 
latter’s structural complexity and lack of supply. However recent advances in 
organic synthesis are overcoming the barriers presented by the structural 
complexity of many natural products. Moreover natural products have been 
termed “privileged structures” as they have been selected by evolutionary 
pressures to interact with biological macromolecules.66 Therefore they 
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represent excellent templates for the synthesis of novel, biologically active 
compounds. 
Although natural products frequently exhibit potent biological activity, they 
did not go through evolutionary selection to serve as human therapeutics.49 
Therefore optimization is usually required to fine-tune the biological activity 
and pharmacokinetics of the compound in a human body. This involves the 
modification of functional groups and stereocenters or even changing the basic 
scaffold of the natural product and these belong to the domain of synthetic 
chemistry. 
The easiest approach to optimizing a natural product lead is derivatization of 
the natural product. A large library can be expediently generated by this 
method. However due to the incompatibilities of many transformations with 
existing functional groups, the structural diversity of the analogs may be 
limited. Examples of drugs developed by this method include taxanes and 
camptothesins previously mentioned.41,42 
1.2.6 Semisynthesis and Total Synthesis of Natural Products 
Sometimes the natural product of interest cannot be isolated in sufficient 
quantities and the total synthesis of it is unfeasible as well. This problem may 
be solved by using another readily available natural product to serve as a 
starting material for the semisynthesis of the target compound. An excellent 
example is paclitaxel (Figure 1.8). The development of paclitaxel was greatly 
impeded by the scarcity of its original source, the bark of Taxus brevifolia. 
Total synthesis was not feasible as well due to paclitaxel’s structural 
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complexity. This issue was solved by semisynthesis using 10-deacetylbaccatin 
III, which is readily available from the needles of several Taxus species, as the 
starting material.67 
 
Figure 1.8. Synthesis of paclitaxel from 10-deacetylbaccatin III 
The structural complexity of many natural products have also attracted the 
attention of many top synthetic groups in the world and their efforts at total 
synthesis have led to great advancements in the field of organic chemistry.68 
An efficient and economical synthetic route to a natural product can eliminate 
the scarcity problem a naturally derived drug might face when it comes to 
clinical trials. One such example was the previously discussed 
(+)‑discodermolide.54,55 
Total synthesis of a natural product can frequently lead to the identification 
of the pharmacophore of the molecule. With this knowledge in hand, medicinal 
chemists will be able to modify the structure of the natural product. This can 
lead to the synthesis of simpler analogs with better biological activity than the 
natural product itself. This approach was described by Danishefsky as 
“diverted total synthesis” (DTS).69,70 DTS involves the synthesis of an 
advanced intermediate which is less complex than the original natural product. 
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Based on the common pharmacophore, analogs are then synthesized either by 
traditional or combinatorial techniques. 
An example of DTS is the development of eribulin (Figure 1.9). In 1992, 
Aicher and co-workers achieved the total synthesis of the marine-derived 
halichondrin B.71 This led to the discovery that the right side of the molecule 
was responsible for most of the anticancer activity. This ultimately resulted in 
the discovery of eribulin which compared to halichondrin B, is structurally 
simpler, has lower toxicity and similar bioactivity.72 Eribulin is currently in 
phase III clinical trials. 
 
Figure 1.9. Structural similarities between halichondrin B and eribulin 
1.2.7 Combinatorial Synthesis Based on Natural Products 
Combinatorial synthesis is a set of techniques that allows the simultaneous 
or parallel synthesis of a large number of different but structural related 
molecules. Since the 1990s, this technology has been used by the 
pharmaceutical industry to generate huge libraries of compounds hoping to 
improve the efficiency of the drug discovery process.49 However the results 
were disappointing and increasingly there is a shift of emphasis towards the 
more measured synthesis of libraries of fewer but well-characterized 
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compounds. In particular, the synthesis of complex natural product-like 
compounds is becoming more common.73 
Natural product scaffolds are “privileged structures” as they have the 
necessary balance of rigidity and flexibility to allow functional groups to bind 
to biological targets in a favorable spatial arrangement.66 Hence they are ideal 
for the synthesis of libraries of analogs for structure-activity studies using 
combinatorial techniques. One of the earliest examples was the synthesis of a 
library of compounds based on the sarcodictyin scaffold (Figure 1.10).74 Other 
examples include the combinatorial synthesis of analogs of pepticinnamin and 
curacin A.75,76 Today the synthesis of a library of compounds based on a 
natural product scaffold is commonplace for the optimization of the biological 





































1.3 Purpose of the Research Work in this Thesis 
Cancer, being a leading cause of death in the world, has attracted the 
attention of the scientific community worldwide in attempts to treat the disease. 
Because cancer refers to a class of diseases, it is unlikely that there will ever be 
a single cure for cancer. Today, natural products or their derivatives account 
for about half of the drugs that are used for the treatment of cancer. This is not 
surprising as natural products have been used for centuries as medicine and it is 
clear that Nature will continue to be a source for many new drug leads. The use 
of natural product scaffolds to synthesize analogs has already produced many 
new drugs for cancer chemotherapy. Here the aim of this thesis is to develop 
different classes of natural product analogs as potential new chemotherapeutic 
agents. 
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Chapter 2: Synthesis and Biological Evaluation of 
Polyenylpyrrole Derivatives as Anti-cancer Agents 
2.1 Introduction 
Cancer, being one of the leading causes of death globally, is a disease of 
worldwide importance. Although anticancer drugs have played a major role in 
the success stories in cancer treatment, there are still many types of cancer 
where effective molecular therapeutics are non-existing. Hence there is an 
impetus to identify and develop more potent therapeutic agents to cancer.  
Activation of apoptotic pathways is a key method by which anticancer drugs 
kill tumor cells.1,2 It is well known that anticancer drugs can stimulate 
apoptotic signaling through two major pathways. One is the death receptor 
(extrinsic) pathway involving death receptor and death ligand interaction, such 
as apoptosis stimulating fragment (Fas) and other members of the tumor-
necrosis factor (TNF) receptor family. These receptors activate caspase-8 and 
subsequently caspase-3, the major caspases participating in the execution phase 
of apoptosis.3 Another apoptotic pathway is the mitochondrial (intrinsic) 
pathway, which is activated by the release of proapoptotic factors from 
mitochondria intermembrane space such as cytochrome c.4 The released 
cytochrome c interacts with apoptotic protease activating factor 1 (Apaf-1) and 
activates caspase-9 which in turn proteolytically activates downstream caspase-
3.5 Activated caspase-3 cleaves many substrates, including poly (ADP-ribose) 
polymerase (PARP), a DNA repair enzyme which leads to inevitable cell death. 
Recently, novel molecules that induce mitochondrial pathways of caspase 
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activation have been developed in cancer chemotherapy.6 Our interest to 
investigate natural products for their potential therapeutic effects has recently 
spurred us to examine the influences of conjugated polyenes on anti-cancer 
properties. 
Conjugated polyenes is an interesting class of widely occurring natural 
products as they have been shown to possess excellent biological properties 
such as antibacterial, antifungal and antitumor activities.7 Some of these 
polyenes that show anticancer activities include rhizoxin8,9 and aurantosides A 
and B10 (Figure 2.1). In addition, some conjugated polyenes that are sold 
commercially include rapamycin and fumagillin.11-14 
 
Figure 2.1. Examples of conjugated polyenes with biological activity. 
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In 2006, Capon and co-workers published a report on the isolation and 
structure elucidation of several polyenylfurans and polyenylpyrroles from the 
soil microbe Gymnoascus reessii.15 In that study, they discovered three new 
conjugated polyenes, 12E-isorumbrin 2-1j, gymnoconjugatin A and B, 
alongside rumbrin and auxarconjugatin A 2-1b which were isolated previously 
(Figure 2.2).16-18 2-1b and 2-1j were subsequently found to possess potent 
cytotoxicity properties against NS-1 cell line whilst earlier studies by 
Yamagishi and co-workers have demonstrated that rumbrin was able to provide 
cytoprotection against cell death caused by calcium overload. Other related 
polyenylpyrroles that had been isolated previously include 12E-
bromoisorumbrin, 12E-dechloroisorumbrin, auxarconjugatin B 2-1a and 
auxarconjugatin C.19 Unlike 2-1b and 2-1j, 12E-bromoisorumbrin, 12E-
dechloroisorumbrin, gymnoconjugatin A and B, were absent of cytotoxicity 
activity, implying the importance of the 3-chloropyrrole moiety in effecting 
cytotoxicity in cancer cell-lines. 
Thus far the main source of conjugated polyenes has been from the isolation 
of fungi or bacteria. The typically small quantities that can be obtained via 
these sources often limit the extent of biological work that can be carried out. 
To address this limitation as well as to provide access to structurally diverse 
analogs of these compounds, it would be useful to develop a synthetic strategy 
that allows conjugated polyenes to be synthesized expediently. To the best of 
our knowledge, there is presently only one reported synthesis of 
gymnoconjugatin A and B20 and there is no literature describing the synthesis 
of polyenylpyrroles such as 2-1b and 2-1j. This, together with the promising 
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cytotoxicity properties of 2-1b and 2-1j, prompted us to synthesize a class of 
polyenylpyrroles and their analogs where the 3-chloropyrrole is replaced with 
other 2- or 3-chlorosubstituted aromatic rings. Hence, we herein describe the 
synthesis of these polyenyl compounds and their in vitro anti-tumor activity 
against human non-small cell lung carcinoma cell lines A549.  
 
 
Figure 2.2. Structures of auxarconjugatin, 12E-isorumbrin and related 
polyenes. 
2.2 Results and Discussion 
2.2.1 Retrosynthesis 
The retrosynthetic route of auxarconjugatin and its analogs 2-1 (Scheme 1) 
was modified from the synthesis of gymnoconjugatin.20 Disconnection of the 
tetraene gave 3 fragments: pyrone 2-2, the central butadiene connector 2-3 and 
vinyl bromide 2-4. It had been shown earlier that hetero-bis-metallated 
butadiene 2-3 could be used for the synthesis of an extended polyene chain via 
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sequential Stille and Suzuki coupling reactions.21 With this strategy in mind, 
we proceeded with the synthesis of 2-1. 
















2-2 2-3 2-4  
 
2.2.2 Synthesis of Compounds 2-2 
The synthesis of compound 2-7e was adapted from the literature describing 
the preparation of compounds 2-7a to 2-7d.22,23(Scheme 2.2 and Scheme 2.3). 
Regioselective alkylation of copper salt 2-5 afforded 2-6 which underwent 
cyclization to afford 2-7e in excellent yield.  




aReagents and conditions: (a) NaH, iodohexane, THF, rt; (b) DBU, toluene, 
85 °C 

































aReagents and conditions: (a) R22SO4, K2CO3, DMSO, rt; (b) SeO2, Dioxane, 
150 °C-160 °C; (c) (i) R3MgBr in Et2O, THF, rt; (ii) DMP, CH2Cl2, rt; (d) CBr4, 
PPh3, CH2Cl2, rt; (e) dimethylphosphite, TEA, DMF, rt; (f) aq. HBr, AcOH, 
90 °C 
Alkylation of the hydroxyl group on 2-7 was achieved using dimethyl 
sulfate or diethyl sulfate to afford 2-8 (Scheme 2.3). The oxidation of 2-8 to 2-
9 was modified from a procedure reported earlier.20 Instead of conventional 
heating in a sealed tube, we applied microwave irradiation which resulted in 
shorter reaction times with improved yields. It should be noted that for the 
desired reaction temperature to be achieved via microwave irradiation, the 
concentration of 2-8 in dioxane should be relatively high (≥ 0.5 M). This is 
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because dioxane itself lacks dipole moment and is therefore a poor absorber of 
microwave radiation. 




2-7 R1  2-8 R1 R2 
a H  a H Me 
b Me  b Me Me 
c nBu  c nBu Me 
d Bn  d Bn Me 
e n-hexyl  e n-hexyl Me 
   f H Et 
   g Me Et 
   h nBu Et 
 
To introduce diversity at the R3 position for 2-2, compounds 2-9a to 2-9h 
were treated with MeMgBr or EtMgBr followed by oxidation of the resulting 
alcohol using Dess-Martin Periodinane (DMP) to afford 2-9i to 2-9q. Attempts 
to convert the aldehyde moiety on 2-9a and 2-9b directly to a vinyl iodide 
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group via Takai olefination failed to provide the desired compound. Hence to 
synthesize 2-2, compounds 2-9 were first converted to vinyl dibromide 2-10 
via Corey-Fuchs olefination followed by reduction using dimethylphosphite.24  










2-9 R1 R2 R3  2-10 R1 R2 R3 
a H Me H  a H Me H 
b Me Me H  b Me Me H 
c nBu Me H  c nBu Me H 
d Bn Me H  d Bn Me H 
e n-hexyl Me H  e n-hexyl Me H 
f H Et H  f H Et H 
g Me Et H  g Me Et H 
h nBu Et H  h nBu Et H 
i H Me Me  i H Me Me 
j Me Me Me  j Me Me Me 
k Me Me Et  k Me Me Et 
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l nBu Me Me  l nBu Me Me 
m nBu Me Et  m nBu Me Et 
n Bn Me Me  n Bn Me Me 
o nhexyl Me Me  o nhexyl Me Me 
p Me Et Me  p Me Et Me 
q nBu Et Me  q nBu Et Me 
 
Table 2.3. Analogs of 2-2 synthesized 
 
2-2 R1 R2 R3  2-2 R1 R2 R3 
a H Me H  k Me Me Et 
b Me Me H  l nBu Me Me 
c nBu Me H  m nBu Me Et 
d Bn Me H  n Bn Me Me 
e n-hexyl Me H  o nhexyl Me Me 
f H Et H  p Me Et Me 
g Me Et H  q nBu Et Me 
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h nBu Et H  r H H H 
i H Me Me  s Me H H 
j Me Me Me      
 
This afforded 2-2a to 2-2q in excellent yields and E/Z ratio greater than 20:1. 
Further treatment of compounds 2-2a and 2-2b with a mixture of aqueous HBr 
and acetic acid gave the demethylated products 2-2r and 2-2s respectively. 
2.2.3 Synthesis of Fluorescent Tags 
Labeling of biomolecules with a radioactive or fluorescent tag is a common 
method used for bioanalytical purposes. The use of the latter over the former is 
generally preferred as the hazards of handling radioactive materials are avoided. 
Fluorescence microscopy is an important technique in the study of 
biomolecules, events and pathways in living cells and tissue. The most widely 
used methods, confocal microscopy and wide-field microscopy, can track 
proteins and other biomolecules in the cell and also resolve various cellular 
organelles such as the nucleus and endoplasmic reticulum.25,26 
It was our intention to attach a fluorescent probe to the polyenyl compounds 
synthesized to track their mode of action in the cancer cell. Commonly used 
fluorescent tags include rhodamine B, fluorescein, dansyl chloride and 4-
chloro-7-nitrobenzooxadiazole chloride (NBD-Cl) (Figure 2.3). For our 
purpose, we chose the latter two due to their smaller molecular weight to 

















f luorescein dansyl chloride
4-chloro-7-nitro-
benzooxadiazole  
Figure 2.3. Commonly used fluorescent tags. 
The synthesis of 2 dansyl tags is shown in Scheme 2.4. The first tag was 
synthesized in excellent yield by the reaction of 3-bromopropylamine 
hydrobromide 2-11 with dansyl chloride.  
Scheme 2.4. Synthesis of dansyl tagsa 
 
aReagents and conditions: (a) dansyl chloride, TEA, DMF, rt; (b) (i) NaH, THF, 
rt; (ii) ethylene glycol, rt; (c) (i) TFA, CH2Cl2, rt; (ii) dansyl chloride, TEA, 
CH2Cl2, rt; (d) CBr4, PPh3, CH2Cl2. 
Compound 2-13 which was synthesized from known protocols27 was used 
as the starting material for the preparation of the other dansyl tag. The SN2 
reaction between ethylene glycol and 2-13 afforded 2-14 in moderate yield. 
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The Boc protecting group on 2-14 was removed via treatment with TFA in 
CH2Cl2 and subsequent reaction with dansyl chloride provided 2-15 over 2 
steps. 2-15 was then converted to 2-16 through the Appel reaction in excellent 
yield. 
The R2 position on 2-2r were chosen as the point of attachment of the 
dansyl tags and 2-12 and 2-16 were attached to 2-2r to afford 2-2t and 2-2u 
respectively (Scheme 2.5). However attempts at tagging 2-2r with a NBD 



























aReagents and conditions: (a) 2-12, K2CO3 DMSO, 85 °C, (b) 2-16, , K2CO3 
DMSO, 85 °C. 
2.2.4 Synthesis of Compounds 2-4 
The second coupling partner, pyrrole 2-4a, was synthesized from 
commercially available 2-methyl-1-pyrroline 2-17 (Scheme 2-6). The 
conversion of 2-17 to compound 2-19 was adapted from an earlier report.28 
Using THF instead of CCl4 as a solvent for the chlorination of 2-17 led to a 
more than 200-fold increase in reaction rate to provide 2-18 which was used 
directly for the synthesis of 2-19 in excellent yield. Initial attempts to reduce 2-
19 directly to the aldehyde 2-20 in a single step by using diisobutylaluminium 
hydride (DIBAL) failed and the fully reduced alcohol was obtained as the 
major product. To obtain 2-20, we therefore attempted to reduce 2-19 
completely to the alcohol with LiAlH4 and then oxidize the alcohol to the 
aldehyde 2-20 with DMP. Unfortunately, the addition of DMP led to the 
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immediate decomposition of the alcohol. This could be attributed to the 
polymerization of pyrrole in the presence of the acetic acid which was formed 
as a byproduct of the DMP oxidation.29 However the addition of sodium 
bicarbonate30,31 and pyridine32,33 to neutralize the acetic acid byproduct did not 
resolve the problem. Swern oxidation, another commonly used method to 
oxidize an alcohol to an aldehyde also failed to give the desired product. Thus 
to circumvent this problem, we tried 2-iodoxybenzoic acid (IBX) which 
gratuitously gave 2-20 in moderate yields. The addition of excess sodium 
bicarbonate to the reaction mixture to neutralize the acidic conditions further 
improved the yield of 2-20. 
With compound 2-20 in our hands, we proceeded to synthesize the 
corresponding vinyl iodide 2-20a via Takai olefination. However in the course 
of drying the vinyl iodide, polymerization occurred and a dark tar was obtained. 
This problem was partially solved by storing 2-20a in a solution of THF. 
However the yield for the final step of the synthesis involving Sukuzi coupling 
between 2-30a and 2-20a was disappointingly low (< 30%). This was very 
likely due to the instability of 2-20a as the yield for the similar Suzuki coupling 
of 2-30a and 2-4b was significantly higher.  This problem was subsequently 
resolved by first protecting 2-20 with a mesyl group whose electron-
withdrawing property served to stabilize the pyrrole for subsequent 
transformations. 
  Earlier studies have shown that the 3-chloropyrrole group plays an 
important role in the cytotoxicity effects of 2-1b and 2-1e. When the chloro 
group was substituted with a bromo or hydrogen or when the 3-chloropyrrole 
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moiety was substituted with a furan ring, the activity was drastically 
reduced.19,20 To study other ring systems besides pyrrole, we replaced 3-
chloropyrrole with other 2- or 3-chlorosubstituted aromatic rings.  















































aReagents and conditions: (a) NCS, THF, 55 °C; (b) (i) MeONa, MeOH, 0 °C–
rt; (ii) aq. HCl; (c) (i) LiAlH4, THF, -20 °C–rt; (ii) IBX, NaHCO3, DMSO, rt; 
(d) NaH, MsCl, THF, rt; (e) (i) CuO, I2, Pyridine, EtOH, reflux; (ii) K2CO3, 
reflux; (f) (i) LiAlH4, THF, 0 °C; (ii) DMP, CH2Cl2, rt; (g) CBr4, PPh3, CH2Cl2, 
rt; (h) dimethylphosphite, TEA, DMF, rt; (i) CrCl2, CHI3, THF, rt. 
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Compound 2-23 was prepared by the oxidation of 2-acetyl-3-
chlorothiophene 2-22 (Scheme 3).34 Reduction of 2-23 with LiAlH4 followed 
by oxidation with DMP gave compound 2-24. Corey-Fuchs olefination of 2-21, 
2-24, 2-25a and 2-25b gave the corresponding vinyl dibromide 2-26(a-d) and 
subsequent reduction of 2-26(a-d) with dimethylphosphite afforded 2-4(a-d). 
Compound 2-4a and 2-4b were obtained as a ca. 2:1 mixture of E and Z 
stereoisomers but for 2-4c and 2-4d, the E isomer was obtained in greater than 
9:1 ratio. 
To establish if the cytotoxic effects of 2-1a would be affected if the 3-
chloropyrrole group was replaced by a methyl group (Scheme 4), compound 2-
28 was synthesized. This synthesis involved the Takai olefination of 2,4-
hexadienal with 2-2735 to afford 2-28 which was then reacted with 2-2b via 
Suzuki coupling to provide 2-29. 
Scheme 2.7. Synthesis of 2-29a 
 
aReagents and conditions: (a) 2,4-hexadienal, CrCl2, LiI, THF, rt; (b) 2-2b, 
Pd2dba3, AsPh3, aq. KOH, THF. 
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Table 2.4. Analogs of 2-4 synthesized. 
 
 





b 3-chlorothiophen-2-yl  b 3-chlorothiophen-2-yl 
c 2-chlorophenyl  c 2-chlorophenyl 
d 3-chlorophenyl  s 3-chlorophenyl 
 
2.2.5 Synthesis of Compounds 2-1 
  Pyrones 2-2(a-u) were treated with 2-3 via Stille coupling to afford trienes 
2-30(a-u). Suzuki coupling of 2-30(a-u) with 2-4a followed by treatment with 
tetrabutylammonium fluoride (TBAF) to remove the mesyl group afforded 2-
30(a-u) (Scheme 2.8). Other attempts at removing the mesyl group on the 
pyrrole via basic hydrolysis were less successful as the reaction proceeded 
much slower. Compounds 2-1(v-z), bearing other aromatic rings besides 3-
chloropyrrole, were synthesized in a similar manner. Interestingly, the 1H 
NMR of crude 2-1(a-z) showed that the E stereoisomer of the respective 
compound was present in 75-85%. As the E stereoisomers of 2-4a, 2-4b and 2-
4(c-d) were present in ca. 66%, 66% and >90% respectively, this indicated that 
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isomerization could have occurred during the coupling process. Table 2.6 
shows the 27 auxarconjugatin analogs 2-1(a-z) and 2-29 synthesized. 
Scheme 2.8. Synthesis of 2-1. 
 
aReagents and conditions: (a) 2-3, Pd2dba3, AsPh3, NMP, rt; (b) (i) 2-4a, 
Pd2dba3, AsPh3, aq. KOH, THF, rt; (ii) TBAF, THF, rt; (c) 2-4(a-d), Pd2dba3, 
AsPh3, aq. KOH, THF, rt. 
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Table 2.5. Analogs of 2-30 synthesized. 
 
2-30 R1 R2 R3  2-30 R1 R2 R3 
a H Me H  k Me Me Et 
b Me Me H  l nBu Me Me 
c nBu Me H  m nBu Me Et 
d Bn Me H  n Bn Me Me 
e n-hexyl Me H  o nhexyl Me Me 
f H Et H  p Me Et Me 
g Me Et H  q nBu Et Me 
h nBu Et H  r H H H 
i H Me Me  s Me H H 
j Me Me Me  ta H R4 H 




2.3 Biological Resultsa 
aAll the biological results were obtained as a result of a collaboration with another 
research group. 
Table 2.6. Cytotoxicity of conjugated polyenes against human lung cancer 
A549 cellsa 
 
Compd R1 R2 R3 Ar IC50 (µM) 
2-1a H Me H 3-chloropyrrol-2-yl 0.6 
2-1b Me Me H 3-chloropyrrol-2-yl 1.2 
2-1c nBu Me H 3-chloropyrrol-2-yl 5.0 
2-1d Bn Me H 3-chloropyrrol-2-yl >1.0c 
2-1e n-hexyl Me H 3-chloropyrrol-2-yl >1.0c 
2-1f H Et H 3-chloropyrrol-2-yl >1.0c 
2-1g Me Et H 3-chloropyrrol-2-yl >1.0c 
2-1h nBu Et H 3-chloropyrrol-2-yl >1.0 c 
2-1i H Me Me 3-chloropyrrol-2-yl 2.5 
2-1j Me Me Me 3-chloropyrrol-2-yl 5.2 
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2-1k Me Me Et 3-chloropyrrol-2-yl 5.6 
2-1l nBu Me Me 3-chloropyrrol-2-yl 0.01 
2-1m nBu Me Et 3-chloropyrrol-2-yl >1.0c 
2-1n Bn Me Me 3-chloropyrrol-2-yl >1.0c 
2-1o nhexyl Me Me 3-chloropyrrol-2-yl >1.0c 
2-1p Me Et Me 3-chloropyrrol-2-yl >1.0c 
2-1q nBu Et Me 3-chloropyrrol-2-yl >1.0c 
2-1r H H H 3-chloropyrrol-2-yl >20b 
2-1s Me H H 3-chloropyrrol-2-yl >20b 
2-1ta H R4 H 3-chloropyrrol-2-yl >20b 
2-1ua H R5 H 3-chloropyrrol-2-yl >20b 
2-1v H Me H 3-chlorothiophen-2-yl >20b 
2-1w Me Me H 3-chlorothiophen-2-yl >20b 
2-1x Me Me H 2-chlorophenyl >20b 
2-1y Me Me H 3-chlorophenyl >20b 
2-1z Me Me H 3-chloro-1-mesyl-pyrrol-2-yl >20b 




aAll treatment media contained the final DMSO concentration of 0.1%. 
AlamarBlue® assay was used to determine the cytotoxicity of the test 
compounds after 48 h of incubation. The procedure was conducted following 
the protocol described in the manufacturer’s instructions (AbD Serotec, 
Oxford). 
bThe IC50 values of these compounds were not determined due to their lack of 
potency. 
cThese compounds were synthesized and tested at a later date. As they 
displayed less activity than 2-1a and 2-1l, their exact IC50 values were not 
determined. 
Compounds 2-1(a-z) and 2-29 were evaluated for their cytotoxicities against 
the human lung cancer cell line A549 after 48 h treatment. As shown in Table 
2.6, the two most potent compounds are 2-1a and 2-1l with IC50 values of 0.6 
and 0.01 µM respectively, indicating that these compounds are more potent 
against A549 cell lines than anti-tumor drugs like Gleevec (IC50 = 2-3 µM) and 
cisplatin (IC50 = 64 µM).36 The loss of activity in compounds 2-1v to 2-1z, 
where other chloro-substituted aromatic rings were present instead of 3-
chloropyrrole, supported our hypothesis that the later group played an 
important role in effecting cytotoxicity.  
Fluorescence imaging of the cell could not be carried out due to the lost of 
cytotoxicity when the dansyl tags were attached in 2-1t and 2-1u. In addition, 
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the lack of cytotoxicity in compounds 2-1r and 2-1u also illustrated the 
importance of a methyl group at the R3 position. The difference in cytotoxicity 
between compounds 2-1a and 2-1f as well as 2-ll and 2-1q when the methyl 
group was replaced by an ethyl group at the R3 position further highlights the 
importance of a methyl group at the R3 position. 
To further explore the selectivity of the polyenyl compounds against A549 
cells, compounds 2-1a and 2-1l were further examined against Beas-2b cells 
which were derived from normal human lung tissue. As can be seen in Figure 2 
compounds 2-1a and 2-1l, despite being very potent against A549 cells (0.6 
and 0.01 µM respectively), were found to be non-cytotoxic towards Beas-2b 
cells at up to 80 µM. 
 
Figure 2.4 Compounds 2-1a and 2-1l were non-cytotoxic to normal human 
lung cells.a 
aAll treatment media contained the final DMSO concentration of 0.1%. 















compounds after 48 h of incubation. The procedure was conducted following 
the protocol described in the manufacturer’s instructions (AbD Serotec, 
Oxford). 
2.4 Conclusion 
In our efforts to develop potential chemotherapeutic agents from natural 
products, we have herein provided the first reported synthesis of a class of 
polyenylpyrrole natural products and their analogs. The compounds were 
evaluated for the cell cytotoxicity against human lung cancer cells A549. Two 
compounds, 2-1a and 2-1l, displayed potent effects in the inhibition of tumor 
cell proliferation with IC50 values of 0.6 µM and 0.01 µM respectively. In 
addition, these two compounds were found to be non-toxic to normal lung cells. 
These results indicated that compounds 2-1a and 2-1l have the potential to be 
developed as anticancer agents due to their high selectivity against A549 cells. 
2.5 Experimental Section 
General Procedures. All chemical reagents and solvents were obtained 
from Sigma Aldrich, Merck, Alfa Aesar, or Fluka and were used without 
further purification. The microwave-assisted reactions were performed using 
the Biotage Initiator microwave synthesizer. Analytical TLC was carried out 
on precoated silica plates (Merck silica gel 60, F254) and visualized with UV 
light or stained with phosphomolybdic acid (PMA) stain. Flash column 
chromatography was performed with silica (Merck, 70-230 mesh). The purities 
of the compounds were determined via HPLC using a Shimadzhu LCMS-IT-
TOF system with a Phenomenex Luma C18 column (50 mm × 3.0 mm, 5 μm). 
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Compounds used in the biological assays have purities of at least 95%. 1H 
NMR and 13C NMR spectra were measured on a Bruker ACF 300 or AMX 500 
Fourier transform spectrometer. Chemical shifts were reported in parts per 
million (δ) relative to the internal standard of tetramethylsilane (TMS). The 
signals observed were described as follows: s (singlet), d (doublet), t (triplet), q 
(quartet), dd (doublet of doublets), m (multiplet). The number of protons (n) 
for a given resonance was indicated as nH. Mass spectra were performed on a 
Finnigan/MAT LCQ mass spectrometer under electron spray ionization (ESI) 
or electron impact (EI) techniques. 
Synthesis of methyl-2-3-hydroxybut-2-enoyl)octanoate (2-6). 60% NaH 
in mineral oil (1.44 g, 36.1 mmol) was added portionwise to 2-5 (6.20 g, 16.4 
mmol) in THF (50 mL) and the reaction mixture was stirred at room 
temperature for 30 min. Next, iodohexane (20.9 g, 98.4 mmol) was added and 
the reaction mixture was stirred at 65 °C for 5 h. The reaction was quenched 
with aqueous 3 M HCl and extracted with Et2O. The combined organic extract 
was washed with saturated NaCl solution, dried over MgSO4, concentrated and 
purified by column chromatography (EtOAc:hexane = 1:10) to afford 2-6 (5.80 
g, 73%) as a pale yellow liquid. 1H NMR (500 MHz, CDCl3) δ 5.58 (s, 1H), 
3.71 (s, 3H), 3.23 (t, J = 7.3 Hz, 1H), 2.05 (s, 3H), 1.92-1.88 (m, 2H), 1.87-
1.78 (m, 2H), 1.27-1.25 (m, 8H), 0.86 (t, J = 6.3 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 191.5, 189.5, 170.8, 99.3, 55.4, 52.3, 31.5, 29.3, 28.9, 27.3, 24.1, 
22.5, 13.9; HRMS (EI): calcd for C13H22O4, 242.1518; found 242.1514. 
Synthesis of 3-hexyl-4-hydroxy-6-methyl-2H-pyran-2-one (2-7e). DBU 
(3.27 g, 21.5 mmol) was added to 2-6 (5.20 g, 21.5 mmol) in toluene (30 mL) 
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and the mixture was stirred at 85 °C for 2 h. The reaction was quenched with 
aqueous 3 M HCl and extracted with EtOAc. The combined organic extract 
was washed with saturated NaCl solution, dried over MgSO4, concentrated and 
purified by column chromatography (EtOAc:hexane = 1:1) to afford 2-7e (4.11 
g, 91%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 6.24 (s, 1H), 2.45 (t, J 
= 7.6 Hz, 2H), 2.21 (s, 3H), 1.52-1.46 (m, 2H), 1.34-1.27 (m, 6H), 0.86 (t, J = 
6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 168.4, 167.4, 159.7, 103.4, 101.8, 
31.8, 29.3, 28.0, 23.0, 22.6, 19.6, 14.1; ; HRMS (EI): calcd for C12H18O3, 
210.1256; found 210.1260. 
General Procedure for the Synthesis of 2-8a to 2-8e. To a mixture of 
K2CO3 (1.73 g, 12.5 mmol) and the corresponding pyrone 2-7 (5.00 mmol) in 
DMSO (10 mL) was added dimethyl sulfate (0.693 g, 5.50 mmol). The mixture 
was stirred at room temperature for 1 h and poured into water (60 mL). The 
mixture was extracted with EtOAc and the combined organic extract was 
washed with saturated NaCl solution, dried over MgSO4, concentrated and 
purified by column chromatography. 
4-methoxy-6-methyl-2H-pyran-2-one (2-8a). The residue was purified 
using flash chromatography (EtOAc:hexane = 2:1) to afford 2-8a (0.588 g, 
86%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 5.74 (d, J = 1.3 Hz, 1H), 
5.36 (d, J = 1.9 Hz, 1H), 3.75 (s, 3H), 2.16 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 171.2, 164.8, 161.9, 100.2, 87.2, 55.7, 19.7; HRMS (EI): calcd for 
C7H8O3, 140.0473; found 140.0472. 
4-methoxy-3,6-dimethyl-2H-pyran-2-one (2-8b). The residue was purified 
using flash chromatography (EtOAc:hexane = 1:1) to afford 2-8b (0.593 g, 
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77%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 6.01 (s, 1H), 3.83 (s, 3H), 
2,21 (s, 3H), 1.85 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 166.0, 165.8, 160.7, 
100.5, 95.0, 56.2, 20.2, 8.3; HRMS (EI): calcd for C8H10O3, 154.0630; found 
154.0629. 
3-butyl-4-methoxy-6-methyl-2H-pyran-2-one (2-8c). The residue was 
purified using flash chromatography (EtOAc:hexane = 1:2) to afford 2-8c 
(0.725 g, 74%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 5.97 (s, 1H), 
3.82 (d, J = 3.2 Hz, 3H), 2.39-2.34 (m, 2H), 2.21 (d, J = 3.8 Hz, 3H), 1.41-1.40 
(m, 2H), 1.32-1.28 (m, 2H), 0.89-0.85 (m, 3H); 13C NMR (125 MHz, CDCl3) δ 
165.8, 165.4, 160.8, 105.6, 94.9, 56.1, 30.1, 22.9, 22.6, 20.2, 13.9; HRMS (EI): 
calcd for C11H16O3, 196.1099; found 196.1098. 
3-benzyl-4-methoxy-6-methyl-2H-pyran-2-one (2-8d). The residue was 
purified using flash chromatography (EtOAc:hexane = 1:2) to afford 2-8d 
(0.891 g, 73%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.32-7.30 (m, 
2H), 7.24-7.21(m, 2H), 7.15-7.13 (m, 1H), 6.02 (s, 1H), 3.85 (s, 3H), 3.74 (s, 
2H), 2.22 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 166.1, 165.2, 161.6, 140.1, 
128.5, 128.0, 125.8, 104.2, 94.9, 56.2, 28.8, 20.2; HRMS (EI): calcd for 
C14H14O3, 230.0943; found 230.0952. 
3-hexyl-4-methoxy-6-methyl-2H-pyran-2-one (2-8e). The residue was 
purified using flash chromatography (EtOAc:hexane = 1:3) to afford 2-8e (1.02 
g, 91%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 5.98 (s, 1H), 3.80 (s, 
3H), 2.34 (t, J = 7.9 Hz, 2H), 2.19 (s, 3H), 1.40 (m, 2H), 1.26-1.23 (m, 6H), 
0.82 (t, J = 6.6 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 165.8, 165.4, 160.7, 
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105.4, 94.9, 56.0, 31.6, 29.1, 27.8, 23.1, 22.5, 20.1, 14.0; HRMS (EI): calcd for 
C13H20O3, 224.1412; found 224.1409. 
General Procedure for the Synthesis of 2-8f to 2-8h. To a mixture of 
K2CO3 (1.73 g, 12.5 mmol) and the corresponding pyrone 2-7 (5.00 mmol) in 
DMSO (10 mL) was added diethyl sulfate (0.693 g, 5.50 mmol). The mixture 
was stirred at room temperature for 90 min and poured into water (60 mL). The 
mixture was extracted with EtOAc and the combined organic extract was 
washed with saturated NaCl solution, dried over MgSO4, concentrated and 
purified by column chromatography. 
4-ethoxy-6-methyl-2H-pyran-2-one (2-8f). The residue was purified using 
flash chromatography (EtOAc:hexane = 1:2) to afford 2-8f (0.601 g, 78%) as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 5.71 (s, 1H), 5.31 (s, 1H), 3.95 (q, J 
= 7.1 Hz, 2H), 2.14 (s, 3H), 1.34 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 170.4, 164.9, 161.8, 100.4, 87.5, 64.4, 19.6, 13.9; HRMS (EI): calcd 
for C8H10O3, 154.0630; found 154.0628. 
4-ethoxy-3,6-dimethyl-2H-pyran-2-one (2-8g). The residue was purified 
using flash chromatography (EtOAc:hexane = 1:2) to afford 2-8g (0.622 g, 
74%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 5.95 (s, 1H), 4.07 (q, J = 
6.9 Hz, 2H), 2.21 (s, 3H), 1.87 (s, 3H), 1.38 (t, J = 7.3 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ 165.9, 165.3, 160.3, 100.6, 95.5, 64.7, 20.1, 14.7, 8.3 ; HRMS 
(EI): calcd for C9H12O3, 168.0786; found 168.0785. 
3-butyl-4-ethoxy-6-methyl-2H-pyran-2-one (2-8h). The residue was 
purified using flash chromatography (EtOAc:hexane = 1:3) to afford 2-8h 
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(0.767 g, 73%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 5.93 (s, 1H), 
4.06 (q, J = 6.9 Hz, 2H), 2.38 (t, J = 7.6 Hz, 2H), 2.19 (s, 3H), 1.43-1.25 (m, 
7H), 0.87 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 165.5, 165.3, 
160.5, 105.4, 95.5, 64.5, 30.0, 22.8, 22.4, 20.1, 14.7, 13.8; HRMS (EI): calcd 
for C12H18O3, 210.1256; found 210.1259. 
General Procedure for the Synthesis of 2-9a to 2-9h. SeO2 (1.11 g, 10.0 
mmol) was added to the corresponding pyrone 2-8 (2.00 mmol) in 1,4-dioxane 
(4 mL). The reaction mixture containing 2-8b to 2-8h was heated at 160 °C for 
15 min while 2-8a was heated at 150 °C for 15 min using microwave 
irradiation in a sealed tube. After which, the mixture was allowed to cool, 
saturated NaHCO3 solution was added and the mixture was extracted with 
CH2Cl2. The combined organic extract was dried over MgSO4, concentrated 
and purified by column chromatography. 
4-methoxy-6-oxo-6H-pyran-2-carbaldehyde (2-9a). The residue was 
purified using flash chromatography (EtOAc:hexane:CH2Cl2 = 1:3:6) to afford 
2-9a (0.188 g, 61%) as a pale brown solid. 1H NMR (500 MHz, DMSO-d6) δ 
9.46 (s, 1H), 7.14 (d, J = 1.9 Hz, 1H), 6.01 (d, J = 1.9 Hz, 1H), 3.89 (s, 3H);  
13C NMR (125 MHz, DMSO-d6) δ 184.3, 169.0, 161.2, 153.7, 112.6, 94.6, 57.1; 
HRMS (EI): calcd for C7H6O4, 154.0266; found 154.0265. 
4-methoxy-5-methyl-6-oxo-6H-pyran-2-carbaldehyde (2-9b). The 
residue was purified using flash chromatography (EtOAc:hexane:CH2Cl2= 
1:4:8) to afford 2-9b (0.239 g, 71%) as a pale brown solid. 1H NMR (500 MHz, 
CDCl3) δ 9.54 (s, 1H), 7.00 (s, 1H), 3.97 (s, 3H), 1.99 (s, 3H); 13C NMR (125 
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MHz, CDCl3) δ 183.2, 163.3, 162.8, 152.3, 111.1, 101.9, 56.8, 9.5; HRMS (EI): 
calcd for C8H8O4, 168.0423; found 168.0424. 
5-butyl-4-methoxy-6-oxo-6H-pyran-2-carbaldehyde (2-9c). The residue 
was purified using flash chromatography (EtOAc:hexane:CH2Cl2 = 1:6:12) to 
afford 2-9c (0.319 g, 76%) as a pale brown solid. 1H NMR (500 MHz, CDCl3) 
δ 9.55 (s, 1H), 6.99 (s, 1H), 3.96 (s, 3H), 2.48 (t, J = 7.6 Hz, 2H), 1.47-1.41 (m, 
2H), 1.35-1.31 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) 
δ 183.3, 163.3, 162.3, 152.4, 115.9, 101.8, 56.7, 29.7, 23.9, 22.6, 13.8; HRMS 
(EI): calcd for C11H14O4, 210.0892; found 210.0893. 
3-benzyl-4-methoxy-2-oxo-2H-pyran-6-carbaldehyde (2-9d). The residue 
was purified using flash chromatography (EtOAc:hexane:CH2Cl2 = 1:4:8) to 
afford 2-9d (0.366g, 75%) as a pale brown solid. 1H NMR (500 MHz, DMSO-
d6) δ 9.49 (s, 1H), 7.65 (s, 1H), 7.26-7.15 (m, 5H), 4.03 (s, 3H), 3.71 (s, 3H); 
13C NMR (125 MHz, DMSO-d6) δ 184.0, 164.5, 161.9, 152.7, 138.7, 128.3, 
128.2, 126.1, 111.6, 108.1, 57.6, 29.1; HRMS (EI): calcd for C14H12O4, 
244.0736; found 244.0735. 
3-hexyl-4-methoxy-2-oxo-2H-pyran-6-carbaldehyde (2-9e). The residue 
was purified using flash chromatography (EtOAc:hexane:CH2Cl2 = 1:6:12) to 
afford 2-9e (0.338g, 71%) as a pale brown solid. 1H NMR (500 MHz, CDCl3) δ 
9.55 (s, 1H), 6.99 (s, 1H), 3.95 (s, 3H), 2.48 (t, J = 7.9 Hz, 2H), 1.49-1.43 (m, 
2H), 1.32-1.27 (m, 6H), 0.86 (t, J = 6.6 Hz, 3H); 13C NMR (125 MHz, CDCl3) 
δ 183.4, 163.2, 162.5, 152.4, 115.9, 101.6, 56.7, 31.6, 29.2, 27.5, 24.2, 22.5, 
14.0; HRMS (EI): calcd for C13H18O4, 238.1205; found 238.1202. 
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4-ethoxy-2-oxo-2H-pyran-6-carbaldehyde (2-9f). The residue was 
purified using flash chromatography (EtOAc:hexane:CH2Cl2 = 1:5:10) to 
afford 2-9f (0.211 g g, 63%) as a pale brown solid. 1H NMR (500 MHz, CDCl3) 
δ 9.50 (s, 1H), 6.66 (d, J = 2.5 Hz, 1H), 5.71 (d, J = 2.5 Hz, 1H), 4.8 (q, J = 6.9 
Hz, 2H), 1.44 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 183.0, 168.1, 
161.7, 153.8, 108.9, 94.9, 65.5, 13.9; HRMS (EI): calcd for C8H8O4, 168.0423; 
found 168.0427. 
4-ethoxy-3-methyl-2-oxo-2H-pyran-6-carbaldehyde (2-9g). The residue 
was purified using flash chromatography (EtOAc:hexane:CH2Cl2 = 1:5:10) to 
afford 2-9g (0.254 g, 70%) as a pale brown solid.  1H NMR (500 MHz, CDCl3) 
δ 9.51 (s, 1H), 6.96 (s, 1H), 4.21 (q, J = 7.2 Hz, 2H), 1.97 (s, 1H), 1.43 (t, J = 
6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 183.3, 162.9, 162.8, 152.2, 111.1, 
103.1, 65.7, 14.8, 9.6; HRMS (EI): calcd for C9H9O3Br, 182.0579; found 
182.0581. 
3-butyl-4-ethoxy-2-oxo-2H-pyran-6-carbaldehyde (2-9h). The residue 
was purified using flash chromatography (EtOAc:hexane:CH2Cl2 = 1:6:12) to 
afford 2-9h (0.323 g, 77%) as a pale brown solid. 1H NMR (500 MHz, CDCl3) 
δ 9.53 (s,1H), 6.94 (s, 1H), 4.20 (q, J = 7.1 Hz, 2H), 2.49 (t, J = 7.6 Hz, 2H), 
1.48-1.41 (m, 5H), 1.35-1.28 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ 183.3, 162.7, 162.5, 152.3, 115.8, 102.6, 65.5, 29.6, 23.8, 22.5, 
14.7, 13.8; HRMS (EI): calcd for C12H16O4, 224.1049; found 224.1049. 
General Procedure for the Synthesis of 2-9i to 2-9q. 3 M MeMgBr or 3 
M EtMgBr in Et2O (2.20 mmol) was added dropwise to the corresponding 
pyrones 2-9 (2.00 mmol) in THF. The mixture was allowed to stir at room 
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temperature for 30 min before quenching with saturated NH4Cl solution. The 
mixture was extracted with CH2Cl2 and the combined organic extract was 
washed with saturated NaCl solution and dried over MgSO4. The solvent was 
removed under reduced pressure to afford a brown residue. DMP (1.02 g, 2.40 
mmol) was added to the residue dissolved in CH2Cl2 (5 mL) and the reaction 
mixture was stirred at room temperature for 1 hr. Subsequently, saturated 
NaHCO3 solution (5 mL) and 15% Na2S2O3 solution (5 mL) were added and 
the mixture was allowed to stir for an additional 15 min. After which, the 
mixture was extracted with CH2Cl2 and the combined organic extract was dried 
over MgSO4, concentrated and purified by column chromatography. 
6-acetyl-4-methoxy-2H-pyran-2-one (2-9i). The residue was purified using 
flash chromatography (EtOAc:hexane = 2:3) to afford 2-9i (0.228 g, 68%) as a 
pale yellow solid. 1H NMR (500 MHz, CDCl3) δ 6.73 (d, J = 1.9 Hz, 1H), 5.70 
(d, J = 1.9 Hz, 1H), 3.84 (s, 3H), 2.49 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
191.3, 169.7, 162.2, 154.5, 103.9, 93.6, 56.4, 25.9; HRMS (EI): calcd for 
C8H8O4, 168.0423; found 168.0425.  
6-acetyl-4-methoxy-3-methyl-2H-pyran-2-one (2-9j). The residue was 
purified using flash chromatography (EtOAc:hexane = 1:2) to afford 2-9j 
(0.277 g, 76%) as a pale yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.05 (s, 
1H), 3.94 (s, 3H), 2.54 (s, 3H), 2.00 (d, J = 1.3 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 191.7, 164.0, 163.2, 153.0, 109.7, 98.0, 56.7, 25.9, 9.4; HRMS (EI): 
calcd for C9H10O4, 182.0579; found 182.0578.  
4-methoxy-3-methyl-6-propionyl-2H-pyran-2-one (2-9k). The residue 
was purified using flash chromatography (EtOAc:hexane = 1:2) to afford 2-9k 
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(0.278 g, 71%) as a pale yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.02 (s, 
1H), 3.91 (s, 3H), 2.90 (q, J = 7.2 Hz, 2H), 1.93 (s, 3H), 1.11 (t, J = 7.3 Hz, 
3H); 13C NMR (75 MHz, CDCl3) δ 194.4, 164.0, 163.1, 152.9, 109.2, 97.8, 
56.6, 31.4, 9.2, 7.1; HRMS (EI): calcd for C10H12O4, 196.0736; found 
196.0739. 
6-acetyl-3-butyl-4-methoxy-2H-pyran-2-one (2-9l). The residue was 
purified using flash chromatography (EtOAc:hexane  = 1:3) to afford 2-9l 
(0.327 g, 73%) as a pale yellow solid. 1H NMR (500 MHz, CDCl3) δ 6.99 (s, 
1H), 3.89 (s, 3H), 2.46 (s, 3H), 2.42 (t, J = 7.6 Hz, 2H), 1.41-1.36 (m, 2H), 
1.31-1.23 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
191.4, 163.9, 162.7, 153.1, 114.1, 98.0, 56.5, 29.6, 25.7, 23.6, 22.5, 13.7; 
HRMS (ESI) [M+Na]+: calcd for C12H16O4Na 247.0946; found 247.0942. 
3-butyl-4-methoxy-6-propionyl-2H-pyran-2-one (2-9m). The residue was 
purified using flash chromatography (EtOAc:hexane  = 1:4) to afford 2-9m 
(0.290 g, 61%) as a pale yellow sticky liquid. 1H NMR (500 MHz, CDCl3) δ 
7.03 (s, 1H), 3.91 (s, 3H), 2.92 (q, J = 7.1 Hz, 2H), 2.45 (t, J = 7.6 Hz, 1H), 
1.45-1.39 (m, 2H), 1.33-1.27 (m, 2H), 1.13 (t, J = 7.3 Hz, 3H), 0.88 (t, J = 7.3 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 194.5, 164.1, 162.9, 153.1, 114.0, 
97.9, 56.6, 31.5, 29.7, 23.7, 22.6, 13.8, 7.1; HRMS (EI): calcd for C13H18O4, 
238.1205; found 238.1208. 
6-acetyl-3-benzyl-4-methoxy-2H-pyran-2-one (2-9n). The residue was 
purified using flash chromatography (EtOAc:hexane  = 1:3) to afford 2-9n 
(0.384 g, 74%) as a pale yellow solid.  1H NMR (500 MHz, CDCl3) δ 7.33-7.31 
(m, 2H), 7.26-7.22 (m, 2H), 7.18-7.17 (m, 1H), 7.06 (s, 1H), 3.96 (s, 3H), 3.82 
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(s, 2H), 2.52 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 191.4, 164.2, 162.7, 153.6, 
138.9, 128.7, 128.3, 126.3, 112.7, 98.1, 56.8, 29.6, 25.8; HRMS (EI): calcd for 
C15H14O4, 258.0892; found 258.0891. 
6-acetyl-3-hexyl-4-methoxy-2H-pyran-2-one (2-9o). The residue was 
purified using flash chromatography (EtOAc:hexane  = 1:4) to afford 2-9o 
(0.413 g, 82%) as a pale yellow sticky liquid. 1H NMR (500 MHz, CDCl3) δ 
7.03 (s, 1H), 3.91 (s, 3H), 2.51 (s, 3H), 2.45 (t, J = 7.9 Hz, 2H), 1.45-1.41 (m, 
2H), 1.28-1.25 (m, 6H), 0.85 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) 
δ 191.6, 164.0, 162.8, 153.2, 114.3, 98.1, 56.6, 31.6, 29.1, 27.5, 25.8, 24.0, 
22.5, 14.0; HRMS (EI): calcd for C14H20O4, 252.1362; found 252.1360. 
6-acetyl-4-ethoxy-3-methyl-2H-pyran-2-one (2-9p). The residue was 
purified using flash chromatography (EtOAc:hexane  = 1:3) to afford 2-9p 
(0.313 g, 80%) as a pale yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.05 (s, 
1H), 4.22 (q, J = 7.2 Hz, 2H), 2.56 (s, 3H), 2.03 (s, 3H), 1.46 (t, J = 6.9 Hz, 
3H); 13C NMR (125 MHz, CDCl3) δ 191.5, 163.4, 163.2, 152.8, 109.4, 98.6, 
65.3, 25.7, 14.7, 9.3; HRMS (EI): calcd for C10H12O4, 196.0736; found 
196.0739. 
6-acetyl-3-butyl-4-ethoxy-2H-pyran-2-one (2-9q). The residue was 
purified using flash chromatography (EtOAc:hexane  = 1:4) to afford 2-9q 
(0.325 g, 68%) as a pale yellow solid. 1H NMR (500 MHz, CDCl3) δ 6.99 (s, 
1H), 4.17 (q, J = 7.2 Hz, 2H), 2.50 (s, 3H), 2.48 (t, J = 7.6 Hz, 2H), 1.47-1.38 
(m, 5H), 1.35-1.27 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 191.7, 163.4, 163.0, 153.0, 114.3, 98.7, 65.3, 29.7, 25.8, 23.6, 22.5, 
14.7, 13.8; HRMS (EI): calcd for C13H18O4, 238.1205; found 238.1204. 
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General Procedure for the Synthesis of 2-10a to 2-10q. CBr4 (0.464 g, 
1.40 mmol) in CH2Cl2 (4 mL) was added to a solution of the corresponding 
pyrone 2-9 (1.00 mmol) and PPh3 (0.734 g, 2.80 mmol) in CH2Cl2 (8 mL). The 
mixture was stirred at room temperature for 30 min and thereafter, the solvent 
was removed under reduced pressure and the residue was purified by column 
chromatography. 
6-(2,2-dibromovinyl)-4-methoxy-2H-pyran-2-one (2-10a). The residue 
was purified using flash chromatography (EtOAc:CH2Cl2 = 1:40) to afford 2-
10a (0.285 g, 92%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.09, (s, 
1H), 6.35 (d, J = 2.6 Hz, 1H), 5.53 (d, J = 1.9 Hz, 1H), 3.81 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 170.2, 162.8, 155.4, 128.5, 103.5, 97.3, 89.9, 56.1; 
HRMS (EI): calcd for C8H6O3Br2, 307.8684; found 307.8678. 
6-(2,2-dibromovinyl)-4-methoxy-3-methyl-2H-pyran-2-one (2-10b). The 
residue was purified using flash chromatography (EtOAc:CH2Cl2 = 1:50) to 
afford 2-10b (0.295 g, 91%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.15 (s, 1H), 6.64 (s, 1H), 3.89 (s, 3H), 1.90 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 164.6, 163.9, 154.0, 128.9, 104.9, 98.1, 96.3, 56.4, 9.0; HRMS (EI): 
calcd for C9H8O3Br2, 321.8847; found 321.8840. 
3-butyl-6-(2,2-dibromovinyl)-4-methoxy-2H-pyran-2-one (2-10c). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:6) to 
afford 2-10c (0.347 g, 95%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.14 (d, J = 1.9 Hz, 1H), 6.63 (s, 1H), 3.87 (d, J = 1.3 Hz, 3H), 2.40-2.39 (m, 
2H), 1.45-1.42 (m, 2H), 1.32-1.31 (m, 2H), 0.91-0.88 (m, 3H); 13C NMR (125 
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MHz, CDCl3) δ 164.6, 163.5, 154.1, 128.9, 109.7, 98.2, 96.2, 56.4, 29.9, 23.5, 
22.6, 13.9; HRMS (EI): calcd for C12H14O3Br2, 363.9310; found 363.9320.  
3-benzyl-6-(2,2-dibromovinyl)-4-methoxy-2H-pyran-2-one (2-10d). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:5) to 
afford 2-10d (0.288 g, 72%) as a white solid.  1H NMR (500 MHz, CDCl3) δ 
7.33-7.32 (m, 2H), 7.24-7.23 (m, 2H), 7.18-7.14 (m, 2H), 6.63 (s, 1H), 3.91 (s, 
3H), 3.76 (s, 2H); 13C NMR (125 MHz, CDCl3) δ 164.9, 163.4, 154.8, 139.5, 
128.8 (2 carbons), 128.3, 126.2, 108.3, 98.3, 96.8, 56.6, 29.4; HRMS (EI): 
calcd for C15H12O379Br81Br, 399.9133; found 399.9136. 
6-(2,2-dibromovinyl)-3-hexyl-4-methoxy-2H-pyran-2-one (2-10e). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:6) to 
afford 2-10e (0.319 g, 81%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.14 (s, 1H), 6.63 (s, 1H), 3.87 (s, 3H), 2.40 (t, J = 7.6 Hz, 2H), 1.45-1.41 (m, 
2H), 1.27 (s, 6H), 0.86 (t, J = 6.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
164.5, 163.5, 154.1, 128.9, 109.7, 98.2, 96.1, 56.3, 31.6, 29.2, 27.6, 23.7, 22.6, 
14.0; HRMS (EI): calcd for C14H18O3Br2, 391.9623; found 391.9638. 
6-(2,2-dibromovinyl)-4-ethoxy-2H-pyran-2-one (2-10f). The residue was 
purified using flash chromatography (EtOAc:hexane = 1:3) to afford 2-10f 
(0.249 g, 77%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.09 (s, 1H), 
6.35 (s, 1H), 5.50 (s, 1H), 4.02 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 6.9 Hz, 3H); 13C 
NMR (125 MHz, CDCl3) δ 169.4, 163.0, 155.4, 128.5, 103.8, 97.1, 90.3, 64.9, 
14.0; HRMS (EI): calcd for C9H8O3Br2, 321.8840; found 321.8841. 
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6-(2,2-dibromovinyl)-4-ethoxy-3-methyl-2H-pyran-2-one (2-10g). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:3) to 
afford 2-10g (0.269 g, 80%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.13 (s, 1H), 6.61 (s, 1H), 4.12 (q, J = 6.9 Hz, 2H), 1.90 (s, 1H), 1.41 (t, J = 7.3 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 164.0, 163.9, 153.7, 128.8, 104.8, 
98.8, 96.0, 65.0, 14.7, 9.0;  HRMS (EI): calcd for C10H10O3Br2, 335.8997; 
found 335.8996. 
3-butyl-6-(2,2-dibromovinyl)-4-ethoxy-2H-pyran-2-one (2-10h). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:4) to 
afford 2-10h (0.321 g, 85%) as a white solid.  1H NMR (500 MHz, CDCl3) δ 
7.12 (s, 1H), 6.59 (s, 1H), 4.10 (q, J = 6.9 Hz, 2H), 2.41 (t, J = 7.6 Hz, 2H), 
1.46-1.37 (m, 5H), 1.34-1.26 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ 163.9, 163.6, 153.9, 128.9, 109.5, 98.9, 95.9, 64.9, 29.8, 23.3, 
22.4, 14.7, 13.8; HRMS (EI): calcd for C13H16O3Br2, 377.9466; found 
377.9468. 
6-(1,1-dibromoprop-1-en-2-yl)-4-methoxy-2H-pyran-2-one (2-10i). The 
residue was purified using flash chromatography (EtOAc:CH2Cl2 = 1:40) to 
afford 2-10i (0.285 g, 88%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
6.13 (d, J = 2.5 Hz, 1H), 5.48 (d, J = 1.9 Hz, 1H), 3.81 (s, 3H), 2.10 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ 170.3, 163.5, 159.2, 134.7, 103.3, 94.9, 89.0, 
56.1, 22.6; HRMS (EI): calcd for C9H8O3Br2, 321.8850; found 321.8840.  
6-(1,1-dibromoprop-1-en-2-yl)-4-methoxy-3-methyl-2H-pyran-2-one (2-
10j). The residue was purified using flash chromatography (EtOAc:CH2Cl2 = 
1:50) to afford 2-10j (0.287 g, 85%) as a white solid. 1H NMR (500 MHz, 
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CDCl3) δ 6.42, (s, 1H), 3.89 (s, 3H), 2.14 (s, 3H), 1.93 (s, 1H); 13C NMR (125 
MHz, CDCl3) δ 164.6, 164.5, 157.7, 135.3, 103.5, 98.1, 94.5, 56.4, 22.7, 8.7; 
HRMS (EI): calcd for C10H10O3Br2, 335.8997; found 335.8998.  
6-(1,1-dibromobut-1-en-2-yl)-4-methoxy-3-methyl-2H-pyran-2-one (2-
10k). The residue was purified using flash chromatography (EtOAc:CH2Cl2 = 
1:50) to afford 2-10k (0.292 g, 83%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 6.34 (s, 1H), 3.88 (s, 3H), 2.56 (q, J = 7.6 Hz, 2H), 1.90 (s, 3H), 1.03 
(t, J = 7.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 164.6 (2 carbons), 157.1, 
141.0, 103.3, 98.6, 94.2, 56.4, 29.8, 11.4, 8.7; HRMS (EI): calcd for 
C11H12O3Br2, 349.9153; found 349.9152. 
3-butyl-6-(1,1-dibromoprop-1-en-2-yl)-4-methoxy-2H-pyran-2-one (2-
10l). The residue was purified using flash chromatography (EtOAc:hexane = 
1:6) to afford 2-10l (0.338 g, 89%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 6.39 (s, 1H), 3.85 (s, 3H), 2.38 (t, J = 7.6 Hz, 2H), 2.10 (s, 3H) 1.44-
1.38 (m, 2H), 1.33-1.25 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H), NMR (125 MHz, 
CDCl3) δ 164.6, 164.1, 157.7, 135.2, 108.0, 98.1, 94.3, 56.3, 29.8, 23.2, 22.6, 
22.5, 13.8; HRMS (ESI) [M+H]+: calcd for C13H17O3Br2 378.9544; found 
378.9532. 
3-butyl-6-(1,1-dibromobut-1-en-2-yl)-4-methoxy-2H-pyran-2-one (2-
10m). The residue was purified using flash chromatography (EtOAc:hexane = 
1:6) to afford 2-10m (0.362 g, 93%) as a colorless sticky liquid.  1H NMR (500 
MHz, CDCl3) δ 6.33 (s, 1H), 3.87 (s, 3H), 2.57 (q, J = 7.6 Hz, 2H), 2.41 (t, J = 
7.8 Hz, 2H), 1.47-1.41 (m, 2H), 1.36-1.29 (m, 2H), 1.05 (t, J = 7.6 Hz, 3H), 
0.90 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 164.5, 164.3, 157.4, 
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141.2, 108.1, 98.7, 94.1, 56.4, 29.9, 29.8, 23.3, 22.6, 13.9, 11.5; HRMS (EI): 
calcd for C14H18O3Br2, 391.9623; found 391.9635. 
3-benzyl-6-(1,1-dibromoprop-1-en-2-yl)-4-methoxy-2H-pyran-2-one (2-
10n). The residue was purified using flash chromatography (EtOAc:hexane = 
1:3) to afford 2-10n (0.380 g, 92%) as a white solid.   1H NMR (500 MHz, 
CDCl3) δ 7.36-7.35 (m, 2H), 7.28-7.24 (m, 2H), 7.19-7.17 (m, 1H), 6.44 (s, 
1H), 3.91 (s, 3H), 3.78 (s, 2H), 2.14 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
164.9, 164.0, 158.4, 139.6, 135.2, 128.7, 128.2, 126.0, 106.9, 98.2, 94.6, 56.6, 
29.2, 22.7; HRMS (EI): calcd for C16H14O3Br2, 413. 9289; found 413.9298. 
6-(1,1-dibromoprop-1-en-2-yl)-3-hexyl-4-methoxy-2H-pyran-2-one (2-
10o). The residue was purified using flash chromatography (EtOAc:hexane = 
1:6) to afford 2-10o (0.318 g, 81%) as a colorless sticky liquid. 1H NMR (500 
MHz, CDCl3) δ 6.39 (s, 1H), 3.85 (s, 3H), 2.39 (t, J = 7.5 Hz, 2H), 2.11 (s, 3H), 
1.44-1.41 (m, 2H), 1.26-1.25 (m, 6H), 0.83 (t, J = 5.7 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ 164.5, 164.1, 157.7, 135.3, 108.2, 98.1, 94.3, 56.3, 31.6, 29.1, 
27.6, 23.5, 22.6, 22.5, 14.0; HRMS (EI): calcd for C15H20O3Br2, 405.9779; 
found 405.9780. 
6-(1,1-dibromoprop-1-en-2-yl)-4-ethoxy-3-methyl-2H-pyran-2-one (2-
10p). The residue was purified using flash chromatography (EtOAc:hexane = 
1:3) to afford 2-10p (0.266 g, 76%) as a white solid.    1H NMR (500 MHz, 
CDCl3) δ 6.37 (s, 1H), 4.13 (q, J = 6.9 Hz, 2H), 2.13 (s, 3H), 1.92 (s, 3H), 1.41 
(t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 164.6, 164.0, 157.4, 135.4, 
103.5, 98.8, 94.3, 65.0, 22.7, 14.8, 8.8; HRMS (EI): calcd for C11H12O3Br2, 




10q). The residue was purified using flash chromatography (EtOAc:hexane = 
1:6) to afford 2-10q (0.320 g, 79%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 6.35 (s, 1H), 4.11 (q, J = 6.9 Hz, 2H), 2.42 (t, J = 7.6 Hz, 2H), 2.12 (s, 
3H), 1.47-1.37 (m, 5H), 1.35-1.28 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR 
(125 MHz, CDCl3) δ 164.3, 164.0, 157.6, 135.4, 108.2, 98.8, 94.2, 64.9, 29.8, 
23.2, 22.6, 22.5, 14.7, 13.9; HRMS (EI): calcd for C14H18O3Br2, 391.9623; 
found 391.9640. 
General Procedure for the Synthesis of 2-2a to 2-2q. To a solution of the 
corresponding pyrone 2-10 (0.80 mmol) and triethylamine (0.364 g, 3.60 mmol) 
in DMF (1.5 mL) was added dimethylphosphite (0.352g, 3.20 mmol). The 
reaction mixture was stirred at room temperature for 1 h following which water 
was added to the mixture and extracted with Et2O. The combined organic 
extract was washed with saturated NaCl solution, dried over MgSO4, 
concentrated under reduced pressure and purified by column chromatography. 
(E)-6-(2-bromovinyl)-4-methoxy-2H-pyran-2-one (2-2a). The residue was 
purified using flash chromatography (EtOAc:hexane = 1:2) to afford 2-2a 
(0.181 g, 98%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.29 (d, J = 
13.9 Hz, 1H), 6.62 (d, J = 13.3 Hz, 1H), 5.83 (d, J = 2.5 Hz, 1H), 5.49 (d, J = 
2.6 Hz, 1H), 3.80 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 170.5, 163.1, 156.3, 
128.2, 116.3, 101.4, 89.5, 56.0; HRMS (EI): calcd for C8H7O3Br, 229.9579; 
found 229.9585. 
(E)-6-(2-bromovinyl)-4-methoxy-3-methyl-2H-pyran-2-one (2-2b). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:4) to 
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afford 2-2b (0.182 g, 93%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.27 (d, J = 13.2 Hz, 1H), 6.64 (d, J = 13.3 Hz, 1H), 6.05 (s, 1H), 3.87 (s, 3H), 
1.89 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 165.0, 164.0, 154.9, 128.5, 115.4, 
104.0, 96.0, 56.3, 8.8; HRMS (EI): calcd for C9H9O3Br, 243.9735; found 
243.9746.  
(E)-6-(2-bromovinyl)-3-butyl-4-methoxy-2H-pyran-2-one (2-2c). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:6) to 
afford 2-2c (0.218 g, 95%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.28 
(d, J = 13.9 Hz, 1H), 6.66 (d, J = 13.3 Hz, 1H), 6.08 (s, 1H), 3.87 (s, 3H), 2.41 
(t, J = 7.6 Hz, 2H), 1.47-1.41 (m, 2H), 1.36-1.29 (m, 2H), 0.91 (t, J = 7.3 Hz, 
3H); 13C NMR (125 MHz, CDCl3) δ 165.0, 163.8, 155.1, 128.6, 115.4, 108.9, 
96.2, 56.3, 30.0, 23.4, 22.6, 13.9; HRMS (EI): calcd for C12H15O3Br, 286.0205; 
found 286.0200. 
(E)-3-benzyl-6-(2-bromovinyl)-4-methoxy-2H-pyran-2-one (2-2d). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:5) to 
afford 2-2d (0.210 g, 82%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.32-7.22 (m, 5H), 7.18-7.15 (m, 1H), 6.64 (d, J = 13.9 Hz, 1H), 6.06 (s, 1H), 
3.88 (s, 3H), 3.76 (s, 2H); 13C NMR (125 MHz, CDCl3) δ 165.3, 163.6, 155.7, 
139.6, 128.6, 128.4, 128.2, 126.0, 116.0, 107.5, 96.1, 56.4, 29.3; HRMS (EI): 
calcd for C15H13O3Br, 320.0048; found 320.0039. 
(E)-6-(2-bromovinyl)-3-hexyl-4-methoxy-2H-pyran-2-one (2-2e). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:6) to 
afford 2-2e (0.226 g, 90%) as a white solid.  1H NMR (500 MHz, CDCl3) δ 
7.25 (d, J = 13.9 Hz, 1H), 6.63 (d, J = 13.9 Hz, 1H), 6.05 (s, 1H), 3.84 (s, 3H), 
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2.38 (t, J = 7.9 Hz, 2H), 1.43-1.30 (m, 2H), 1.29-1.25 (m, 6H), 0.85 (t, J = 6.3 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 164.9, 163.7, 155.0, 128.5, 115.3, 
108.9, 96.1, 56.2, 31.6, 29.1, 27.8, 23.6, 22.5, 14.0; HRMS (EI): calcd for 
C14H19O3Br, 314.0518; found 314.0517. 
(E)-6-(2-bromovinyl)-4-ethoxy-2H-pyran-2-one (2-2f). The residue was 
purified using flash chromatography (EtOAc:hexane = 1:3) to afford 2-2f 
(0.178 g, 91%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 
13.9 Hz, 1H), 6.61 (d, J = 13.9 Hz, 1H), 5.81 (d, J = 1.9 Hz, 1H), 5.45 (d, J = 
1.9 Hz, 1H), 4.00 (q, J = 6.9 Hz, 2H), 1.39 (t, J = 7.0 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ 169.7, 163.2, 156.1, 128.2, 116.0, 101.6, 89.8, 64.8, 13.9;  
HRMS (EI): calcd for C9H9O3Br, 243.9735; found 243.9736. 
(E)-6-(2-bromovinyl)-4-ethoxy-3-methyl-2H-pyran-2-one (2-2g). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:3) to 
afford 2-2g (0.171 g, 83%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.25 (d, J = 13.3 Hz, 1H), 6.62 (d, J = 13.9 Hz, 1H), 6.02 (s, 1H), 4.10 (q, J = 
6.9 Hz, 2H), 1.98 (s, 3H), 1.40 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) 
δ 164.4, 164.1, 154.7, 128.5, 115.2, 104.0, 96.7, 64.9, 14.7, 8.9; HRMS (EI): 
calcd for C10H11O3Br, 257.9892; found 257.9890 
 (E)-6-(2-bromovinyl)-3-butyl-4-ethoxy-2H-pyran-2-one (2-2h). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:4) to 
afford 2-2h (0.192 g, 80%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.25 (d, J = 13.9 Hz, 1H), 6.62 (d, J = 13.9 Hz, 1H), 6.01 (s, 1H), 4.09 (q, J = 
6.9 Hz, 2H), 2.41 (t, J = 7.6 Hz, 2H), 1.46-1.38 (m, 5H), 1.35-1.27 (m, 2H), 
0.89 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 164.4, 163.8, 154.9, 
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128.6, 115.2, 108.9, 96.8, 64.8, 29.9, 23.3, 22.5, 14.7, 13.9; HRMS (EI): calcd 
for C13H17O3Br, 300.0361; found 300.0355. 
(E)-6-(1-bromoprop-1-en-2-yl)-4-methoxy-2H-pyran-2-one (2-2i). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:4) to 
afford 2-2i (0.180 g, 92%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.34 
(d, J = 1.3 Hz, 1H), 6.02 (d, J = 1.9 Hz, 1H), 5.49 (d, J = 1.9 Hz, 1H), 3.82 (s, 
3H), 2.03 (d, J = 1.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 170.8, 163.3, 
158.3, 131.5, 115.5, 99.1, 89.1, 56.0, 15.6; HRMS (EI): calcd for C9H9O3Br, 
243.9735; found 243.9741.  
(E)-6-(1-bromoprop-1-en-2-yl)-4-methoxy-3-methyl-2H-pyran-2-one (2-
2j). The residue was purified using flash chromatography (EtOAc:hexane = 1:4) 
to afford 2-2j (0.196 g, 95%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.33 (d, J = 1.3 Hz, 1H), 6.21 (s, 1H), 3.91 (s, 3H), 2.07 (d, J = 1.3 Hz, 3H), 
1.91 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 165.2, 164.2, 157.0, 131.8, 114.9, 
103.6, 93.4, 56.2, 15.7, 8.7; HRMS (EI): calcd for C10H11O3Br, 257.9892; 
found 257.9892.  
(E)-6-(1-bromobut-1-en-2-yl)-4-methoxy-3-methyl-2H-pyran-2-one (2-
2k). The residue was purified using flash chromatography (EtOAc:hexane = 
1:5) to afford 2-2k (0.205 g, 94%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 7.22 (s, 1H), 6.23 (s, 1H), 3.89 (s, 3H), 2.53 (q, J = 7.6 Hz, 2H), 1.89 
(s, 3H), 1.09 (t, J = 7.6 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 165.3, 164.4, 
156.5, 137.9, 114.1, 103.5, 93.4, 56.3, 23.2, 12.3, 8.7; HRMS (EI): calcd for 




2l). The residue was purified using flash chromatography (EtOAc:hexane = 1:8) 
to afford 2-2l (0.232 g, 96%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.32 (d, J = 1.3 Hz, 1H), 6.20 (s, 1H), 3.89 (s, 3H), 2.41 (t, J = 7.6 Hz, 2H), 
2.06 (d, J = 1.3 Hz, 1H), 1.46-1.39 (m, 2H), 1.35-1.28 (m, 2H), 0.89 (t, J = 7.3 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 165.2, 163.9, 157.2, 131.8, 114.8, 
108.4, 93.5, 56.2, 30.0, 23.2, 22.6, 15.7, 13.9; HRMS (EI): calcd for 
C13H17O3Br, 300.0361; found 300.0357. 
(E)-6-(1-bromobut-1-en-2-yl)-3-butyl-4-methoxy-2H-pyran-2-one (2-
2m). The residue was purified using flash chromatography (EtOAc:hexane = 
1:8) to afford 2-2m (0.231 g, 92%) as a colorless sticky liquid. 1H NMR (500 
MHz, CDCl3) δ 7.25 (s, 1H), 6.25 (s, 1H), 3.91 (s, 3H), 2.56 (q, J = 7.6 Hz, 
2H), 2.43 (t, J = 7.6 Hz, 2H), 1.48-1.42 (m, 2H), 1.38-1.30 (m, 2H), 1.13 (t, J = 
7.6 Hz, 3H), 0.92 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 165.2, 
164.0, 156.6, 137.9, 114.0, 108.4, 93.4, 56.2, 30.0, 23.2, 23.1, 22.6, 13.9, 12.2; ; 
HRMS (EI): calcd for C14H19O3Br, 314.0518; found 314.0515. 
(E)-3-benzyl-6-(1-bromoprop-1-en-2-yl)-4-methoxy-2H-pyran-2-one (2-
2n). The residue was purified using flash chromatography (EtOAc:hexane = 
1:6) to afford 2-2n (0.238 g, 89%) as a white solid. 1H NMR (500 MHz, CDCl3) 
δ 7.37-7.33 (m, 3H), 7.29-7.25 (m, 2H), 7.20-7.17 (m, 1H), 6.25 (s, 1H), 3.95 
(s, 3H), 3.79 (s, 2H), 2.10 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 165.5, 163.7, 
157.8, 139.7, 131.8, 128.6, 128.2, 126.0, 115.3, 107.1, 93.5, 56.4, 29.2, 15.7; 




2o). The residue was purified using flash chromatography (EtOAc:hexane = 
1:8) to afford 2-2o (0.241 g, 92%) as a white solid.  1H NMR (500 MHz, 
CDCl3) δ 7.31 (s, 1H), 6.20 (s, 1H), 3.89 (s, 3H), 2.39 (t, J = 7.6 Hz, 2H), 2.06 
(s, 3H), 1.44-1.41 (m, 2H), 1.30-1.27 (m, 6H), 0.86 (t, J = 6.3 Hz, 3H); 13C 
NMR (125 MHz, CDCl3) δ 165.2, 163.8, 157.2, 131.8, 114.8, 108.4, 93.5, 56.2, 
31.7, 29.2, 27.8, 23.5, 22.6, 15.7, 14.0; HRMS (EI): calcd for C15H21O3Br, 
328.0674; found 328.0665. 
(E)-6-(1-bromoprop-1-en-2-yl)-4-ethoxy-3-methyl-2H-pyran-2-one (2-
2p). The residue was purified using flash chromatography (EtOAc:hexane = 
1:4) to afford 2-2p (0.196 g, 90%) as a white solid. 1H NMR (500 MHz, CDCl3) 
δ 7.29 (s, 1H), 6.17 (s, 1H), 4.13 (q, J = 7.1 Hz, 2H), 2.04 (s, 3H), 1.89 (s, 3H), 
1.41 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 164.7, 164.3, 156.8, 
131.7, 114.6, 103.5, 94.1, 64.9, 15.6, 14.7, 8.8; HRMS (EI): calcd for 
C11H13O3Br , 272.0048; found 272.0044. 
(E)-6-(1-bromoprop-1-en-2-yl)-3-butyl-4-ethoxy-2H-pyran-2-one (2-2q). 
The residue was purified using flash chromatography (EtOAc:hexane = 1:4) to 
afford 2-2q (0.216 g, 86%) as a white solid.  1H NMR (500 MHz, CDCl3) δ 
7.30 (s, 1H), 6.17 (s, 1H), 4.13 (q, J = 6.9 Hz, 2H), 2.42 (t, J = 7.3 Hz, 2H), 
2.05 (s, 3H), 1.47-1.39 (m, 5H), 1.35-1.28 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 164.6, 163.9, 157.0, 131.8, 114.7, 108.4, 94.2, 
64.8, 30.0, 23.1, 22.5, 15.7, 14.7, 13.9; HRMS (EI): calcd for C14H19O3Br, 
314.0518; found 314.0516. 
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General Procedure for the Synthesis of 2-2r and 2-2s. Acetic acid (1 mL) 
and 45% aqueous HBr (1 mL) were added to 2-2a or 2-2b (0.500 mmol) and 
the mixture was stirred at 90 °C for 45 min and 2 h for 2-2a and 2-2b 
respectively. Thereafter, the mixture was cooled to room temperature and 3 M 
aqueous NaOH was added until the reaction mixture achieved pH 4~5. 
Saturated NaCl solution (5 mL) was then added and the mixture was extracted 
with EtOAc. The combined organic extract was dried over MgSO4 and purified 
using flash chromatography (MeOH:CH2Cl2 = 1:30 with 0.5% AcOH).  
(E)-6-(2-bromovinyl)-4-hydroxy-2H-pyran-2-one (2-2r). 2-2r (76 mg, 
70%) was obtained as a brown solid. 1H NMR (500 MHz, Acetone-d6) δ 7.31-
7.28 (d, J = 13.9 Hz, 1H), 6.94 (d, J = 13.9 Hz, 1H), 6.19 (d, J = 1.9 Hz, 1H), 
5.45 (d, J = 1.9 Hz, 1H); 13C NMR (125 MHz, Acetone-d6) δ 169.1, 162.0, 
156.8, 128.7, 114.3, 101.2, 90.7; HRMS (EI): calcd for C7H5O3Br, 215.9422; 
found 215.9421.  
(E)-6-(2-bromovinyl)-4-hydroxy-3-methyl-2H-pyran-2-one (2-2s). 2-2s 
(0.106 g, 92%) was obtained as a brown solid. 1H NMR (500 MHz, DMSO-d6) 
δ 11.4, (br, 1H), 7.24 (d, J = 13.9 Hz, 1H), 7.06 (d, J = 13.9 Hz, 1H), 6.23 (s, 
1H), 1.77 (s, 3H); 13C NMR (125 MHz, DMSO-d6) δ 164.2, 163.5, 153.5, 
129.1, 113.9, 101.7, 99.6, 8.7; HRMS (EI): calcd for C8H7O3Br, 229.9579; 
found 229.9589. 
Synthesis of N-(3-bromopropyl)-5-(dimethylamino)naphthalene-1-
sulfonamide (2-12). To dansyl chloride (0.270 g, 1.00 mmol) and compound 
2-11 (0.438 g, 2.00 mmol) in DMF (2 mL) was added triethylamine (0.202 g, 
2.00 mmol). The reaction mixture was stirred at room temperature for 20 min 
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after which water was added and the mixture was extracted with Et2O. The 
combined organic extract organic extract was washed with saturated NaCl 
solution, dried over MgSO4 and concentrated. The residue was purified using 
flash chromatography (EtOAc:hexane = 1:3) to afford 2-12 (0.368 g, 99%) as a 
yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.56 (d, J = 8.9 Hz, 1H), 8.30-8.25 
(m, 2H), 7.58-7.51 (m, 2H), 7.19 (d, J = 7.6 Hz, 1H), 5.00 (t, J = 6.6 Hz, 2H), 
3.30 (t, J = 6.3 Hz, 2H), 3.08-3.04 (m, 2H), 2.89 (s, 6H), 1.96-1.91 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ 152.1, 134.4, 130.6, 129.9, 129.7, 129.5, 128.5, 
123.2, 118.5, 115.2, 45.4, 41.4, 32.3, 30.1; HRMS (EI): calcd for 
C15H19N2O2BrS , 370.0351; found 370.0341. 
Synthesis of  tert-butyl 3-(2-hydroxyethoxy)propylcarbamate (2-14). 
60% NaH in mineral oil (0.192 g, 4.80 mmol) was added to ethylene glycol 
(0.297 g, 4.80 mmol) in DMF. After the evolution of hydrogen gas had ceased, 
compound 2-13 (0.571 g, 2.40 mmol) was added and the reaction mixture was 
stirred overnight at room temperature. EtOAc was added and the mixture was 
washed with H2O thrice followed by saturated NaCl. The organic layer was 
dried over MgSO4, concentrated and purified using flash chromatography 
(EtOAc:hexane = 1:1) to afford 2-14 (0.273 g, 54%) as a colorless liquid. 1H 
NMR (500 MHz, CDCl3) δ 4.92 (s, 1H), 3.67 (t, J = 4.7 Hz, 2H), 3.52-3.47 (m, 
4H), 3.19 (s, 2H), 2.82 (s, 1H), 1.73-1.68 (m, 2H), 1.39 (s, 9H); 13C NMR (125 
MHz, CDCl3) δ 156.1, 79.0, 72.3, 68.6, 61.5, 37.8, 29.8, 28.3; HRMS (EI): 
calcd for C10H21NO4, 219.1471; found 219.1474. 
Synthesis of 5-(dimethylamino)-N-(3-(2-
hydroxyethoxy)propyl)naphthalene-1-sulfonamide (2-15). TFA (0.50 mL) 
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was added to 2-14 (0.262 g, 1.20 mmol) in CH2Cl2 and stirred for 1 h at room 
temperature and after which TFA and CH2Cl2 were removed under reduced 
pressure. To the residue was added CH2Cl2 (2 mL), dansyl chloride (0.389 g, 
1.44 mmol) and triethylamine (0.30 mL) and the reaction mixture was stirred at 
room temperature for 30 min. Water was added and the mixture was extracted 
with EtOAc. The combined organic extract was washed with saturated NaCl 
solution, dried over MgSO4 and purified using flash chromatography to afford 
2-15 (0.321 g, 76%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.51 (d, J 
= 8.8 Hz, 1H), 8.31 (d, J = 8.2, 1H), 8.22-8.20 (m, 1H), 7.54-7.47 (m, 2H), 
7.15 (d, J = 7.6 Hz, 1H), 5.78 (t, J = 6.0 Hz, 1H), 3.65 (t, J = 4.7 Hz, 2H), 3.41-
3.37 (m, 4H), 3.03-2.99 (m, 2H), 2.86 (s, 6H), 1.66-1.62 (m, 2H); 13C NMR 
(125 MHz, CDCl3) δ 151.8, 134.8, 130.2, 129.8, 129.5, 129.3, 128.2, 123.1, 
118.9, 115.1, 71.9, 68.9, 61.5, 45.3, 41.3, 28.9; HRMS (EI): calcd for 
C17H24N2O4S, 352.1457; found 352.1451. 
Synthesis of N-(3-(2-bromoethoxy)propyl)-5-
(dimethylamino)naphthalene-1-sulfonamide (2-16). CBr4 (0.370 g, 1.12 
mmol) in CH2Cl2 (2 mL) was added to a solution of 2-15 (0.282 g, 0.80 mmol) 
and PPh3 (0.587 g, 2.24 mmol) in CH2Cl2 (4 mL) and stirred at room 
temperature for 1 h. The solvent was removed under reduced pressure and the 
residue purified using flash chromatography (EtOAc:hexane = 1:3) to afford 2-
16 (0.249 g, 75%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.52 (d, J = 
8.2 Hz, 1H), 8.33 (d, J = 8.2 Hz, 1H), 8.2 (d, J = 7.0 Hz, 1H), 7.55-7.48 (m, 
2H), 7.17 (d, J = 7.6 Hz, 1H), 5.46 (s, 1H), 3.54 (m, 2H), 3.39-3.31 (m, 4H), 
3.04-3.01 (m, 2H), 2.87 (s, 6H), 1.66-1.64 (m, 2H); 13C NMR (125 MHz, 
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CDCl3) δ 151.8, 134.7, 130.2, 129.8, 129.5, 129.4, 128.2, 123.1, 118.9, 115.1, 
70.4, 69.2, 45.3, 41.5, 30.4, 28.9; HRMS (EI): calcd for C17H23N2O3BrS, 
414.0607; found 414.0613. HRMS (EI): calcd for C17H23N2O3BrS, 414.0613; 
found 414.0607. 
General Procedure for the Synthesis of 2-2t and 2-2u Compounds 2-12 
or 2-16 (0.39 mmol) was added to a mixture of 2-2r (0.30 mmol) and K2CO3 
(0.39 mmol) in DMSO and stirred at 85 °C for 45 min. Water was added and 
the mixture was extracted with Et2O. The combined organic extract was 
washed with saturated NaCl solution, dried over MgSO4 and purified using 
flash chromatography. 
(E)-N-(3-(6-(2-bromovinyl)-2-oxo-2H-pyran-4-yloxy)propyl)-5-
(dimethylamino)naphthalene-1-sulfonamide (2-2t). The residue was purified 
using flash chromatography to afford 2-2t (79.0 mg, 52%) as a pale yellow 
solid. 1H NMR (500 MHz, CDCl3) δ 8.49 (d, J = 8.8 Hz, 1H), 8.28 (d, J = 8.8 
Hz, 1H), 8.23 (d, J = 8.2 Hz, 1H), 7.51-7.47 (m, 2H), 7.24 (d, J = 13.9 Hz, 1H), 
7.14 (d, J = 7.6 Hz, 1H), 6.54 (d, J = 13.3 Hz, 1H), 5.62-5.57 (m, 2H), 5.19 (d, 
J = 1.9 Hz, 1H), 3.78 (t, J = 6.0 Hz, 2H), 3.09-3.06 (m, 2H), 2.86 (m, 6H), 
1.86-1.81 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 169.3, 163.0, 156.0, 152.0, 
134.2, 130.6, 129.8, 129.7, 129.5, 128.4, 128.1, 122.9, 118.4, 116.1, 115.1, 
101.3, 89.9, 65.7, 45.3, 39.4, 28.2; HRMS (EI): calcd for C22H23N2O5BrS , 
506.0511; found 506.0518. 
(E)-N-(3-(2-(6-(2-bromovinyl)-2-oxo-2H-pyran-4-yloxy)ethoxy)propyl)-
5-(dimethylamino)naphthalene-1-sulfonamide (2-2u). The residue was 
purified using flash chromatography to afford 2-2u (82.7 mg, 50%) as a pale 
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yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.52 (d, J = 8.2 Hz, 1H), 8.27 (d, J 
= 8.8 Hz, 1H), 8.21 (d, J = 6.3 Hz, 1H), 7.51-7.47 (m, 2H), 7.23 (d, J = 13.9 Hz, 
1H), 7.15 (d, J = 7.6 Hz, 1H), 6.57 (d, J = 13.9 Hz, 1H), 6.02 (d, J = 1.9 Hz, 
1H), 5.62 (t, J = 5.7 Hz, 1H), 5.49 (d, J = 2.6 Hz, 1H), 4.01 (t, J = 4.4 Hz, 2H), 
3.61 (t, J = 4.4 Hz, 2H), 3.45 (t, J = 5.7 Hz, 2H), 3.04-3.00 (m, 2H), 2.87 (s, 
6H), 1.69-1.64 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 169.8, 163.1, 156.3, 
151.9, 134.7, 130.3, 129.8, 129.6, 129.5, 128.3, 128.1, 123.1, 118.7, 116.1, 
115.1, 101.6, 90.0, 69.9, 68.0, 68.0, 45.3, 41.8, 28.6; HRMS (ESI) [M+Na]+: 
calcd for C24H27N2O6BrS, 573.0665; found 573.0656. 
Synthesis of methyl 3-chloro-1H-pyrrole-2-carboxylate (2-19). 2-Methyl-
1-pyrroline 2-17 (0.831 g, 10.0 mmol) was added to a suspension of N-
cholorosuccinimide (10.7 g, 80.0 mmol) in THF (25 mL) and the reaction 
mixture was heated at 55 °C for 20 min. After the reaction mixture was cooled 
to room temperature, water was added and the mixture was extracted with 
hexane. The combined organic extract was concentrated under reduced 
pressure to afford 2-18 which was directly used for the next step. Compound 2-
18 was dissolved in MeOH (10 mL) and cooled to 0 °C. 3 M MeONa in MeOH 
(20 mL, 60.0 mmol) was added dropwise over 5 min and thereafter, the 
reaction mixture was warmed to room temperature and stirred for an additional 
30 min. The mixture was acidified using 2 M HCl and extracted with EtOAc. 
The combined organic extract was washed with saturated NaCl solution, dried 
over MgSO4, concentrated and the residue purified using flash chromatography 
(EtOAc:hexane = 1:4) to afford 2-19 (1.50 g, 94%) as a yellow solid. 1H NMR 
(500 MHz, CDCl3) δ 9.56 (br, 1H), 6.86 (s, 1H), 6.23 (s, 1H), 3.89 (s, 3H); 13C 
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NMR (125 MHz, CDCl3) δ 160.9, 122.0, 119.2, 118.2, 111.9, 51.6; HRMS (EI): 
calcd for C6H6NO2Cl, 159.0087; found 159.0088. 
Synthesis of 3-chloro-1H-pyrrole-2-carbaldehyde (2-20). 2 M LiAlH4 in 
THF solution (4.80 mL, 9.60 mmol) was added dropwise to 2-19 (1.28 g, 8.00 
mmol) in THF (15 mL) at -20 °C. The reaction mixture was warmed to 0 °C 
and stirred for 30 min before quenching with EtOAc (5 mL). Water (20 mL) 
and 2 M aqueous NaOH (20 mL) was added to the reaction mixture and the 
solid formed was filtered and washed with EtOAc. The filtrate was extracted 
with EtOAc and the combined organic extract was washed with saturated NaCl 
solution and then concentrated to obtain the crude alcohol product. 2-
iodoxybenzoic acid (5.60 g, 20.0 mmol) was dissolved in DMSO (20 mL) 
before the addition of NaHCO3 (4.03 g, 48.0 mmol) and the crude alcohol 
product. The mixture was stirred at room temperature for 16 h and quenched 
with 0.5 M aqueous NaOH (150 mL). The solid was filtered and washed with 
EtOAc and the filtrate was extracted with EtOAc. The combined organic 
extract was washed with saturated NaCl solution, dried over MgSO4, 
concentrated and the residue was purified using flash chromatography 
(EtOAc:hexane = 1:3) to afford 2-20 (0.777 g, 75%) as a pale brown solid. 1H 
NMR (500 MHz, CDCl3) δ 10.7 (br, 1H), 9.63 (s, 1H), 7.10-7.08 (m, 1H), 
6.29-6.28 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 177.8, 127.7, 126.3, 125.3, 
111.6; HRMS (EI): calcd for C5H4NO2Cl, 128.9981; found 129.9977. 
Synthesis of 3-chloro-1-(methylsulfonyl)-1H-pyrrole-2-carbaldehyde (2-
21). 60% NaH in mineral oil (0.132 g, 3.30 mmol) was added to 2-20 (0.388 g, 
3.00 mmol) in THF portionwise. After evolution of hydrogen gas had ceased, 
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methanesulfonyl chloride (0.378 g, 3.30 mmol) was added and the reaction 
mixture was stirred at room temperature for 20 min. Subsequently, the solvent 
was removed and the residue was purified by flash chromatography 
(EtOAc:hexane = 1:3) to afford 2-21 (0.573 g, 92%) as a pale brown solid. 1H 
NMR (500 MHz, CDCl3) δ 9.83 (s, 1H), 7.58-7.57 (d, J = 3.2 Hz, 1H), 6.37 (d, 
J = 3.2 Hz, 1H), 3.68 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 176.8, 132.5, 
129.2, 127.2, 112.2, 42.9; HRMS (EI): calcd for C6H6NO3ClS, 206.9757; 
found 206.9755. 
Synthesis of ethyl 3-chlorothiophene-2-carboxylate (2-23), To a solution 
of 2-acetyl-3-chlorothiophene 2-22 (0.321 g, 2.00 mmol) in EtOH was added 
CuO (0.318 g , 4.00 mmol), I2 (1.02 g , 4.00 mmol) and pyridine (0.632 g, 8.00 
mmol) and the mixture was refluxed for 16 h. After which, K2CO3 (0.552 g, 
4.00 mmol) was added carefully and the mixture was refluxed for an additional 
2 h. The mixture was then cooled to room temperature, filtered and the filtrate 
was concentrated under reduced pressure. 5% Na2S2O3 was added to the 
residue and the reaction mixture was extracted with EtOAc. The combined 
organic extract was dried over MgSO4, concentrated and purified using flash 
chromatography (EtOAc:hexane = 1:20) to afford 2-23 (0.294 g, 77%) as a 
yellow syrup. 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 5.7 Hz, 1H), 6.99 (d, 
J = 5.1 Hz, 1H), 4.34 (q, J = 7.1 Hz, 2H), 1.36 (t, J = 7.0 Hz, 3H); 13C NMR 
(125 MHz, CDCl3) δ 160.6, 131.3, 130.1, 130.1, 125.9, 61.3, 14.2; HRMS (EI): 
calcd for C7H7O2ClS, 189.9855; found 189.9858.  
Synthesis of 3-chlorothiophene-2-carbaldehyde (2-24). 2 M LiAlH4 in 
THF solution (0.912 mL, 1.83 mmol) was added dropwise to 2-23 (0.290 g, 
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1.52 mmol) in THF (6 mL) at 0 °C. The reaction mixture was stirred for 30 
min before quenching with EtOAc (2 mL). Water (10 mL) and 2 M aqueous 
NaOH (10 mL) was added to the reaction mixture and the solid that formed 
was filtered and washed with EtOAc. The filtrate was extracted with EtOAc 
and the combined organic extract was washed with saturated NaCl solution and 
concentrated. The residue obtained was dissolved in CH2Cl2 (8 mL). DMP 
(0.776 g, 1.83 mmol) was added and the reaction mixture was stirred at room 
temperature for 30 min. Subsequently, saturated NaHCO3 solution (5 mL) and 
15% Na2S2O3 solution (5 mL) was added and the mixture was allowed to stir 
for an additional 15 min. After which, the mixture was extracted with CH2Cl2 
and the combined organic extract was dried over MgSO4 and concentrated. The 
residue was purified using flash chromatography (EtOAc:hexane = 1:15) to 
afford 2-24 (0.189 g, 85%) as a pale yellow liquid. 1H NMR (500 MHz, CDCl3) 
δ 10.0, (s, 1H), 7.71 (d, J = 5.0 Hz, 1H), 7.06(d, J = 5.1 Hz, 1H); 13C NMR 
(125 MHz, CDCl3) δ 181.7, 135.6, 134.4, 134.2, 129.4; HRMS (EI): calcd for 
C5H3OClS, 145.9593; found 145.9592. 
General Procedures for the Synthesis of 2-26a to 2-26d. CBr4 (0.345 g, 
1.04 mmol) in CH2Cl2 (2 mL) was added to a solution of PPh3 (0.545 g, 2.08 
mmol) and 2-21, 2-24, 2-25a or 2-25b (0.800 mmol) in CH2Cl2 (4 mL). The 
mixture was stirred at room temperature for 30 min, concentrated and purified 
by column chromatography 
3-chloro-2-(2,2-dibromovinyl)-1-(methylsulfonyl)-1H-pyrrole (2-26a). 
The residue was purified using flash chromatography (EtOAc:hexane = 1:10) 
to afford 2-26a (0.194 g, 85%) as a pale brown solid. 1H NMR (500 MHz, 
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CDCl3) δ 7.40 (s, 1H), 7.19 (d, J = 3.2 Hz, 1H), 6.33 (d, J = 3.8 Hz, 1H), 3.13 
(s, 3H); 13C NMR (125 MHz, CDCl3) δ 126.1, 124.7, 122.1, 119.3, 113.4, 98.5, 
42.9; HRMS (EI): calcd for C7H6NO2Br2ClS, 360.8175; found 360.8177. 
3-chloro-2-(2,2-dibromovinyl)thiophene (2-26b). The residue was purified 
using flash chromatography (EtOAc:hexane = 1:60) to afford 2-26b (0.205 g, 
92%) as a pale yellow liquid. 1H NMR (500 MHz, CDCl3) δ 7.78 (s, 1H), 7.38 
(d, J = 5.7 Hz, 1H), 6.96 (d, J = 5.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 
130.9, 128.1, 127.2, 127.0, 126.1, 89.0; calcd for C6H3Br2ClS, 299.8011; found 
299.8013.  
1-chloro-2-(2,2-dibromovinyl)benzene (2-26c). The residue was purified 
using flash chromatography with hexane as the eluent to afford 2-26c (0.226 g, 
95%) as a pale yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.65-7.64 (m, 1H), 
7.57 (s, 1H), 7.41-7.39 (m, 1H), 7.30-7.28 (m, 2H); 13C NMR (125 MHz, 
CDCl3) δ 134.4, 134.1. 133.0. 130.1. 129.7. 129.5. 126.5. 92.8; HRMS (EI): 
calcd for C8H5Br2Cl, 293.8447; found 293.8443.  
1-chloro-3-(2,2-dibromovinyl)benzene (2-26d). The residue was purified 
using flash chromatography with hexane as the eluent to afford 2-26d (0.228 g, 
96%) as a pale yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.54 (s, 1H), 7.43 (s, 
1H), 7.40-7.39 (m, 1H), 7.31-7.30 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 
136.9, 135.5, 134.3, 129.6, 128.6, 128.2, 126.6, 91.3; HRMS (EI): calcd for 
C8H5Br2Cl, 293.8447; found 293.8443. 
General Procedure for the Synthesis of 2-4a to 2-4d. To a solution of 2-
26 (0.735 mmol) and triethylamine (0.334 g, 0.331 mmol) in DMF (1.5 mL) 
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was added dimethylphosphite (0.323 g, 0.294 mmol) and the reaction mixture 
was stirred at room temperature for 1 h. Thereafter, water was added to the 
mixture and extracted with Et2O. The combined organic extract was washed 
with saturated NaCl solution, dried over MgSO4, concentrated under reduced 
pressure and purified by column chromatography. 
2-(2-bromovinyl)-3-chloro-1-(methylsulfonyl)-1H-pyrrole (2-4a). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:10) to 
afford a pale brown solid 2-4a (0.147 g, 97%) as a mixture of E/Z isomers in 
ca. 2:1 ratio.  1H NMR (500 MHz, CDCl3) (mixture of E/Z isomers) δ 7.40 (d, 
J = 13.9 Hz, 1H), 7.19 (d J = 3.2 Hz, 1H), 7.16-7.13 (m, 1.8H), 6.77 (d, J = 7.6 
Hz, 0.4H), 6.34 (d, J = 3.2 Hz, 0.4 H), 6.30 (d, J = 3.8 Hz, 1H), 3.14 (s, 3H), 
3.08 (s, 1.3H); 13C NMR (125 MHz, CDCl3) (mixture of E/Z isomers) δ 125.2, 
124.2, 122.8, 122.6, 122.0, 121.6, 118.8, 117.5, 115.5, 113.6, 113.3, 112.6, 
42.8, 42.7; HRMS (EI): calcd for C7H7NO2BrClS, 282.9069; found 282.9069. 
2-(2-bromovinyl)-3-chlorothiophene (2-4b). The residue was purified 
using flash chromatography with hexane as the eluent to afford a pale yellow 
liquid 2-4b (0.150 g, 92%) as a mixture of E/Z isomers in ca 2:1 ratio. 1H 
NMR (500 MHz, CDCl3) δ 7.49 (d, J = 8.2 Hz, 0.4H), 7.44 (d, J = 5.7 Hz, 
0.4H), 7.30 (d, J = 13.9 Hz, 1H), 7.20 (d, J = 5.0 Hz, 1H), 7.02 (d, J = 5.7 Hz, 
0.4H), 6.92 (d, J = 5.1 Hz, 1H), 6.765 (d, J = 14.5 Hz, 1H), 6.48 (d, J = 8.2 Hz, 
0.4H) 13C NMR (125 MHz, CDCl3) δ 132.6, 131.0, 128.3, 127.4, 127.1, 127.0, 
125.9, 123.8, 123.8, 123.4, 107.2, 106.1; HRMS (EI): calcd for C6H4BrClS, 
221.8096; found 221.8095.  
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(E)-1-(2-bromovinyl)-2-chlorobenzene (2-4c). The residue was purified 
using flash chromatography with hexane as the eluent to afford 2-4c (0.150 g, 
94%) as a pale yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.48 (d, J = 13.9 Hz, 
1H), 7.41-7.36 (m, 2H), 7.24-7.22 (m, 2H), 6.81 (d, J = 13.9 Hz, 1H); 13C 
NMR (125 MHz, CDCl3) δ 134.1, 133.8, 132.5, 129.9, 129.3, 127.0, 126.9, 
109.2; HRMS (EI): calcd for C8H6BrCl, 215.9341; found 215.9342.  
(E)-1-(2-bromovinyl)-3-chlorobenzene (2-4d). The residue was purified 
using flash chromatography with hexane as the eluent to afford 2-4d (0.153 g, 
96%) as a pale yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.31-7.28 (m, 3H), 
7.20-7.19 (m, 1H), 7.07 (d, J = 13.9 Hz, 1H), 6.83 (d, J = 13.9 Hz, 1H); 13C 
NMR (125 MHz, CDCl3) δ 137.6, 135.9, 134.8, 130.0, 128.2, 126.0, 124.3, 
108.1; HRMS (EI): calcd for C8H6BrCl, 215.9341; found 215.9343. 
Synthesis of 2-((1E,3E,5E)-hepta-1,3,5-trienyl)-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane (2-28). A mixture of boronate 2-27 (1.27 g, 6.00 mmol) 
and 2,4-hexadienal (0.192 g, 2.00 mmol) in THF (3 mL) was added to a 
suspension of CrCl2 (2.46 g, 20.0 mmol) and LiI (1.61 g, 12.0 mmol) in THF 
(20 mL) and the mixture was stirred at room temperature for 6 h. Thereafter the 
reaction mixture was poured into water (120 mL) and the mixture was 
extracted with Et2O. The combined organic extract was washed with saturated 
NaCl solution,dried over MgSO4, concentrated under reduced pressure and the 
residue was purified using a short column (ca. 5 cm) of silica gel 
(EtOAc:hexane = 1:40) to afford 2-28 (0.361 g, 82%) as a pale yellow liquid. 
1H NMR (500 MHz, CDCl3) δ 7.01 (dd, J = 10.7, 17.7 Hz, 1H), 6.32 (dd, J = 
10.7, 15.1 Hz, 1H), 6.19-6.07 (m, 2H), 5.84-5.77 (m, 1H), 5.50 (d, J = 17.7 Hz, 
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1H), 1.80-1.77 (m, 3H), 1.26 (s, 12H); 13C NMR (125 MHz, CDCl3) δ 150.0, 
136.7, 132.5, 131.9, 131.5, 83.1, 24.7, 18.4; HRMS (EI): calcd for C13H21O2B, 
220.1635; found 220.1634. 
Synthesis of 4-methoxy-3-methyl-6-((1E,3E,5E,7E)-nona-1,3,5,7-
tetraenyl)-2H-pyran-2-one (2-29). Pd2dba3 (5.5 mg, 6.0 μmol) and AsPh3 (9.2 
mg, 30 μmol) was added to THF (2 mL), followed by 2-2b (48.6 mg, 0.200 
mmol) and 1.8 M aqueous KOH (0.222 mL, 0.400 mmol). 2-28 (48.4 mg, 
0.220 mmol) was dissolved in THF (0.5 mL) and added dropwise to the 
reaction mixture over 5 min with stirring. The reaction mixture was stirred for 
1 h at room temperature and quenched with saturated NH4Cl. EtOAc was 
added and the mixture was washed with H2O thrice followed by saturated NaCl 
solution. The organic extract was dried over MgSO4, concentrated under 
reduced pressure and the residue was purified using flash chromatography 
(acetone:CH2Cl2 = 1:100) to afford 2-29 (44.4 mg, 86%) as a yellow solid. 1H 
NMR (500 MHz, CDCl3) δ 7.18 (dd, J = 11.3, 15.1 Hz, 1H), 6.50 (dd, J = 11.4, 
14.5 Hz, 1H), 6.37-6.24 (m, 2H), 6.20-6.10 (m, 2H), 6.03-6.00 (m, 2H), 5.87-
5.80 (m, 1H), 3.87 (s, 3H), 1.94 (s, 3H), 1.81 (d, J = 7.0 Hz, 3H); 13C NMR 
(125 MHz, CDCl3) δ 165.7, 164.8, 157.6, 138.8, 136.5, 135.7, 132.5, 131.7, 
130.2, 129.8, 121.2, 102.6, 95.3, 56.1, 18.5, 8.8; HRMS (ESI) [M+Na]+: calcd 
for C16H18O3Na, 281.1154; found 281.1145. 
General Procedure for the Synthesis of 2-30. Pd2dba3 (5.5 mg, 6.0 µmol) 
and AsPh3 (7.3 mg, 24 µmol) were added to a mixture of the respective 
compound 2-2 (0.20 mmol) and 2-3 (0.169 g, 0.36 mmol) in NMP (1 mL) and 
allowed to stir at room temperature for 6 h. After which, water was added and 
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the mixture was extracted with Et2O. The combined organic extract was 
washed with saturated NaCl solution, dried over MgSO4 and concentrated. The 
residue obtained was dissolved in CH3CN (15 mL) and washed with pentane 
(15 mL x 5) to remove the tributyltin bromide byproduct. Following that, 
CH3CN was removed under reduced pressure and the residue was purified 
using a short column (ca. 5 cm) of silica gel. 
4-methoxy-6-((1E,3E,5E)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)hexa-1,3,5-trienyl)-2H-pyran-2-one (2-30a). The residue was purified 
using flash chromatography (EtOAc:hexane = 1:1) to afford 2-30a (48.2 mg, 
73%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 7.14 (dd, J = 10.7, 
15.1 Hz, 1H), 7.03 (dd, J = 10.7, 17.8 Hz, 1H), 6.51 (dd, J = 10.8, 14.5 Hz, 1H), 
6.41 (dd, J = 10.7, 14.5 Hz, 1H), 6.09 (d, J = 15.2 Hz, 1H), 5.84 (d, J = 1.9 Hz, 
1H), 5.70 (d, J = 17.7 Hz, 1H), 5.45 (d, J = 2.5 Hz, 1H), 3.79 (s, 3H), 1.26 (s, 
12H); 13C NMR (125 MHz, CDCl3) δ 170.8, 163.8, 158.3, 148.4, 139.5, 135.4, 
133.9, 123.5, 101.5, 88.9, 83.3, 55.9, 24.7; HRMS (ESI) [M+Na]+: calcd for 
C18H23O5BNa, 353.1536; found 353.1522. 
4-methoxy-3-methyl-6-((1E,3E,5E)-6-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hexa-1,3,5-trienyl)-2H-pyran-2-one (2-30b). The residue 
was purified using flash chromatography (EtOAc:hexane = 1:1) to afford 2-30b 
(48.8 mg, 71%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 7.14 (dd, J = 
10.7, 15.1 Hz, 1H), 7.04 (dd, J = 10.7, 17.7 Hz, 1H), 6.51 (dd, J = 10.7, 14.5 
Hz, 1H), 6.40 (dd, J = 11.4, 15.2 Hz, 1H), 6.12 (d, J = 15.1 Hz, 1H), 6.06 (s, 
1H), 5.74 (d, J =17.7 Hz, 1H), 3.85 (s, 3H), 1.92 (s, 3H), 1.26 (s, 12H); 13C 
NMR (125 MHz, CDCl3) δ 165.4, 164.5, 156.9, 148.4, 139.2, 134.7, 134.1, 
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123.9, 103.3, 96.2, 83.3, 56.1, 24.7, 8.8; HRMS (ESI) [M+Na]+: calcd for 
C19H25O5BNa, 367.1693; found 367.1685.  
3-butyl-4-methoxy-6-((1E,3E,5E)-6-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hexa-1,3,5-trienyl)-2H-pyran-2-one (2-30c). The residue 
was purified using flash chromatography (EtOAc:hexane = 1:2) to afford 2-30c 
(52.5 mg, 68%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 7.14 (dd, J = 
11.4, 15.1 Hz, 1H), 7.04 (dd, J = 10.8, 17.7 Hz, 1H), 6.51 (dd, J = 10.1, 14.5 
Hz, 1H), 6.41 (dd, J = 11.4, 15.2 Hz, 1H), 6.11 (d, J = 15.2, 1H), 6.05 (s, 1H), 
5.74 (d, J = 17.7 Hz, 1H), 3.84 (s, 3H), 2.41 (t, J = 7.6 Hz, 2H), 1.45-1.39 (m, 
2H), 1.35-1.28 (m, 2H), 1.26 (s, 12H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ 165.4, 164.2, 157.1, 148.4, 139.2, 134.7, 134.1, 123.9, 108.2, 
96.3, 83.2, 56.1, 30.2, 24.7, 23.3, 22.6, 13.9; HRMS (ESI) [M+H]+: calcd for 
C22H32O5B, 387.2343; found 387.2352.  
3-benzyl-4-methoxy-6-((1E,3E,5E)-6-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hexa-1,3,5-trienyl)-2H-pyran-2-one (2-30d). The residue 
was purified using flash chromatography (EtOAc:hexane = 1:2) to afford 2-30d 
(63 mg, 75%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 7.32 (d, J = 
7.6 Hz, 2H), 7.24-7.21 (m, 2H), 7.16-7.13 (m, 2H), 7.05 (dd, J = 10.1, 17.0 Hz, 
1H), 6.53 (dd, J = 10.8, 15.2 Hz, 1H), 6.41 (dd, J = 10.7, 14.5 Hz, 1H), 6.11 (d, 
J = 15.1 Hz, 1H), 6.06 (s, 1H), 5.72 (d, J = 17.7 Hz, 1H), 3.86 (s, 3H), 3.76 (s, 
2H), 1.27 (s, 12H); 13C NMR (125 MHz, CDCl3) δ 165.7, 164.1, 157.7, 148.4, 
140.0, 139.5, 135.2, 134.0, 128.6, 128.2, 125.9, 123.8, 106.8, 96.2, 83.3, 56.3, 




dioxaborolan-2-yl)hexa-1,3,5-trienyl)-2H-pyran-2-one (2-30e). The residue 
was purified using flash chromatography (EtOAc:hexane = 1:6) to afford 2-30e 
(58.8 mg, 71%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 7.14 (dd, J = 
11.4, 15.2 Hz, 1H), 7.04 (dd, J = 10.7, 17.7 Hz, 1H), 6.51 (dd, J = 10.7, 14.5 
Hz, 1H), 6.40 (dd, J =10.7, 14.5 Hz, 1H), 6.11 (d, J = 15.2 Hz, 1H), 6.05 (s, 
1H), 5.69 (d, J = 17.7 Hz, 1H), 3.84 (s, 3H), 2.40 (t, J = 7.6 Hz, 2H), 1.45-1.40 
(m, 2H), 1.30-1.26 (m, 18H), 0.85 (t, J = 6.6 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 165.3, 164.2, 157.1, 148.4, 139.2, 134.7, 134.1, 123.9, 108.3, 96.3, 
83.3, 56.1, 31.7, 29.2, 28.0, 24.7, 23.6, 22.6, 14.0; HRMS (EI): calcd for 
C24H35O5B, 414.2578; found 414.2574. 
4-ethoxy-6-((1E,3E,5E)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)hexa-1,3,5-trienyl)-2H-pyran-2-one (2-30f). The residue was purified 
using flash chromatography (EtOAc:hexane = 1:2) to afford 2-30f (57.1 mg, 
83%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 7.13 (dd, J = 10.8, 
15.2 Hz, 1H), 7.03 (dd, J = 10.7, 17.7 Hz, 1H), 6.51 (dd, J =10.8, 14.5 Hz, 1H), 
6.41 (dd, J = 11.4, 15.1 Hz, 1H), 6.09 (d, J = 15.2 Hz, 1H), 5.83 (d, J = 1.3 Hz, 
1H), 5.70 (d, J = 17.7 Hz, 1H), 5.41 (d, J = 1.9 Hz, 1H), 4.00 (q, J = 6.9 Hz, 
2H), 1.39 (t, J = 7.0 Hz, 3H), 1.26 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
170.0, 163.9, 158.2, 148.4, 139.5, 135.3, 134.0, 123.6, 101.7, 89.3, 83.3, 64.6, 
24.7, 14.0; HRMS (EI): calcd for C19H25O5B, 344.1795; found 344.1802. 
4-ethoxy-3-methyl-6-((1E,3E,5E)-6-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hexa-1,3,5-trienyl)-2H-pyran-2-one (2-30g). The residue 
was purified using flash chromatography (EtOAc:hexane = 1:2) to afford 2-30g 
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(56.6 mg, 79%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 7.12 (dd, J = 
10.8, 15.1 Hz, 1H), 7.02 (dd, J = 10.1, 17.7 Hz, 1H), 6.48 (dd, J = 10.7, 15.2 
Hz, 1H), 6.39 (dd, J = 10.7, 14.5 Hz, 1H), 6.09 (d, J = 15.1 Hz, 1H), 6.02 (s, 
1H), 5.67 (d, J = 17.7 Hz, 1H), 4.03 (q, J = 6.9 Hz, 1H), 1.91 (s, 3H); 1.38 (t, J 
= 7.3 Hz, 3H), 1.25 (s, 12H), 13C NMR (125 MHz, CDCl3) δ 164.8, 164.6, 
156.7, 148.4, 139.1, 134.5, 134.1, 123.9, 103.3, 96.9, 83.3, 64.7, 24.7, 14.7, 8.9; 
HRMS (EI): calcd for C20H27O5B, 358.1952; found 358.1958. 
3-butyl-4-ethoxy-6-((1E,3E,5E)-6-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hexa-1,3,5-trienyl)-2H-pyran-2-one (2-30h). The residue 
was purified using flash chromatography (EtOAc:hexane = 1:4) to afford 2-30h 
(64.8 mg, 81%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 7.13(dd, J = 
10.7, 15.2 Hz, 1H), 7.03 (dd, J = 10.1, 17.1 Hz, 1H), 6.50 (dd, J = 10.7, 15.1 
Hz, 1H), 6.40 (dd, J = 11.4, 15.2 Hz, 1H), 6.09 (d, J = 15.1 Hz, 1H), 6.01 (s, 
1H), 5.69 (d, J = 17.7 Hz, 1H), 4.08 (q, J = 6.9 Hz, 2H), 2.43 (t, J = 7.6 Hz, 
2H), 1.47-1.33 (m, 5H), 1.29-1.25 (m, 14H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR 
(125 MHz, CDCl3) δ 164.8, 164.3, 156.9, 148.5, 139.1, 134.6, 134.1, 124.0, 
108.3, 97.0, 83.3, 64.6, 30.1, 24.7, 23.3, 22.5, 14.7, 13.9; HRMS (EI): calcd for 
C23H33O5B, 400.2421; found 400.2423. 
4-methoxy-6-((2E,4E,6E)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)hepta-2,4,6-trien-2-yl)-2H-pyran-2-one (2-30i). The residue was purified 
using flash chromatography (EtOAc:hexane = 1:2) to afford 2-30i (46.8 mg, 
68%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 7.13-7.05 (m, 2H), 
6.66 (dd, J = 12.0, 15.2 Hz, 1H), 6.53 (dd, J = 10.8, 14.5 Hz, 1H), 5.98 (d, J = 
1.9 Hz, 1H), 5.68 (d, J = 17.7 Hz, 1H), 5.44 (d, J = 1.9 Hz, 1H), 3.78 (s, 3H), 
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1.93 (s, 3H), 1.24 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 171.0, 163.8, 160.4, 
148.8, 139.5, 131.6, 130.9, 127.3, 98.8, 88.6, 83.2, 55.9, 24.7, 12.4; HRMS 
(ESI) [M+Na]+: calcd for C19H25O5BNa, 367.1693; found 367.1679.  
4-methoxy-3-methyl-6-((2E,4E,6E)-7-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hepta-2,4,6-trien-2-yl)-2H-pyran-2-one (2-30j). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:2) to 
afford  2-30j (47.2 mg, 66%) an orange solid. 1H NMR (500 MHz, CDCl3) δ 
7.19-7.08 (m, 2H), 6.69 (dd, J = 11.4, 14.5 Hz, 1H), 6.58 (dd, J = 10.8, 14.5 Hz, 
1H), 6.20 (s, 1H), 5.71 (d, J = 17.7 Hz, 1H), 3.91 (s, 3H), 2.00 (s, 3H), 1.94 (s, 
3H), 1.28 (s, 12H); 13C NMR (125 MHz, CDCl3) δ 165.5, 164.7, 159.3, 148.9, 
139.4, 131.3, 131.1, 127.5, 103.1, 93.1, 83.3, 56.1, 24.8, 12.6, 8.8; HRMS (ESI) 
[M+H]+: calcd for C20H28O5B, 359.2030; found 359.2022.  
4-methoxy-3-methyl-6-((3E,5E,7E)-8-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)octa-3,5,7-trien-3-yl)-2H-pyran-2-one (2-30k). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:3) to 
afford 2-30k (46.1 mg, 62%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 
7.11 (d, 2H), 6.68 (dd, J = 11.4, 14.5 Hz, 1H), 6.57 (dd, J = 10.7, 14.5 Hz, 1H), 
6.25 (s, 1H), 5.70 (d, J = 17.7 Hz, 1H), 3.90 (s, 3H), 2.47 (q, J = 7.6 Hz, 2H), 
1.93 (s, 3H), 1.27 (s, 12H), 1.11 (t, J = 7.6 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 165.7, 164.8, 158.6, 149.0, 139.4, 134.5, 130.8, 130.6, 102.9, 92.9, 
83.3, 56.1, 24.8, 20.2, 14.3, 8.7; HRMS (ESI) [M+H]+: calcd for C21H30O5B, 
373.2186; found 373.2210. 
3-butyl-4-methoxy-6-((2E,4E,6E)-7-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hepta-2,4,6-trien-2-yl)-2H-pyran-2-one (2-30l). The 
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residue was purified using flash chromatography (EtOAc:hexane = 1:4) to 
afford 2-30l (48.8 mg, 61%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 
7.20-7.10 (m, 2H), 6.71 (dd, J = 12.0, 15.1 Hz, 1H), 6.60 (dd, J = 10.7, 14.5 Hz, 
1H), 6.21 (s, 1H), 5.72 (d, J = 17.7 Hz, 1H), 3.91 (s, 3H), 2.45 (t, J = 7.6 Hz, 
2H), 2.01 (s, 3H), 1.49-1.44 (m, 2H), 1.38-1.29 (m, 2H), 1.25 (s, 12H), 0.93-
0.90 (t, J = 7.6 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 165.5, 164.3, 159.3, 
148.9, 139.3, 131.1, 131.2, 127.6, 107.9, 93.1, 83.3, 56.0, 30.2, 24.7, 23.2, 22.6, 
13.9, 12.6; HRMS (ESI) [M+Na]+: calcd for C23H33O5BNa, 423.2319; found 
423.2334. 
3-butyl-4-methoxy-6-((3E,5E,7E)-8-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)octa-3,5,7-trien-3-yl)-2H-pyran-2-one (2-30m). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:6) to 
afford 2-30m (58.8 mg, 71%) as an orange solid.  1H NMR (500 MHz, CDCl3) 
δ 7.14-7.06 (m, 2H), 6.68 (dd, J = 11.4, 14.5 Hz, 1H), 6.57 (dd, J = 10.8, 15.2 
Hz, 1H), 6.23 (s, 1H), 5.75 (d, J = 17.7 Hz, 1H), 3.88 (s, 3H), 2.48-2.41 (m, 
4H), 1.47-1.41 (m, 2H), 1.33-1.27 (m, 14H), 1.10 (t, J = 7.6 Hz, 3H), 0.90 (t, J 
= 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 165.5, 164.4, 158.7, 149.0, 
139.3, 134.5, 130.9, 130.6, 107.9, 92.9, 83.3, 56.0, 30.2, 24.7, 23.2, 22.6, 20.2, 
14.3, 13.9; HRMS (EI): calcd for C24H35O5B, 414.2578; found 414.2576. 
3-benzyl-4-methoxy-6-((2E,4E,6E)-7-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hepta-2,4,6-trien-2-yl)-2H-pyran-2-one (2-30n). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:3) to 
afford 2-30n (63.3 mg, 73%) as an orange solid.  1H NMR (500 MHz, CDCl3) 
δ 7.32 (d, J = 7.0 Hz, 2H), 7.24-7.21 (m, 2H), 7.18-7.08 (m, 3H), 6.71 (dd, J = 
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12.0, 15.2 Hz, 1H), 6.58(dd, J = 10.1, 14.5 Hz, 1H), 6.20 (s, 1H), 5.71 (d, J = 
17.7 Hz, 1H), 3.90 (s, 3H), 3.77 (s, 2H), 1.98 (s, 3H), 1.27 (s, 12H); 13C NMR 
(125 MHz, CDCl3) δ 165.8, 164.1, 160.0, 148.9, 140.1, 139.5, 131.6, 131.0, 
128.6, 128.1, 127.5, 125.9, 106.5, 93.1, 83.3, 56.2, 29.2, 24.7, 12.5; HRMS 
(EI): calcd for C26H31O5B, 434.2265; found 434.2271. 
3-hexyl-4-methoxy-6-((2E,4E,6E)-7-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hepta-2,4,6-trien-2-yl)-2H-pyran-2-one (2-30o). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:5) to 
afford 2-30o (63.3 mg, 74%) as an orange solid.   1H NMR (500 MHz, CDCl3) 
δ 7.17-7.08 (m, 2H), 6.69 (dd, J = 12.0, 15.2 Hz, 1H), 6.57 (dd, J = 10.8, 14.5 
Hz, 1H), 6.19 (s, 1H), 5.70 (d, J = 17.7 Hz, 1H), 3.88 (s, 3H), 2.42 (t, J = 7.9 
Hz, 2H), 1.99 (s, 3H), 1.46-1.41 (m, 2H), 1.28-1.27 (m, 18H), 0.86 (t, J = 6.6 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 165.5, 164.3, 159.3, 148.9, 139.3, 
131.2, 131.1, 127.6, 108.0, 93.1, 83.3, 56.0, 31.7, 29.2, 28.0, 24.7, 23.5, 22.6, 
14.1, 12.6; HRMS (EI): calcd for C25H37O5B, 428.2734; found 428.2732. 
4-ethoxy-3-methyl-6-((2E,4E,6E)-7-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hepta-2,4,6-trien-2-yl)-2H-pyran-2-one (2-30p). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:4) to 
afford 2-30p (52.1 mg, 70%) as an orange solid.    1H NMR (500 MHz, CDCl3) 
δ 7.14-7.06 (m, 2H), 6.69-6.63 (m, 1H), 6.54 (dd, J = 10.1, 13.9 Hz, 1H), 6.15 
(s, 1H), 5.68 (d, J = 17.1 Hz, 1H), 4.12 (q, J = 6.9 Hz, 2H), 1.96 (s, 3H), 1.92 
(s, 3H), 1.40 (t, J = 6.9 Hz, 3H), 1.25 (s, 12H); 13C NMR (125 MHz, CDCl3) δ 
165.0, 164.7, 159.0, 148.9, 139.2, 131.0, 131.0, 127.6, 103.0, 93.8, 83.3, 64.7, 
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24.7, 14.8, 12.5, 8.8; HRMS (EI): calcd for C21H29O5B, 372.2108; found 
372.2114. 
3-butyl-4-ethoxy-6-((2E,4E,6E)-7-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hepta-2,4,6-trien-2-yl)-2H-pyran-2-one (2-30q). The 
residue was purified using flash chromatography (EtOAc:hexane = 1:5) to 
afford 2-30q (60.4 mg, 73%) as an orange solid.  1H NMR (500 MHz, CDCl3) 
δ 7.14-7.05 (m, 2H), 6.68-6.63 (m, 1H), 6.54 (dd, J = 10.8, 14.5 Hz, 1H), 6.14 
(s, 1H), 5.67 (d, J = 17.0 Hz, 1H), 4.11 (q, J = 6.9 Hz, 2H), 2.42 (t, J = 7.6 Hz, 
2H), 1.95 (s, 3H), 1.44-1.38 (m, 5H), 1.37-1.25 (m, 14H), 0.88 (t, J = 7.3 Hz, 
3H); 13C NMR (125 MHz, CDCl3) δ 164.9, 164.4, 159.1, 148.9, 139.1, 131.1, 
131.0, 127.6, 107.9, 93.9, 83.2, 64.5, 30.1, 24.7, 23.1, 22.4, 14.7, 13.9, 12.5; 
HRMS (EI): calcd for C24H35O5B, 414.2578; found 414.2582. 
4-hydroxy-6-((1E,3E,5E)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)hexa-1,3,5-trienyl)-2H-pyran-2-one (2-30r). The residue was purified 
using flash chromatography (MeOH:CH2Cl2 = 1:20) to afford 2-30r (41.1 mg, 
65%) as an orange solid. 1H NMR (500 MHz, DMSO-d6) δ 11.70 (br, 1H), 
7.04-6.97 (m, 2H), 6.70-6.60 (m, 2H), 6.44 (d, J = 15.1 Hz, 1H), 6.19 (s, 1H), 
5.63 (d, J = 17.7 Hz, 1H), 5.31 (s, 1H), 1.21 (s, 12H); 13C NMR (125 MHz, 
DMSO-d6) δ 169.9, 162.7, 158.6, 148.8, 138.7, 134.8, 133.9, 124.9, 102.2, 90.2, 
83.0, 24.5; HRMS (ESI) [M-H]-: calcd for C17H20O5B, 315.1404; found 
315.1394.  
4-hydroxy-3-methyl-6-((1E,3E,5E)-6-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hexa-1,3,5-trienyl)-2H-pyran-2-one (2-30s). The residue 
was purified using flash chromatography (MeOH:CH2Cl2 = 1:20) to afford 2-
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30s (43.6 mg, 66%) as an orange solid. 1H NMR (500 MHz, Acetone-d6) δ 
7.06-7.01 (m, 2H), 6.66 (dd, J = 10.1, 15.1 Hz, 1H), 6.58 (dd, J = 10.7, 15.2 Hz, 
1H), 6.34 (d, J =15.1 Hz, 1H), 6.20 (s, 1H), 5.67 (d, J = 17.7 Hz, 1H), 1.90 (s, 
3H), 1.25 (s, 12H); 13C NMR (125 MHz, Acetone-d6) δ 163.7, 163.6, 155.6, 
148.5, 138.2, 134.4, 133.1, 124.4, 101.4, 100.1, 82.8, 23.9, 7.9; HRMS (ESI) 
[M-H]-: calcd for C18H22O5B, 329.1560; found 329.1546. 
5-(dimethylamino)-N-(3-(2-oxo-6-((1E,3E,5E)-6-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)hexa-1,3,5-trienyl)-2H-pyran-4-
yloxy)propyl)naphthalene-1-sulfonamide (2-30t). The residue was purified 
using flash chromatography (EtOAc:hexane = 1:1) to afford 2-30t (75.5 mg, 
60%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 8.50 (d, J = 8.2 Hz, 
1H), 8.27-8.24 (m, 2H), 7.53-7.48 (m, 2H), 7.16-7.02 (m, 3H), 6.52 (dd, J = 
10.7, 14.5 Hz, 1H), 6.42 (dd, J = 11.3, 15.1 Hz, 1H), 6.04 (d, J = 15.2 Hz, 1H), 
5.72 (d, J = 17.7 Hz, 1H), 5.62 (d, J = 1.9 Hz, 1H), 5.22-5.14 (m, 2H), 3.77 (t, 
J = 5.7 Hz, 2H), 3.11-3.07 (m, 2H), 2.86 (s, 6H), 1.88-1.83 (m, 2H), 1.28 (s, 
12H); 13C NMR (125 MHz, CDCl3) δ 169.5, 163.6, 158.2, 152.1, 148.4, 139.6, 
135.4, 134.2, 133.9, 130.7, 129.8 (2 carbons), 129.5, 128.5, 123.4, 123.0, 118.4, 
115.2, 101.3, 89.4, 83.4, 65.6, 45.3, 39.7, 28.4, 24.7; HRMS (ESI) [M+Na]+: 
calcd for C32H39N2O7BSNa, 629.2463; found 629.2494. 
General Procedure for the Synthesis of 2-1a to 2-1t. Pd2dba3 (2.7 mg, 3.0 
µmol) and AsPh3 (4.6 mg, 15 µmol) was added to THF (1 mL) followed by 2-
4a (56 mg, 0.195 mmol) and 1.8 M aqueous KOH (0.167 mL, 0.300 mL). The 
respective compound 2-30 (0.150 mmol) was dissolved in THF (0.5 mL) and 
added dropwise to the reaction mixture over 5 min with stirring. The reaction 
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mixture was stirred for 20 min at room temperature and quenched with 
saturated NH4Cl. EtOAc was added and the mixture was washed thrice with 
water followed by saturated NaCl solution. The organic extract was dried over 
MgSO4, concentrated under reduced pressure and the residue obtained was 
dissolved in THF (1 mL) and 1 M TBAF in THF (0.300 mL, 0.300 mmol) was 
added. The mixture was stirred at room temperature for 30 min and thereafter 
EtOAc was added and the mixture was washed thrice with water followed by 
saturated NaCl solution. The organic extract was dried over MgSO4, 
concentrated under reduced pressure and purified by column chromatography.  
Auxarconjugatin B (2-1a). The residue was purified using flash 
chromatography (acetone:hexane:CH2Cl2 = 1:5:10) to afford 2-1a (36.8 mg, 
74%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.45 (br, 1H), 7.05 (dd, 
J = 11.4, 15.1 Hz, 1H), 6.90-6.89 (m, 1H), 6.79-6.69 (m, 2H), 6.60 (dd, J = 
11.4, 14.5 Hz, 1H), 6.54-6.37 (m, 3H), 6.29 (d, J = 15.1 Hz, 1H), 6.23 (d, J = 
1.9 Hz, 1H), 6.14-6.13 (m, 1H), 5.59 (d, J = 2.5 Hz, 1H), 3.81 (s, 3H); 13C 
NMR (125 MHz, DMSO-d6) δ 170.7, 162.6, 158.4, 138.8, 136.8, 135.1, 131.1, 
130.5, 126.0, 124.7, 121.6, 120.8, 120.5, 111.9, 109.1, 100.6, 88.4, 56.3; 
HRMS (ESI) [M-H]-: calcd for C18H15NO3Cl, 328.0740; found 328.0738. 
Auxarconjugatin A (2-1b). The residue was purified using flash 
chromatography (acetone:hexane:CH2Cl2 = 1:5:10) to afford 2-1b (34.7 mg, 
70%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.46 (br, 1H), 7.07 (dd, 
J = 11.4, 15.1 Hz, 1H), 6.90-6.89 (m, 1H), 6.80-6.70 (m, 2H), 6.65-6.59 (m, 
2H), 6.54-6.47 (m, 2H), 6.42 (dd, J = 11.4, 14.5 Hz, 1H), 6.33 (d, J = 15.2 Hz, 
1H), 6.13-6.12 (m, 1H), 3.90 (s, 3H), 1.81 (s, 3H); 13C NMR (125 MHz, 
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DMSO-d6) δ 165.9, 163.4, 157.0, 138.5, 136.7, 134.5, 131.1, 130.7, 126.0, 
124.7, 121.9, 120.7, 120.5, 111.8, 109.1, 100.5, 96.5, 56.7, 8.8; HRMS (ESI) 
[M-H]-: calcd for C19H17NO3Cl, 342.0915; found 342.0897.  
3-butyl-6-((1E,3E,5E,7E)-8-(3-chloro-1H-pyrrol-2-yl)octa-1,3,5,7-
tetraenyl)-4-methoxy-2H-pyran-2-one (2-1c). The residue was purified using 
flash chromatography (acetone:hexane:CH2Cl2 = 1:8:16) to afford 2-1c (45.9 
mg, 75%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.47 (br, 1H), 7.07 
(dd, J = 11.4, 14.5 Hz, 1H), 6.91-6.90 (m, 1H), 6.81-6.70 (m, 2H), 6.64-6.60 
(m, 2H), 6.55-6.48 (m, 2H), 6.42 (dd, J = 11.4, 14.5 Hz, 1H), 6.33 (d, J = 15.1 
Hz), 6.15-6.14 (m, 1H), 3.89 (s, 3H), 2.34-2.31, (t, J = 7.3 Hz, 2H), 1.39-1.36 
(m, 2H), 1.30-1.25 (m, 2H), 0.88 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, 
acetone-d6) δ 166.5, 163.9, 158.4, 139.2, 137.3, 135.4, 132.2, 131.5, 127.2, 
125.7, 123.0, 121.5, 120.7, 113.5, 110.3, 107.1, 96.9, 56.8, 30.9, 23.8, 23.1, 
14.1; HRMS (ESI) [M+Na]+: calcd for C22H24NO3ClNa, 408.1342; found 
408.1320. 
3-benzyl-6-((1E,3E,5E,7E)-8-(3-chloro-1H-pyrrol-2-yl)octa-1,3,5,7-
tetraenyl)-4-methoxy-2H-pyran-2-one (2-1d).  The residue was purified 
using flash chromatography (acetone:hexane:CH2Cl2 = 1:8:16) to afford 2-1d 
(44.6 mg, 71%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.46 (br, 1H), 
7.25-7.19 (m, 4H), 7.15-7.06 (m, 2H), 6.90 (t, J = 2.8 Hz, 1H), 6.80-6.70 (m, 
3H), 6.63 (dd, J = 10.7, 14.5 Hz, 1H), 6.55-6.51 (m, 2H), 6.42 (dd, J = 11.4, 
13.9 Hz, 1H), 6.34 (d, J = 15.2 Hz, 1H), 6.14 (t, J = 2.5 Hz, 1H), 3.92 (s, 3H), 
3.63 (s, 2H); 13C NMR (125 MHz, DMSO-d6) δ 166.4, 163.1, 157.9, 139.9, 
138.9, 136.9, 135.1, 131.1, 130.6, 128.1, 128.1, 126.0, 125.8, 124.7, 121.8, 
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120.8, 120.5, 111.9, 109.1, 104.1, 96.5, 56.9, 28.7; HRMS (EI): calcd for 
C25H22NO3Cl, 419.1288; found 419.1282. 
6-((1E,3E,5E,7E)-8-(3-chloro-1H-pyrrol-2-yl)octa-1,3,5,7-tetraenyl)-3-
hexyl-4-methoxy-2H-pyran-2-one (2-1e). The residue was purified using 
flash chromatography (acetone:hexane:CH2Cl2 = 1:10:20) to afford 2-1e (43.3 
mg, 70%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.45 (br, 1H), 7.06 
(dd, J = 11.4, 1H), 6.90 (t, J = 2.8 Hz, 1H), 6.80-6.70 (m, 2H), 6.63-6.47 (m, 
2H), 6.54-6.47 (m, 2H), 6.41 (dd, J = 11.4, 14.5 Hz, 1H), 6.32 (d, J = 15.2 Hz, 
1H), 6.13 (t, J = 2.8 Hz, 1H), 3.88 (s, 3H), 2.31 (t, J = 7.6 Hz, 2H), 1.38-1.36 
(m, 2H), 1.28-1.25 (m, 6H), 0.85 (t, J = 6.6 Hz, 3H); 13C NMR (125 MHz, 
DMSO-d6) δ 165.9, 163.1, 157.2, 138.5, 136.7, 134.6, 131.1, 130.7, 126.0, 
124.7, 121.9, 120.7, 120.4, 111.8, 109.1, 105.4, 96.5, 56.7, 31.0, 28.5, 27.5, 
23.0, 22.0, 13.9; HRMS (EI): calcd for C24H28NO3Cl, 413.1739; found 
413.1758. 
6-((1E,3E,5E,7E)-8-(3-chloro-1H-pyrrol-2-yl)octa-1,3,5,7-tetraenyl)-4-
ethoxy-2H-pyran-2-one (2-1f). The residue was purified using flash 
chromatography (acetone:hexane:CH2Cl2 = 1:6:12) to afford 2-1f (38.1 mg, 
74%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.5 (br, 1H), 7.04 (dd, 
J = 11.4, 15.2 Hz, 1H), 6.90 (d, J = 2.5 Hz, 1H), 6.79-6.69 (m, 2H), 6.64-6.37 
(m, 4H), 6.28 (d, J = 15.1 Hz, 1H), 6.21 (s, 1H), 6.13 (s, 1H), 5.55 (d, J = 1.9 
Hz, 1H), 4.08 (q, J = 6.9 Hz, 2H), 1.31 (t, J = 7.3 Hz, 3H); 13C NMR (125 
MHz, DMSO-d6) δ 169.9, 162.6, 158.4, 138.8, 136.8, 135.1, 131.1, 130.5, 
126.0, 124.7, 121.6, 120.8, 120.5, 111.9, 109.1, 100.8, 88.7, 64.7, 13.9; HRMS 




ethoxy-3-methyl-2H-pyran-2-one (2-1g). The residue was purified using flash 
chromatography (acetone:hexane:CH2Cl2 = 1:6:12) to afford 2-1g (40.2 mg, 
75%) as a red solid.  1H NMR (500 MHz, DMSO-d6) δ 11.5 (br, 1H), 7.08 (dd, 
J = 11.4, 15.2 Hz, 1H), 6.90 (s, 1H), 6.79-6.69 (m, 2H), 6.63-6.58 (m, 2H), 
6.54-6.46 (m, 2H), 6.41 (dd, J = 11.4, 14.5 Hz, 1H), 6.31 (d, J = 15.1 Hz, 1H), 
6.13 (s, 1H), 4.19 (q, J = 6.9 Hz, 2H), 1.81 (s, 3H), 1.32 (t, J = 6.9 Hz, 3H); 13C 
NMR (125 MHz, DMSO-d6) δ 165.2, 163.4, 156.9, 138.4, 136.6, 134.4, 131.1, 
130.7, 126.0, 124.7, 122.0, 120.7, 120.4, 111.8, 109.1, 100.6, 97.0, 64.8, 14.6, 
8.8; HRMS (EI): calcd for C20H20NO3Cl, 357.1132; found 357.1132. 
3-butyl-6-((1E,3E,5E,7E)-8-(3-chloro-1H-pyrrol-2-yl)octa-1,3,5,7-
tetraenyl)-4-ethoxy-2H-pyran-2-one (2-1h). The residue was purified using 
flash chromatography (acetone:hexane:CH2Cl2 = 1:8:16) to afford 2-1h (41.9 
mg, 70%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.5 (br, 1H), 7.07-
7.02 (dd, J = 11.4, 15.1 Hz, 1H), 6.90 (t, J = 2.9 Hz, 1H), 6.80-6.69 (m, 2H), 
6.63-6.58 (m, 2H), 6.54-6.46 (m, 2H), 6.41 (dd, J = 11.4, 14. 5Hz, 1H), 6.30 (d, 
J = 15.2 Hz, 1H), 6.13 (t, J =2.9 Hz, 1H), 4.18 (q, J = 7.2 Hz, 2H), 2.33 (t, J = 
7.3 Hz, 2H), 1.41-1.35 (m, 2H), 1.32-1.22 (m, 5H), 0.88 (t, J = 7.3 Hz, 3H); 
13C NMR (125 MHz, DMSO-d6) δ 165.2, 163.1, 157.1, 138.5, 136.6, 134.5, 
131.1, 130.7, 126.0, 124.7, 122.0, 120.7, 120.4, 111.8, 109.1, 105.5, 97.1, 64.7, 
29.7, 22.7, 21.8, 14.6, 13.7; HRMS (EI): calcd for C23H26NO3Cl, 399.1601; 
found 399.1591. 
6-((2E,4E,6E,8E)-9-(3-chloro-1H-pyrrol-2-yl)nona-2,4,6,8-tetraen-2-yl)-
4-methoxy-2H-pyran-2-one (2-1i). The residue was purified using flash 
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chromatography (acetone:hexane:CH2Cl2 = 1:5:10) to afford 2-1i (39.2 mg, 
76%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.45 (br, 1H), 7.03 (d, 
J = 10.1 Hz, 1H), 6.90-6.89 (m, 1H), 6.80-6.72 (m, 3H), 6.62 (dd, J = 11.4, 
15.1 Hz, 1H) 6.55-6.44 (m, 2H), 6.26 (d, J = 1.9 Hz, 1H), 6.13-6.12 (m, 1H), 
5.61 (d, J = 1.9 Hz, 1H), 3.83 (s, 3H), 1.98 (s, 3H); 13C NMR (125 MHz, 
DMSO-d6) δ 170.9, 162.6, 160.1, 138.8, 136.4, 131.5, 131.5, 127.7, 126.0, 
125.3, 124.8, 120.6, 120.4, 111.8, 109.1, 98.3, 88.2, 56.3, 12.3; HRMS (ESI) 
[M-H]-: calcd for C19H17NO3Cl, 342.0915; found 342.0913. 
12E-isorumbrin (2-1j). The residue was purified using flash 
chromatography (acetone:hexane:CH2Cl2 = 1:5:10) to afford 2-1j (38.1 mg, 
71%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.46 (br, 1H), 7.05 (d, 
J = 10.1 Hz, 1H), 6.90-6.89 (m, 1H), 6.80-6.72 (m, 3H), 6.61-6.47 (m, 4H), 
6.13-6.12 (m, 1H), 3.95 (s, 3H), 2.05 (s, 3H), 1.81 (s, 3H); 13C NMR (125 
MHz, DMSO-d6) δ 166.0, 163.3, 158.8, 138.5, 136.3, 131.6, 131.0, 127.9, 
126.0, 125.8, 124.8, 120.5, 120.4, 111.8, 109.1, 100.3, 93.6, 56.7, 12.4, 8.7; 
HRMS (ESI) [M-H]-: calcd for C20H19NO3Cl, 356.1053; found 356.1043.  
6-((3E,5E,7E,9E)-10-(3-chloro-1H-pyrrol-2-yl)deca-3,5,7,9-tetraen-3-
yl)-4-methoxy-3-methyl-2H-pyran-2-one (2-1k) The residue was purified 
using flash chromatography (acetone:hexane:CH2Cl2 = 1:6:12) to afford 2-1k 
(37.9 mg, 68%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.47 (br, 1H), 
7.01-6.99 (m, 1H), 6.90-6.89 (m, 1H), 6.80-6.72 (m, 3H), 6.64-6.59 (m, 2H), 
6.53-6.48 (m, 2H), 6.13-6.12 (m, 1H), 3.95 (s, 3H), 2.56 (q, J = 7.4 Hz, 2H), 
1.81 (s, 3H), 1.07, (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 166.1, 
163.5, 158.2, 138.8, 136.4, 132.4, 131.6, 130.7, 127.4, 126.0, 124.8, 120.5, 
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120.4, 111.8, 109.1, 100.2, 93.3, 56.7, 30.6, 14.3, 8.7; HRMS (ESI) [M-H]-: 
calcd for C21H21NO3Cl, 370.1210; found 370.1202. 
3-butyl-6-((2E,4E,6E,8E)-9-(3-chloro-1H-pyrrol-2-yl)nona-2,4,6,8-
tetraen-2-yl)-4-methoxy-2H-pyran-2-one (2-1l). The residue was purified 
using flash chromatography (acetone:hexane:CH2Cl2 = 1:8:16) to afford 2-1l 
(49.2 mg, 82%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.45 (br, 1H), 
7.05 (d, J = 10.7 Hz, 1H), 6.90-6.89 (m, 1H), 6.80-6.69 (m, 3H), 6.64-6.44 (m, 
4H), 6.13-6.12 (m, 1H), 3.94 (s, 3H), 2.32 (t, J = 7.3 Hz, 2H), 2.05 (s, 3H), 
1.40-1.34 (m, 2H), 1.30-1.23 (m, 2H), 0.88 (t, J = 7.3 Hz); 13C NMR (125 
MHz, DMSO-d6) δ 166.0, 163.1, 159.0, 138.5, 136.3, 131.6, 131.1, 127.9, 
126.0, 125.8, 124.8, 120.5, 120.4, 111.8, 109.1, 105.1, 93.7, 56.7, 29.7, 22.7, 
22.0, 13.8, 12.3; HRMS (ESI) [M+Na]+: calcd for C23H26NO3ClNa, 422.1499; 
found 422.1510. 
3-butyl-6-((3E,5E,7E,9E)-10-(3-chloro-1H-pyrrol-2-yl)deca-3,5,7,9-
tetraen-3-yl)-4-methoxy-2H-pyran-2-one (2-1m). The residue was purified 
using flash chromatography (acetone:hexane:CH2Cl2 = 1:10:20) to afford 2-1m 
(42.7 mg, 69%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.45 (br, 1H), 
7.01-6.99 (m, 1H), 6.90 (t, J = 2.8 Hz, 1H), 6.80-6.72 (m, 3H), 6.64-6.59 (m, 
2H), 6.54-6.50 (m, 2H), 6.13 (t, J = 2.5 Hz, 1H), 3.94 (s, 3H), 2.56 (q, J = 7.4 
Hz, 2H), 2.32 (t, J = 7.3 Hz, 2H), 1.40-1.34 (m, 2H), 1.31-1.25 (m, 2H), 1.07 (t, 
J = 7.6 Hz, 3H), 0.88 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 
166.1, 163.2, 158.4, 138.8, 136.3, 132.4, 131.5, 130.7, 127.3, 126.0, 124.7, 
120.5, 120.3, 111.8, 109.1, 105.1, 93.3, 56.7, 29.7, 22.6, 21.9, 19.2, 14.3, 13.7; 




tetraen-2-yl)-4-methoxy-2H-pyran-2-one (2-1n). The residue was purified 
using flash chromatography (acetone:hexane:CH2Cl2 = 1:8:16) to afford 2-1n 
(47.4 mg, 73%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.46 (br, 1H), 
7.25-7.19 (m, 4H), 7.16-7.13 (m, 1H), 7.07 (d, J = 10.1 Hz, 1H), 6.90 (t, J = 
2.8 Hz, 1H), 6.81-6.73 (m, 3H), 6.64-6.59 (m, 2H), 6.53-6.45 (m, 2H), 6.14 (t, 
J = 2.5 Hz, 1H), 3.98 (s, 3H), 3.64 (s, 2H), 2.05 (s, 3H); 13C NMR (125 MHz, 
DMSO-d6) δ 166.4, 163.1, 159.7, 139.9, 138.8, 136.4, 131.6, 131.5, 128.1, 
128.1, 127.8, 126.0, 125.8, 125.8, 124.8, 120.6, 120.4, 111.8, 109.1, 104.0, 
93.7, 56.9, 28.6, 12.4; HRMS (EI): calcd for C26H24NO3Cl, 433.1445; found 
433.1440. 
6-((2E,4E,6E,8E)-9-(3-chloro-1H-pyrrol-2-yl)nona-2,4,6,8-tetraen-2-yl)-
3-hexyl-4-methoxy-2H-pyran-2-one (2-1o). The residue was purified using 
flash chromatography (acetone:hexane:CH2Cl2 = 1:10:20) to afford 2-1o (44.8 
mg, 70%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.45 (br, 1H), 7.05 
(d, J = 10.1 Hz, 1H); 6.90 (t, J = 2.8 Hz, 1H), 6.80-6.69 (m, 3H), 6.63-6.44 (m, 
4H), 6.13 (t, J = 2.5 Hz, 1H), 3.94 (s, 3H), 2.31 (t, J = 7.6 Hz, 2H), 2.04 (s, 3H), 
1.38 (m, 2H), 1.25 (m, 6H), 0.85 (t, J = 6.6 Hz, 3H); 13C NMR (125 MHz, 
DMSO-d6) δ 166.0, 163.0, 159.0, 138.5, 136.3, 131.6, 131.1, 127.9, 126.0, 
125.8, 124.8, 120.5, 120.4, 111.8, 109.1, 105.2, 93.7, 56.6, 31.1, 28.5, 27.5, 
22.9, 22.0, 13.9, 12.3; HRMS (EI): calcd for C25H30NO3Cl, 427.1914; found 
427.1904. 
6-((2E,4E,6E,8E)-9-(3-chloro-1H-pyrrol-2-yl)nona-2,4,6,8-tetraen-2-yl)-
4-ethoxy-3-methyl-2H-pyran-2-one (2-1p). The residue was purified using 
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flash chromatography (acetone:hexane:CH2Cl2 = 1:6:12) to afford 2-1p (40.6 
mg, 73%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.45 (br, 1H), 7.04 
(d, J = 10.1 Hz, 1H), 6.89 (s, 1H), 6.80-6.71 (m, 3H), 6.63-6.58 (m, 1H), 6.53-
6.44 (m, 3H), 6.12 (s, 1H), 4.27 (q, J = 6.7 Hz, 2H), 2.03 (s, 3H), 1.82 (s, 3H), 
1.33 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 165.3, 163.4, 158.7, 
138.4, 136.2, 131.6, 130.9, 127.9, 126.0, 125.8, 124.8, 120.4, 120.4, 111.7, 
109.1, 100.5, 94.2, 64.8, 14.6, 12.4, 8.7; HRMS (EI): calcd for C21H22NO3Cl, 
371.1288; found 371.1283. 
3-butyl-6-((2E,4E,6E,8E)-9-(3-chloro-1H-pyrrol-2-yl)nona-2,4,6,8-
tetraen-2-yl)-4-ethoxy-2H-pyran-2-one (2-1q). The residue was purified 
using flash chromatography (acetone:hexane:CH2Cl2 = 1:10:20) to afford 2-1q 
(42.1 mg, 68%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.5 (br, 1H), 
7.04 (d, J = 10.7 Hz, 1H), 6.89 (s, 1H), 6.80-6.68 (m, 3H), 6.61 (dd, J = 11.3, 
15.1 Hz, 1H), 6.53-6.44 (m, 3H), 6.13 (s, 1H), 4.26 (q, J = 6.9 Hz, 2H), 2.34 (t, 
J = 7.6 Hz, 2H), 2.03 (s, 3H), 1.41-1.35 (m, 2H), 1.33-1.24 (m, 5H), 0.88 (t, J = 
7.3 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 165.3, 163.1, 158.9, 138.5, 
136.2, 131.6, 131.0, 127.9, 126.0, 125.8, 124.8, 120.4, 120.4, 111.7, 109.1, 
105.3, 94.3, 64.7, 29.6, 22.6, 21.8, 14.6, 13.7, 12.3; HRMS (EI): calcd for 
C24H28NO3Cl, 413.1758; found 413.1751. 
6-((1E,3E,5E,7E)-8-(3-chloro-1H-pyrrol-2-yl)octa-1,3,5,7-tetraenyl)-4-
hydroxy-2H-pyran-2-one (2-1r). The residue was purified using flash 
chromatography (MeOH:CH2Cl2 = 1:20 ) to afford 2-1r (30.8 mg, 65%) as a 
red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.45 (br, 1H), 7.03 (dd, J = 11.4, 
15.2 Hz, 1H), 6.90-6.89 (m, 1H), 6.79-6.69 (m, 2H), 6.62 (dd, 11.4, 15.1 Hz, 
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1H), 6.54-6.44 (m, 2H), 6.40 (dd, J = 11.3 Hz, 14.5, 1H), 6.31 (d, J = 15.1 Hz, 
1H), 6.14-6.13 (m, 1H), 6.11 (d, J = 1.9 Hz, 1H); 13C NMR (125 MHz, DMSO-
d6) δ 170.7, 163.0, 159.0, 138.5, 136.6, 134.7, 131.1, 130.6, 126.0, 124.8, 122.1, 
120.7, 120.4, 111.8, 109.1, 101.7, 89.4; HRMS (ESI) [M-H]-: calcd for 
C17H13NO3Cl, 314.0589; found 314.0578.  
6-((1E,3E,5E,7E)-8-(3-chloro-1H-pyrrol-2-yl)octa-1,3,5,7-tetraenyl)-4-
hydroxy-3-methyl-2H-pyran-2-one (2-1s). The residue was purified using 
flash chromatography (MeOH:CH2Cl2 = 1:20 ) to afford 2-1s (34.7 mg, 70%) 
as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 11.44 (br, 1H), 6.97 (dd, J = 
11.4, 15.1 Hz, 1H), 6.90-6.88 (m, 1H), 6.77 (dd, J = 10.8, 15.2 Hz, 1H), 6.69 
(dd, J = 10.7, 14.5 Hz, 1H), 6.59 (dd, J = 11.4, 14.5 Hz, 1H), 6.52 (d, J = 15.8 
Hz, 1H), 6.46 (dd, J = 11.4, 14.5 Hz, 1H), 6.39 (dd, J = 10.7, 14.5 Hz, 1H), 
6.30 (d, J = 15.8 Hz, 1H), 6.13-6.12 (m, 2H), 1.80 (s, 3H); 13C NMR (125 MHz, 
DMSO-d6) δ 164.7, 164.0, 155.7, 137.9, 136.3, 133.8, 131.2, 130.7, 126.0, 
124.8, 122.1, 120.5, 120.4, 111.7, 109.1, 101.0, 98.5, 8.8; HRMS (ESI) [M-H]-: 
calcd for C18H15NO3Cl, 328.0740; found 328.0744. 
N-(3-(6-((1E,3E,5E,7E)-8-(3-chloro-1H-pyrrol-2-yl)octa-1,3,5,7-
tetraenyl)-2-oxo-2H-pyran-4-yloxy)propyl)-5-
(dimethylamino)naphthalene-1-sulfonamide (2-1t). The residue was purified 
using flash chromatography (acetone:hexane = 1:2) to afford 2-1t (62.6 mg, 
69%) as a red solid. 1H NMR (500 MHz, DMSO-d6) δ 8.43 (d, J = 8.2 Hz, 1H), 
8.28 (d, J = 8.9 Hz, 1H), 8.11 (d, J = 7.0 Hz, 1H), 7.98-7.96 (m, 1H), 7.61-7.56 
(m, 2H), 7.22 (d, J = 7.6 Hz, 1H), 7.03 (dd, J = 11.4, 15.1 Hz, 1H), 6.90 (t, J = 
3.2 Hz, 1H), 6.80-6.70 (m, 2H), 6.63 (dd, J = 10.8, 14.5 Hz, 1H), 6.54-6.38 (m, 
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3H), 6.25 (d, J = 15.2 Hz, 1H), 6.14-6.13 (t, J = 2.5 Hz, 1H), 6.00 (d, J = 2.5 
Hz, 1H), 5.26 (d, J = 1.9 Hz, 1H), 3.85 (t, J = 4.5 Hz, 2H), 2.94-2.90 (m, 2H), 
2.81 (s, 6H), 1.76-1.71 (m, 2H); 13C NMR (125 MHz, DMSO-d6) δ 169.5, 
162.4, 158.2, 151.3, 138.8, 136.8, 135.6, 135.0, 131.1, 130.5, 129.5, 129.0, 
129.0, 128.4, 127.8, 126.0, 124.7, 123.4, 121.6, 120.8, 120.4, 118.8, 115.0, 
111.8, 109.1, 100.6, 88.5, 65.5, 54.8, 44.9, 28.0; HRMS (EI): calcd for 
C32H32N3O5ClS, 605.1751; found 605.1748. 
Synthesis of N-(3-(2-(6-((1E,3E,5E,7E)-8-(3-chloro-1H-pyrrol-2-yl)octa-
1,3,5,7-tetraenyl)-2-oxo-2H-pyran-4-yloxy)ethoxy)propyl)-5-
(dimethylamino)naphthalene-1-sulfonamide (2-1u). Pd2dba3 (5.5 mg, 6.0 
µmol) and AsPh3 (7.3 mg, 24 µmol) were added to a mixture of  compound 2-
2u (0.20 mmol) and 2-3 (0.169 g, 0.36 mmol) in NMP (1 mL) and allowed to 
stir at room temperature for 6 h. After which, water was added and the mixture 
was extracted with Et2O. The combined organic extract was washed with 
saturated NaCl solution, dried over MgSO4 and concentrated The residue 
obtained was dissolved in CH3CN (15 mL) and washed with pentane (15 mL x 
5) to remove the tributyltin bromide byproduct. Following that, CH3CN was 
removed under reduced pressure and the residue was purified using a short 
column (ca. 5 cm) of silica gel to afford 2-30u as a orange solid. Pd2dba3 (2.7 
mg, 3.0 µmol) and AsPh3 (4.6 mg, 15 µmol) was added to THF (1 mL) 
followed by 4a (56 mg, 0.195 mmol) and 1.8 M aqueous KOH (0.167 mL, 
0.300 mL). Compoun 2-30u (0.150 mmol) was dissolved in THF (0.5 mL) and 
added dropwise to the reaction mixture over 5 min with stirring. The reaction 
mixture was stirred for 20 min at room temperature and quenched with 
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saturated NH4Cl. EtOAc was added and the mixture was washed thrice with 
water followed by saturated NaCl solution. The organic extract was dried over 
MgSO4, concentrated under reduced pressure and the residue obtained was 
dissolved in THF (1 mL) and 1 M TBAF in THF (0.300 mL, 0.300 mmol) was 
added. The mixture was stirred at room temperature for 30 min and thereafter 
EtOAc was added and the mixture was washed thrice with water followed by 
saturated NaCl solution. The organic extract was dried over MgSO4, 
concentrated under reduced pressure and purified by column chromatography 
(acetone:hexane = 1:3) to afford 2-2u (52.0 mg, 40%) as a red solid. 1H NMR 
(500 MHz, Acetone-d6) δ 10.6 (br, 1H), 8.56 (d, J = 8.8 Hz, 1H), 8.39 (d, J = 
8.2 Hz, 1H), 8.22 (d, J = 7.0 Hz, 1H), 7.63-7.55 (m, 2H), 7.26 (d, J = 7.6 Hz, 
1H), 7.09 (dd, J = 11.4, 15.2 Hz, 1H), 6.88 (t, J = 2.9 Hz, 1H), 6.81-6.69 (m, 
2H), 6.65-6.60 (m, 3H), 6.46-6.38 (m, 2H), 6.20 (d, J = 15.2 Hz, 1H), 6.13 (d, 
J = 2.5 Hz, 1H), 6.04 (d, J = 1.9 Hz, 1H), 5.46 (d, J = 1.9 Hz, 1H), 4.09 (t, J = 
4.7 Hz, 2H), 3.58 (t, J = 4.7 Hz, 2H), 3.42 (t, J = 6.0 Hz, 2H), 3.03-3.00 (m, 
2H), 2.99 (s, 6H), 1.69-1.64 (m, 2H); 13C NMR (125 MHz, Acetone-d6) δ 
169.8, 162.2, 158.6, 151.7, 138.5, 136.5, 135.9, 135.1, 131.2, 130.4, 129.6, 
129.5, 129.5, 128.7, 127.6, 126.2, 124.6, 123.1, 121.6, 120.5, 119.7, 119.2, 
114.9, 112.5, 109.3, 100.4, 88.5, 68.0 (2 carbons), 67.8, 44.5, 40.3, 29.1; . 
HRMS (EI): calcd for C34H36N3O6ClS, 649.2013; found 649.1986. 
General Procedure for the Synthesis of 2-1v to 2-1z. Pd2dba3 (2.7 mg, 3.0 
μmol) and AsPh3 (4.6 mg, 15 μmol) was added to THF (1 mL) followed by the 
respective compound 2-4 (0.195 mmol) and 1.8 M aqueous KOH (0.167 mL, 
0.300 mL). Compound 2-30a or 2-30b (0.150 mmol) was dissolved in THF 
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(0.5 mL) and added dropwise to the reaction mixture over 5 min with stirring. 
The reaction mixture was stirred for 20 min at room temperature and quenched 
with saturated NH4Cl. EtOAc was added and the mixture was washed with 
H2O thrice followed by saturated NaCl solution. The organic extract was dried 
over MgSO4, concentrated under reduced pressure and purified by column 
chromatography.  
6-((1E,3E,5E,7E)-8-(3-chlorothiophen-2-yl)octa-1,3,5,7-tetraenyl)-4-
methoxy-2H-pyran-2-one (2-1v). The residue was purified using flash 
chromatography (acetone:CH2Cl2 = 1:30) to afford 2-1v (44.2 mg, 85%) as an 
orange solid. 1H NMR (500 MHz, CDCl3) δ 7.20 (dd, J = 11.4, 15.2 Hz, 1H), 
7.15 (d, J = 5.1 Hz, 1H), 6.89 (d, J = 5.7 Hz, 1H), 6.84 (d, J = 15.1 Hz, 1H), 
6.67 (dd, J = 10.8, 15.2 Hz, 1H), 6.59-6.50 (m, 2H), 6.45-6.34 (m, 2H), 6.06 (d, 
J = 15.1 Hz, 1H), 5.84 (d, J = 1.9 Hz, 1H), 5.45 (d, J = 1.9 Hz, 1H), 3.80 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 171.0, 164.0, 158.7, 138.4, 136.0, 135.7, 
135.3, 133.4, 131.6, 129.8, 128.6, 124.5, 123.7, 123.7, 121.9, 101.0, 88.7, 55.9; 
HRMS (ESI) [M+Na]+: calcd for C18H15NO3ClNaS, 369.0328; found 369.0325.  
6-((1E,3E,5E,7E)-8-(3-chlorothiophen-2-yl)octa-1,3,5,7-tetraenyl)-4-
methoxy-3-methyl-2H-pyran-2-one (2-1w). The residue was purified using 
flash chromatography (acetone:CH2Cl2 = 1:30) to afford 2-1w (43.8 mg, 81%) 
as an orange solid. 1H NMR (500 MHz, CDCl3) δ 7.22 (dd, J = 11.4, 15.2 Hz, 
1H), 7.15 (d, J = 5.1 Hz, 1H), 6.89 (d, J = 5.7 Hz, 1H), 6.84 (d, J = 15.2 Hz, 
1H), 6.67 (dd, J = 10.7, 15.1 Hz, 1H), 6.59-6.50 (m, 2H), 6.45-6.34 (m, 2H), 
6.08 (d, J = 15.2 Hz, 1H), 6.04 (s, 1H), 3.88 (s, 3H), 1.95 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 165.6, 164.7, 157.4, 138.2, 135.5, 135.4, 135.3, 133.4, 
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131.7, 129.8, 128.6, 124.5, 123.7, 123.6, 122.2, 103.0, 95.7, 56.2, 8.9; HRMS 
(ESI) [2M+Na]+: calcd for C38H34N2O6Cl2NaS, 743.1072; found 743.1079.  
6-((1E,3E,5E,7E)-8-(2-chlorophenyl)octa-1,3,5,7-tetraenyl)-4-methoxy-
3-methyl-2H-pyran-2-one (2-1x). The residue was purified using flash 
chromatography (acetone:CH2Cl2 = 1:40) to afford 2-1x (44.2 mg, 83%) as an 
orange solid. 1H NMR (500 MHz, CDCl3) δ 7.59-7.57 (m, 1H), 7.36-7.34 (m, 
1H), 7.24-7.14 (m, 3H), 7.05 (d, J = 15.2 Hz, 1H), 6.85 (dd, J = 10.7, 15.2 Hz, 
1H), 6.64-6.56 (m, 2H) 6.48-6.35 (m, 2H), 6.08 (d, J = 15.2 Hz, 1H), 6.05 (s, 
1H), 3.88 (s, 3H), 1.95 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 165.6, 164.7, 
157.4, 138.2, 136.1, 135.4, 135.0, 133.7, 133.4, 131.8, 131.0, 129.9, 129.9, 
128.7, 126.8, 126.2, 122.2, 103.0, 95.7, 56.1, 8.9; HRMS (ESI) [2M+Na]+: 
calcd for C42H38O6Cl2Na, 731.1943; found 731.1928.  
6-((1E,3E,5E,7E)-8-(3-chlorophenyl)octa-1,3,5,7-tetraenyl)-4-methoxy-
3-methyl-2H-pyran-2-one (2-1y). The residue was purified using flash 
chromatography (acetone:CH2Cl2 = 1:40) to afford 2-1y (42.1 mg, 79%) as an 
orange solid. 1H NMR (500 MHz, CDCl3) δ 7.40 (s, 1H), 7.28-7.18 (m, 4H), 
6.85 (dd, J = 10.1, 15.2 Hz, 1H), 6.58-6.50 (m, 3H), 6.47-6.35 (m, 2H), 6.09 (d, 
J = 15.2 Hz, 1H), 6.05 (s, 1H), 3.88 (s, 3H), 1.95 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 165.6, 164.7, 157.3, 139.0, 138.1, 135.7, 135.4, 134.7, 133.6, 132.6, 
131.8, 130.1, 129.9, 127.7, 126.2, 124.8, 122.2, 103.0, 95.8, 56.2, 8.9; HRMS 
(ESI) [M+Na]+: calcd for C21H19O3ClNa, 377.0920; found 377.0914.  
6-((1E,3E,5E,7E)-8-(3-chloro-1-(methylsulfonyl)-1H-pyrrol-2-yl)octa-
1,3,5,7-tetraenyl)-4-methoxy-3-methyl-2H-pyran-2-one (2-1z). The residue 
was purified using flash chromatography (acetone:CH2Cl2 = 1:20) to afford 2-
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1z (46.7 mg, 74%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 7.26-7.19 
(m, 2H), 7.16 (d, J = 3.2 Hz, 1H), 6.94 (d, J = 15.8 Hz, 1H), 6.60-6.44 (m, 3H), 
6.39 (dd, J = 11.4, 13.9 Hz, 1H), 6.31 (d, J = 3.2 Hz, 1H), 6.09 (d, J = 14.5 Hz, 
1H), 6.05 (s, 1H), 3.88 (s, 3H), 3.13 (s, 3H), 1.95 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 165.5, 164.7, 157.3, 138.0, 136.1, 135.3, 134.2, 133.4, 132.1, 127.4, 
122.4, 121.7, 118.6, 117.4, 114.0, 103.1, 95.8, 56.2, 42.5, 8.9; HRMS (ESI) 
[M+Na]+: calcd for C20H20NO5ClNaS, 444.0648; found 444.0652. 
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Synthesis and Biological Evaluation of Lignan Natural Products 
as Potential Chemotherapeutic Agents 
3.1 Introduction 
In our continued search for potential antitumor agents from natural products, 
we were attracted by the numerous biological properties displayed by lignans. 
Some of these biological effects include antioxidant antitumor, antiviral and 
antibacterial.1-7 Lignan is an important class of natural products that is derived 
from plants. They are secondary plant metabolites produced by the oxidative 
dimerization of two phenylpropanoid units and are structurally diverse based 
on the basic scaffold of two phenylpropane units.8 Typically, lignans are 
classified into 3 categories based on the types of C-C bond and the oxygen 
bridge joining the two phenylpropane units.9 The first class comprises acylic 
lignan derivatives 3-1 and includes dibenzylbutanes, dibenzyl substituted 
tetrahydrofuran and dibenzylbutyrolactones (Figure 3.1). The second class 
consists of cyclohexyl lignan derivatives 3-2 such as podophyllotoxin and the 
third class is the dibenzocyclooctadienes. 
3-1 3-2 3-3  
Figure 3.1. Classes of lignan compounds 
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Among the numerous biological activities displayed by lignans, their 
antitumor activity is of particular interest to us. Etoposide and teniposide are 
two clinical drugs that are derived from plant lignans.8 
 
Figure 3.2. Lignan-derived anticancer drugs. 
 
 
Figure 3.3. Lignans with antitumor properties. 
Other examples of anticancer plants lignans include matairesinol and 2-
hydroxyarctigenin which were isolated from safflower seeds and found to 
exhibit potent cytotoxic effects against human promyleocytic leukemia HL-60 
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cells (Figure 3.3).10 Hydroxymatairesinol was able reduce tumor volume in rats 
and short-term toxicity studies had shown that it is essentially non-toxic to 
rats.1,2 
In 2003, Harn and co-workers discovered that the acetone extract of 
Bupleurum scorzonerifolium inhibits the proliferation of A549 human lung 
cancer cells in vitro.11 Bupleurum scorzonerifolium, also known as Nan Chai 
Hu, is an important Chinese herb that is used in traditional Chinese medicine 
formulations.12 In that same year, Lin and co-workers isolated two new lignans, 
isochaihulactone 3-4a and chaihunapthone, along with 11 known compounds 
including nemerosin 3-5a from the root of Bupleurum scorzonerifolium (Figure 
3.3).13 3-4a and to a lesser extent, 3-5a were subsequently found to inhibit 
proliferation of various human cancer cells.14,15 
The synthesis of 3-5a has earlier been reported while the synthesis of 3-4a 
has never been reported before. This, together with the cytotoxicity effects of 
3-4a and 3-5a, prompted us to carry the asymmetric synthesis of 3-4a and 3-5a 
as well as their enanotiomers, sylvestrin 3-4b and 3-5b. The synthesis of all 4 
stereoisomers is desired as enanotiomers may possess differing biological 




















































isochaihulactone 3-4a: R = OMe
isokaerophyllin: R = H
nemerosin 3-5a: R = OMe
kaerophyllin: R = H
chaihunaphthone
isoscutellarein-8-methyl ether: R1 = H, R2 = OMe, R3 = OH
oroxylin: R1 = OMe, R2 = H, R3 = H
wogonin: R1 = H, R2 = OMe, R3 = H
1,2,3,7-tetramethoxyxanthone eugenin: R = H




Figure 3.4. Natural products isolated from the root of Bupleurum 
scorzonerifolium. 
Asymmetric synthetic methodologies are gaining in importance as 
illustrated by the recent trends in the FDA approval of new drug applications. 
The percentage of chiral drugs approved has increased from 58% in 1992 to 
75% in 2006 while achiral drugs approvals had fallen over that same period. In 
addition, chiral drugs obtained using purely asymmetric synthetic techniques 
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(excluding the use of chirality pool starting material) has increased from 20% 
in 1992 to over 50% in 2006.16 
Of the asymmetric techniques available, asymmetric hydrogenation is by far 
the most commonly used in academia and the industry. The field of 
asymmetric hydrogenation began when Wilkinson discovered the ability of Rh-
PPh3 complex to catalyze the hydrogenation of alkenes in solution.17 This 
meant that the catalysis and reaction are occurring within the complex and not 
on the surface of the metal. This allows chemists to synthesize various ligands 
which can form different complexes with the metal for asymmetric 
hydrogenation to take place. The earliest industrial application of asymmetric 
hydrogenation is in the production of the anti-Parkinsonian drug L-3,4-
dihydroxyphenylalanine (L-DOPA) at Monsanto in the 1970s.18 Since then 
asymmetric hydrogenation has become one of the most important tool for the 
preparation of optically active compounds. This is due to several advantages of 
this transformation: high enantioselectivity, low catalyst loading, quantitative 
yields, perfect atom economy and mild conditions.19 
Scheme 3.1. Asymmetric hydrogenation step of the Monsanto L-DOPA process 
 
3.2 Results and Discussion 
Of the 4 compounds we intend to synthesize, 3-4a and 3-4b are natural 
products which had been isolated previously but never synthesized. 3-5a is a 
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natural product which had previously been synthesized while there are no 
reports on the isolation or synthesis of 3-5b. 
 
Figure 3.5. Compounds synthesized. 
Prior to the asymmetric synthesis of the 4 compounds, a synthetic route was 
developed for the synthesis of the racemic compounds 3-4 and 3-5. Compound 
3-7a and 3-7b were readily obtained via Stobbe condensation of piperonal and 
diethyl succinate. Initially, ethanol and sodium ethoxide were used as the 
solvent and base respectively which afforded 3-7a while the use of methanol 
and sodium methoxide provided 3-7b. Although both reactions gave 
comparable yield, the latter reaction was preferred as 3-7b is a solid and can be 
purified via recrystallization unlike 3-7a which requires chromatographic 
methods as it exists as a sticky liquid. This allows the synthesis of 3-7b in large 






















































aReagents and conditions: :  (a) diethyl succinate, EtONa, EtOH, 70 °C; (b) 
diethyl succinate, MeONa, MeOH, reflux;  (c) 10% Pd/C, H2, MeOH, rt; (d) (i) 
KOH, CaCl2, EtOH, 0 °C; (ii) NaBH4, rt; (iii) 3 M HCl, rt; (e) LDA, 3,4,5-
trimethoxybenzaldehyde, THF, -78 °C, (f) MsCl, TEA, CH2Cl2, 0 °C; (g) DBU, 
CH3CN, rt; (h) Ac2O, TEA, DMAP, CH2Cl2, rt; (i) DBU, PhCH3, 80 °C. 
Subsequent hydrogenation of 3-7b afforded 3-8 in excellent yield and the 
chemoselective reduction of the potassium salts of 3-8 with CaCl2/NaBH4 in 
ethanol gave the desired lactone 3-9. Aldol condensation of 3-9 with 3,4,5-
trimethoxybenzaldehyde gave alcohol 3-10 which was treated with either 
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methanesulfonyl chloride or acetic anhydride to afford the corresponding 
meslyate 3-11 or acetate 3-12 respectively. Base promoted elimination of the 
formed acetate afforded 3-5 exclusively but elimination of the mesylate 
intermediate to afford 3-4 proved less selective. Varying the reaction 
conditions failed to increase the ratio of 3-4 to 3-5 beyond 3:1. The ratio of 3-4 
and 3-5 were determined by 1H NMR.  
Table 3.1. Optimization of the synthesis of 3-4. 
Solvent Base Temp. (°C) 3-4 : 3-5 
CH3CN DBU rt 3:1 
CH3CN DBU -40 3:1 
DMF DBU rt 3:1 
DMF DBU 0 3:1 
DMF KOH rt 3:1 
Toluene DBU rt 1:2 
EtOH KOH rt 3:1 
EtOH DBU rt 3:1 
 
With the racemic synthesis of 3-4 and 3-5 achieved, we proceeded with the 
asymmetric hydrogenation of 3-7b. Although there are many chiral ligands 
available for the successful asymmetric hydrogenation of itaconic acid and its 
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dimethyl ester derivatives 3-13a and 3-13b,  there have been far fewer reports 
on the successful asymmetric hydrogenation of β-substituted itaconic acid 
derivatives.20-24 Ligands which afforded high enantioselectivity for the 
hydrogenation are MOD-DIOP25,26, Et-DuPhos27, TangPhos28 and catASium 
M29. 
 
Figure 3.6. Structure of itaconic acid 3-13a, its dimethyl derivative 3-13b and 
ligands used for asymmetric hydrogenation. 
Initial attempts at asymmetric hydrogenation of 3-7b began with the use of 
commercially available catASium M. To our disappointment, the reaction 
failed to proceed and the starting material 3-7b was recovered. Despite the 
meticulous degassing of solvent and increasing the pressure of H2, there was no 
improvement. We eventually tried (S)-Et-DuPhos and gratifying, the 
hydrogenation of 3-7b proceeded readily to furnish 3-8a in 97% enantiomeric 
excess (ee). To obtain the other enantiomer, (R)-Et-DuPhos was used and 3-8b 
was obtained in 90% ee. The enantio enrichment of 3-8a and 3-8b was carried 
out by washing the crude products 3-8a and 3-8b with Et2O which improved 
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the ee of the two products to at least 98%. The ee of the compounds were 
determined by HPLC after converting 3-8a and 3-8b to their dimethyl ester 
derivatives. This simple enantio enrichment method, coupled with the readily 
available starting material 3-7b prompted us to adopt commercially available 
Et-DuPhos as the chiral ligand for the hydrogenation of 3-7b.  
Scheme 3.3. Asymmetric synthesis of 3-4 and 3-5a 
 
aReagents and conditions: (a) [{(S,S)-(Et-DuPhos)}Rh(COD)]BF4, MeONa, 8 
bar H2, MeOH, rt; (b) [{(R,R)-(Et-DuPhos)}Rh(COD)]BF4, MeONa, 8 bar H2, 
MeOH, rt; (c) (i) KOH, CaCl2, EtOH, 0 °C; (ii) NaBH4, rt; (iii) 3 M HCl, rt; (d) 
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LDA, 3,4,5-trimethoxybenzaldehyde, THF, -78 °C, (e) MsCl, TEA, CH2Cl2, 
0 °C; (f) DBU, CH3CN, rt; (g) Ac2O, TEA, DMAP, CH2Cl2, rt; (h) DBU, 
PhCH3, 80 °C. 
With both 3-8a and 3-8b in hand, we proceeded with the synthesis based on 
the synthetic route of the racemic 3-4 and 3-5 (Scheme 3.3) to afford the 4 final 
compounds, 3-4a, 3-4b, 3-5a and 3-5b. 
3.3 Biological Resultsa 
aAll the biological results were obtained as a result of a collaboration with 
another research group. 
Table 3.2. Cytotoxicity of synthesized compounds against various cancer cellsa 
  IC50 (µM) 
Cell line Origin 3-4a 3-4b 3-5a 3-5b 
PC3 Androgen-independent 7.2 1.1 13.5 8.7 
prostate adenocarcinoma 
LNCaP Androgen-dependent 6.5 0.96 12.5 13.8 
prostate adenocarcinoma 





OECM-1 Oral squamous cell 
carcinoma 




aThe viability of the cells after treatment with various chemicals was evaluated 
using an MTT assay preformed in triplicate after 48 h of incubation. 
The cytotoxicities of the 4 compounds against various cancer cells are 
shown in Table 3.2. As illustrated, the Z-isomers 3-4a and 3-4b displayed more 
potent cytotoxicities against all the classes of cancer cells tested compared to 
the E-isomers 3-5a and 3-5b. Comparing between 3-5a and 3-5b, it appears 
that there is little difference between the cytotoxicities of the two enanotiomers. 
However comparison of the 2 Z-isomers 3-4a and 3-4b showed that the S-
enantiomer 3-4b is significantly more potent than its mirror image 3-4a. This is 
especially so against OECM-1 cancer cells where 3-4b is 18-fold more potent 
than 3-4a. 
3.4 Conclusion 
Earlier in Chapter 2, we described the synthesis of a class of 
polyenylpyyrole natural products and their analogs which displayed excellent 
cytotoxicity against A549 human lung cancer cells. In continuing our efforts to 
develop natural product-based antitumor agents, we have herein provided the 
synthesis of isochaihulactone 3-4a and nemerosin 3-5a as well as their 
enantiomers slyvestrin 3-4b and 3-5b. This represents the first reported 
synthesis of 3-4a, 3-4b and 3-5b. The Z-isomers of these 4 compounds showed 
higher cytotoxicity against the cancer cells tested compared to the E-isomers. 
In particular 3-4b displayed excellent activity against OECM-1 oral cancer 




3.5 Experimental Section 
General Procedures. All chemical reagents and solvents were obtained from 
Sigma Aldrich, Merck, Alfa Aesar, or Fluka and were used without further 
purification. Analytical TLC was carried out on precoated silica plates (Merck 
silica gel 60, F254) and visualized with UV light or stained with 
phosphomolybdic acid (PMA) stain. Flash column chromatography was 
performed with silica (Merck, 70-230 mesh). The ee of the dimethyl esters of 
3-8a, 3-8b, 3-4a, 3-4b, 3-5a and 3-5b were determined via HPLC using a 
CHIRALPAK IB analytical column. The purities of the compounds were 
determined via HPLC using a Shimadzhu LCMS-IT-TOF system with a 
Phenomenex Luma C18 column. Compounds used in the biological assays 
have purities of at least 95%. 1H NMR and 13C NMR spectra were measured on 
a Bruker ACF 300 or AMX 500 Fourier transform spectrometer. Chemical 
shifts were reported in parts per million (δ) relative to the internal standard of 
tetramethylsilane (TMS). The signals observed were described as follows: s 
(singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), m 
(multiplet). The number of protons (n) for a given resonance was indicated as 
nH. Mass spectra were performed on a Finnigan/MAT LCQ mass spectrometer 
under electron spray ionization (ESI) or electron impact (EI) techniques. 
4-(benzo[d][1,3]dioxol-5-yl)-3-(ethoxycarbonyl)but-3-enoic acid (3-7a). 
21% sodium ethoxide solution (9.0 mL, 24.0 mmol) was added to a mixture of 
piperonal (3.0 g, 20.0 mmol) and diethyl succinate (5.2 g, 30.0 mmol) in 
ethanol (30 mL) and stirred at 70 °C for 1 h.  The reaction mixture was cooled 
to room temperature before adding 3 N HCl until pH 2~3 was achieved.  The 
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mixture was extracted with Et2O and the combined organic extracts were 
washed with brine and dried over MgSO4.  After evaporation of the solvent, the 
residue was purified using flash chromatography (MeOH:CH2Cl2 = 1:30) to 
afford 3 (4.60 g, 82%) as a pale yellow, viscous oil: 1H NMR (500 MHz, 
CDCl3) δ 7.80 (s, 1H), 6.89-6.83 (m, 3H), 5.99 (s, 2H), 4.28 (q, J = 6.9 Hz, 
2H), 3.58 (s, 2H), 1.33 (t, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) δ 177.0, 
167.5, 148.4, 147.9, 142.0, 128.7, 124.0, 123.9, 109.1, 108.6, 101.4, 61.3, 33.6, 
14.1; HRMS (ESI) [M+Na]+: calcd for C14H14O6Na 301.0688, found 301.0686. 
4-(benzo[d][1,3]dioxol-5-yl)-3-(methoxycarbonyl)but-3-enoic acid (3-7b). 
MeONa (1.30 g, 24.0 mmol) was added to a mixture of piperonal (3.0 g, 20.0 
mmol) and diethyl succinate (5.2 g, 30.0 mmol) in methanol (30 mL) and 
refluxed for 1 h.  After which, the solvent was removed under reduced pressure 
before adding 3 N HCl until pH 2~3 was achieved.  The mixture was extracted 
with Et2O and the combined organic extracts was washed with brine and dried 
over MgSO4. The solvent was removed under reduced pressure and the residue 
was washed with Et2O to afford 3-7b (4.12 g, 78%) as a yellow solid. 1H NMR 
(500 MHz, DMSO-d6) δ 12.5 (s, 1H), 7.68 (s, 1H), 7.00-6.94 (m, 3H), 6.07 (s, 
2H), 3.73 (s, 3H), 3.43 (s, 2H); 13C NMR (125 MHz, DMSO-d6) δ 172.0, 167.5, 
148.1, 147.6, 140.5, 128.4, 124.6, 124.1, 108.9, 108.6, 101.5, 52.0, 33.5; 
HRMS (EI): calcd for C13H12O6 264.0634, found 264.0626. 
3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-ethoxy-4-oxobutanoic acid (3-8).  
A mixture of 10% Pd/C (300 mg) and 3-7a (3.96 g, 15.0 mmol) was dissolved 
in MeOH (30 mL) and stirred under a hydrogen atmosphere for 12 h.  The 
reaction mixture was filtered and the filtrate concentrated to give 3-8 (3.83 g, 
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96%) as a colorless, viscous oil: 1H NMR (500 MHz, CDCl3) δ 6.72 (d, J = 8.1 
Hz, 1H), 6.64 (d, J = 1.1 Hz, 1H), 6.60-6.58 (m, 1H), 5.93 (s, 2H), 3.68 (s, 3H), 
3.08-2.95 (m, 2H), 2.72-2.67 (m, 2H), 2.47-2.42 (m, 1H); 13C NMR (75 MHz, 
CDCl3) δ 177.0, 174.4, 147.8, 146.4, 131.6, 122.1, 109.2, 108.3, 100.9, 52.0, 
42.9, 37.3, 34.5; HRMS (ESI) [M-H]-: calcd for C13H14O6 266.0790, found 
266.0793. 
(R)-3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-methoxy-4-oxobutanoic acid 
(3-8a). Compound 3-7b (2.64 g, 10.0 mmol), MeONa (54 mg, 1.00 mmol) and 
[{(S,S)-(Et-DuPhos)}Rh(COD)]BF4 (6.6 mg, 0.01 mmol) was added to 
degassed MeOH in a 100 mL hydrogenation vessel. The reaction vessel was 
stirred at room temperature under a hydrogen atmosphere (8 bar) for 48 h. 
Subsequently, the solvent was removed under reduced pressure and the residue 
was acidified with 1M HCl and extracted with EtOAc. The combined organic 
extract was washed with brine, dried over MgSO4 and concentrated. The 
residue was washed with Et2O twice to afford 3-8a (2.00 g, 75%, 99% ee) as a 
pale yellow solid. [α]25 +14.1° (c 1.0, CH2Cl2). 1H NMR and 13C NMR 
matches that of 3-8. 
(S)-3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-methoxy-4-oxobutanoic acid 
(3-8b). Compound 3-7b (2.64 g, 10.0 mmol), MeONa (54 mg, 1.00 mmol) and 
[{(R,R)-(Et-DuPhos)}Rh(COD)]BF4 (6.6 mg, 0.01 mmol) were added to 
degassed MeOH in a 100 mL hydrogenation vessel. The reaction vessel was 
stirred at room temperature under a hydrogen atmosphere (8 bar) for 48 h. 
Subsequently, the solvent was removed under reduced pressure and the residue 
was acidified with 1M HCl and extracted with EtOAc. The combined organic 
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extract was washed with brine, dried over MgSO4 and concentrated. The 
residue was washed with Et2O twice to afford 3-8b (2.00 g, 71%, 98% ee) as a 
pale yellow solid. [α]25 -13.8° (c 1.0, CH2Cl2). 1H NMR and 13C NMR matches 
that of 3-8. 
General procedure for the esterification of 3-8a and 3-8b. To 3-8a or 3-
8b (53.2 mg, 0.20 mmol) in MeOH (2 mL) was added TMSCl (86.9 mg, 0.80 
mmol) and stirred at 40 °C for 30 min. After which, H2O was added and the 
reaction mixture was extracted with EtOAc. The combined organic extract was 
washed with brine, dried over MgSO4 and concentrated to afford the methyl 
ester derivatives of 3-8a and 3-8b in essentially quantitative yield. 
General procedure for the synthesis of 4-(Benzo[d][1,3]dioxol-5-
ylmethyl)-dihydrofuran-2(3H)-one (3-9). KOH (85%, 1.04 g, 15.7 mmol) 
and CaCl2 (1.84 g 16.6 mmol) were successively added to 3-8 (4.40 g, 15.7 
mmol) in EtOH (40 mL) at 0 °C and stirred for 5 min. Thereafter, NaBH4 (1.30 
g, 34.4 mmol) was added and the reaction mixture was warmed to room 
temperature and stirred for 4 h. After which, 3 M HCl was added until the 
reaction mixture achieved pH 0-1. The reaction mixture was then stirred for an 
additional 1 h. After evaporation of the solvent, water was added to the mixture 
and extracted with CH2Cl2. The combined organic extract was washed with 
brine, dried over MgSO4, concentrated and the residue obtained was purified 
using flash chromatography (EtOAc:hexane = 1:4). 
4-(Benzo[d][1,3]dioxol-5-ylmethyl)-dihydrofuran-2(3H)-one (3-9). 3-9  
(2.82 g, 82%) was obtained as a colorless viscous oil. 1H NMR (500 MHz, 
CDCl3) δ 6.74 (d, J = 8.3 Hz, 1H), 6.63-6.58 (m, 2H), 5.94 (s, 2H), 4.32 (t, J = 
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8.2 Hz, 1H), 4.03-3.99 (m, 1H), 2.82-2.72 (m, 1H), 2.69-2.64 (m, 2H), 2.59 (dd, 
J = 8.2, 17.8 Hz, 1H), 2.27 (dd, J = 7.0, 17.6 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 176.7, 148.0, 146.4, 131.9, 121.6, 108.8, 108.4, 101.0, 72.5, 38.6, 
37.3, 34.1; HRMS (EI): calcd for C12H12O4 220.0736, found 220.0737. 
(R)-4-(Benzo[d][1,3]dioxol-5-ylmethyl)-dihydrofuran-2(3H)-one (3-9a). 
3-9a (2.82 g, 82%) was obtained as a colorless viscous oil. [α]25 +4.2° (c 1.0, 
CH2Cl2). 1H NMR and 13C NMR matches that of 3-8. 
(S)-4-(Benzo[d][1,3]dioxol-5-ylmethyl)-dihydrofuran-2(3H)-one (3-9b). 
3-9b (2.54 g, 75%) was obtained as a colorless viscous oil. [α]25 -3.8° (c 1.0, 
CH2Cl2). 1H NMR and 13C NMR matches that of 3-9. 
  General procedure for the synthesis of (Z)-4-(benzo[d][1,3]dioxol-5-
ylmethyl)-3-(3,4,5-trimethoxybenzylidene)dihydrofuran-2(3H)-one (3-4). A 
solution of 2 M lithium diisopropylamine in THF (6.5 mL) was added 
dropwise to a solution of 3-9 (2.20 g, 10.0 mmol) in THF (30 mL) at -78 °C 
and stirred for 45 min.  Subsequently, a solution of 3,4,5-
trimethoxybenzaldehyde (2.55 g, 13.0 mmol) in THF (7 mL) was added to the 
reaction mixture and stirred at -78 °C for 10 min. The mixture was quenched 
using saturated NH4Cl solution and allowed to warm to room temperature 
before extracting with CH2Cl2. The combined organic extract was dried over 
MgSO4, concentrated and the residue obtained was purified using flash 
chromatography (EtOAc:hexane = 2:3) to obtain a pale yellow viscous oil 3-10. 
Triethylamine (3.63 g, 35.9 mmol) was added to the oil in CH2Cl2 (25 mL) and 
cooled to 0 °C. Methanesulfonyl chloride (3.39 g, 29.6 mmol) was then added 
at 0 °C and stirred for 15 min. The reaction mixture was quenched with water 
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and extracted with Et2O. The combined organic extract was washed with brine, 
dried over MgSO4, concentrated to afford a yellow viscous oil 3-11. 3-11 was 
dissolved in CH3CN (15 mL) with DBU (1.52 g, 10.0 mmol) added. The 
reaction mixture was stirred for 15 min, before water was added and extracted 
with EtOAc. The combined organic extract was washed with brine, dried over 
MgSO4, concentrated and the residue obtained was purified using flash 
chromatography (EtOAc:Hexane = 1:3).  
(Z)-4-(benzo[d][1,3]dioxol-5-ylmethyl)-3-(3,4,5-
trimethoxybenzylidene)dihydrofuran-2(3H)-one (3-4). 3-4 (2.71 g, 68%) 
was obtained as white powder. 1H NMR (500 MHz, CDCl3) of 2 δ 7.25 (s, 2H), 
6.75 (d, J = 8.2 Hz, 1H), 6.68 (d, J = 1.3 Hz, 1H), 6.63-6.61 (m, 2H), 5.94 (d, J 
= 3.2 Hz), 4.32 (dd, J = 7.5, 9.5 Hz, 1H), 4.10 (dd, J = 3.8, 9.5 Hz, 1H), 3.80 
(s, 6H), 3.80 (s, 3H), 3.31-3.28 (m, 1H), 2.93 (dd, J = 6.3, 13.3 Hz, 1H), 2.79 
(dd, J = 8.8, 13.9 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 169.2, 152.6, 147.9, 
146.4, 140.5, 139.6, 131.3, 128.8, 126.3, 122.2, 109.2, 108.6, 108.3, 101.0, 
69.8, 60.8, 56.1, 44.3, 40.6; HRMS (ESI) [M+Na]+: calcd for C22H22O7Na 
421.1263, found 421.1252. 
Isochaihulactone (3-4a). 3-4a (2.75 g, 69%) was obtained as a white 
powder. [α]25 -68.5° (c 1.0, CH2Cl2). 1H NMR and 13C NMR matches that of 3-
4. 
Slyvestrin (3-4b). 3-4b (2.63 g, 66%) was obtained as a white powder. [α]25 
+75.2° (c 1.0, CH2Cl2). 1H NMR and 13C NMR matches that of 3-4. 
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General procedure for the synthesis of (E)-4-(benzo[d][1,3]dioxol-5-
ylmethyl)-3-(3,4,5-trimethoxybenzylidene)dihydrofuran-2(3H)-one (3-5). A 
solution of 2 M lithium diisopropylamine in THF (6.5 mL) was added 
dropwise to a solution of 3-9 (2.20 g, 10.0 mmol) in THF (30 mL) at -78 °C 
and stirred for 45 min. Subsequently, a solution of 3,4,5-
trimethoxybenzaldehyde (2.55 g, 13.0 mmol) in THF (7 mL) was added to the 
reaction mixture and stirred at -78 °C for 10 min. The mixture was quenched 
with saturated NH4Cl solution and allowed to warm to room temperature 
before extracting with CH2Cl2. The combined organic extract was dried over 
MgSO4, concentrated and the residue obtained was purified using flash 
chromatography (EtOAc:hexane = 2:3) to yield a pale yellow viscous oil 3-10. 
To the oil was added CH2Cl2 (10 mL), Ac2O (1.30 g, 12.7 mmol), 
triethylamine (1.30 g, 12.9 mmol), DMAP (30 mg, 0.25 mmol) and stirred for 
20 min. The reaction mixture was diluted with CH2Cl2 (20 mL) and washed 
successively with 1.5 M HCl, water and saturated NaHCO3 solution. The 
organic extract was dried over MgSO4 and then concentrated to provide 3-12 as 
a yellow oil. 3-12 and DBU (1.1 mL, 7.4 mmol) were dissolved in toluene (20 
mL) and stirred at 80 °C for 1 h. After evaporation of the solvent, the residue 
was purified by flash chromatography (EtOAc:Hexane = 1:3) 
(E)-4-(benzo[d][1,3]dioxol-5-ylmethyl)-3-(3,4,5-
trimethoxybenzylidene)dihydrofuran-2(3H)-one (3-5). 3-5 (1.81 g, 91%) 
was obtained as a white powder. 1H NMR (500 MHz, CDCl3) δ 7.49 (s, 1H), 
6.76 (s, 1H), 6.68 (d, J = 7.6 Hz, 1H), 6.60-6.57 (m, 2H), 5.91 (d, J = 5.1 Hz), 
4.30-4.23 (m, 2H), 3.88 (s, 3H), 3.87 (s, 6H), 3.85-3.81 (m, 1H), 3.01 (dd, J = 
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5.0, 14.5 Hz, 1H), 2.65 (dd, J = 10.1, 14.5 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 172.2, 153.3, 147.9, 146.5, 139.8, 137.6, 131.2, 129.4, 127.0, 121.8, 
109.0, 108.4, 107.3, 101.0, 69.6, 60.9, 56.2, 39.4, 37.7; HRMS (ESI) [M+Na]+: 
calcd for C22H22O7Na 421.1263, found 421.1248. 
Nemerosin (3-5a). 3-5a (1.77 g, 89%) was obtained as a white powder. 
[α]25 -18.6° (c 1.0, CH2Cl2). 1H NMR and 13C NMR matches that of 3-5. 
(S,Z)-4-(benzo[d][1,3]dioxol-5-ylmethyl)-3-(3,4,5-
trimethoxybenzylidene)dihydrofuran-2(3H)-one (3-5b). 3-5b (1.73 g, 87%) 
was obtained as a white powder. [α]25 +22.5° (c 1.0, CH2Cl2). 1H NMR and 13C 
NMR matches that of 3-5. 
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Chapter 4:  
A Rapid and Convenient Synthesis of 5-Unsubstituted 3,4-
Dihydropyrimidin-2-ones and thiones 
4.1 Introduction 
It has been more than 100 years since Pietro Biginelli discovered a 
multicomponent reaction that formed the 3,4-dihydropyrimidin-2-one 
compound 4-1 in 1893.1 It involves a one-pot reaction between urea, 
benzaldehyde and ethyl acetoacetate (Scheme 4.1). However this reaction was 
largely ignored in the decades that followed until 1980s when interest in this 
efficient reaction picked up significantly. This is due to the discovery of 3,4-
dihydropyrimidine-2-ones/thiones as useful targets in chemical synthesis 
because they have been associated with a diverse range of therapeutic and 
medicinal properties.2-11 The dihydropyrimidinone scaffold is also found in 
various marine alkaloids which have been shown to possess antiviral, 
antibacterial and anti-inflammatory activities.12 Moreover the batzelladine 
alkaloids are known to be potent HIV gp-120-CD4 inhibitors.13 




In particular, monastrol and their analogs have been found to inhibit human 
kinesin Eg5, which plays an essential role in mitosis (Figure 4.1).14,15 Because 
compounds that cause mitotic arrests have been known to possess anticancer 
activity, we were interested in synthesizing a small library of monastrol 
analogs. In addition, our group had earlier explored the sodium channel 
blockade activities of pyrimidin-2-ones and pyrimidi-2-thiones and identified 
two compounds, 4-2 and 4-3 which possess neuronal sodium channel blockade 
activities (Figure 4.2).16 In continuing our interest in the investigation of 
pyrimidin-2-ones and pyrimidi-2-thiones for their sodium channel blockade 
and anti-tumor activities, the synthesis of these compounds carrying different 
substituents from 4-2 and 4-3 was explored. 
 
Figure 4.1. Structures of (S)-monastrol and its analogs as inhibitors of kinase 
Eg5. 
4.2 Results and Discussion 
Typically, dihydropyrimidinones obtained via Biginelli reaction would 
house an ester at the C5 position.17 However Bussolari and co-worker had 
demonstrated that replacing alkyl acetoacetate with oxalacetic acid 4-6 as a 
substrate for the Biginelli reaction led to the formation of 5-unsubstituted 3,4-
dihydropyrimidin-2-ones due to in-situ decarboxylation after cyclization.18 
136 
 
These compounds are of interest to us as they bear resemblance to monastrol 
and compounds 4-2 and 4-3. Moreover, there already exists in the literature a 
large library of dihydropyrimidinones with an ester at the C5 position.  As such, 








4-2 4-3  
Figure 4.2. Pyrimidi-2-thione 4-2 and pyrimidin-2-one 4-3 with sodium 
channel blockage ability. 
One of the major drawbacks to the reaction reported by Bussolari and co-
worker is the long reaction time (12 h). For library preparation, it would be 
desirable if the reaction could be (i) conducted expeditiously with good yield 
and (ii) applied to a variety of reagents. To achieve this, we explored the use of 
microwave irradiation and also expanded the diversity by applying thiourea 
and substituted urea/thiourea to the reaction (Scheme 4.2).  




According to Bussolari and co-worker, 5-unsubstituted 3,4-
dihydropyrimidin-2-ones  could be effectively synthesized from oxalacetic acid, 
urea and aldehyde when TFA was used as a catalyst and dichloroethane as the 
solvent. In our initial synthesis of 6-phenyl-2-thioxo-1,2,3,6-tetrahydro-
pyrimidine-4-carboxylic acid 4-7a, we adopted Bussolari’s procedure but 
replaced urea with thiourea and obtained the compound in 64% yield. This 
result was encouraging as it demonstrated the first synthesis of 2-thioxo-
1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid. To optimize the reaction, we 
explored microwave irradiation under different reaction conditions (Table 4.1) 
and found that 4-7a was obtained in good yields when the reaction was 
performed in solvents like CH2Cl2, THF or dichloroethane (entries ii, viii and x, 
Table 1). To demonstrate the versatility of these reaction conditions for the 
synthesis of 4-7, we carried out the reaction with different aldehydes. 
Table 4.1. Optimization of the synthesis of 4-7a. 
 
Entry  4-4a    
(equiv) 
4-5a    
(equiv)  
4-6    
(equiv) 






i 1.5 1.2 1 EtOH  10 120 60 
ii 1.3 1.2 1 CH2Cl2 10 90 79 
iii 1.3 1.2 1 CH2Cl2 15 90 74 
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iv 1.3 1.2 1 Toluene 10 90 - 
v 1.3 1.2 1 THF 10 90 61 
vi 1.3 1.2 1 THF 15 90 69 
vii 1.3 1.2 1 THF 15 100 76 
viii 1.2 1 1.2 THF 20 100 82 
ix 1.3 1.2 1 ClCH2CH2Cl 10 90 78 
x 1.2  1  1.2  ClCH2CH2Cl 10  90  84  
 
However further experimentation showed that when CH2Cl2 and 
dichloroethane were used in the synthesis of certain analogs, in particular 4-7b 
and 4-7c, the desired product was not obtained and instead a black tar-like 
substance was found coated to the sides of the microwave vessel. A possible 
reason is that the product is less soluble in CH2Cl2 and dicholoroethane and 
precipitated on the sides of the microwave vessel during the reaction. The 
intense heat from the microwave radiation subsequently caused the 
decomposition of the product into the tar-like substance. Consequently, the 
reaction condition shown in entry viii of Table 1 was used as the general 
procedure for our synthesis and a diverse set of 4-7 was prepared in good 
yields with both electron-withdrawing and electron-donating aldehydes (Table 
4.1). For reactions with substituted thiourea/urea, the reaction was observed to 
proceed chemoselectively to provide only the N3-substituted 3,4-
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dihydropyrimidin-2-ones/thiones (determined by X-ray structure of 4-7w and 
1D NoE of 4-7p and 4-7r). 
 
 
Figure 4.3. X-ray crystal structure of 4-7w 
4.3 Conclusion 
In summary, we have demonstrated an expeditious and high yielding 
synthesis of 5-unsubstituted 3,4-dihydropyrimidin-2-thiones and 5-
unsubstituted 3,4-dihydropyrimidin-2-ones (Table 4.2). We have shown that 
under microwave irradiation, the reaction time was shortened from 12 h to 15 
min. These results further demonstrate the value of microwave-assisted 
synthesis in increasing yield, shortening reaction time and streamlining high 
throughput synthesis. 
Table 4.2 List of compounds synthesized. 
 
Compound X R1 R2 Yield (%)a 
4-7a S H C6H5 82 (64b) 
4-7b S H 4-FC6H4 83 
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4-7c S H 2,4-(MeO)2C6H3 83 
4-7d S H 2-furyl 93 
4-7e S H 2-thienyl 76 
4-7f S H 2-naphthyl 82 
4-7g O H C6H5 94 (88c) 
4-7h O H 4-FC6H4 73 
4-7i O H 2,4-(MeO)2C6H3 91 
4-7j O H 2-furyl 83 
4-7k O H 2-thienyl 71 (72c) 
4-7l O H 2-naphthyl 89 
4-7m S CH3 C6H5 89 
4-7n S CH3 4-FC6H4 84 
4-7o S allyl C6H5 78 
4-7p S allyl 3-ClC6H4 75 
4-7q S allyl 2-naphthyl 79 
4-7r O CH3 C6H5 84 
4-7s O CH3 4-FC6H4 83 
4-7t O CH3 2,4-(MeO)2C6H3 76 
4-7u O allyl C6H5 83 
4-7v O allyl 3,5-Br2C6H3 77 
4-7w O allyl 2-naphthyl 81 
     
a isolated yield 
b using the conventional heating method as reported by Bussolari et al (ref 6) 
c yield reported in ref 18 
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4.4 Experimental Section 
General Procedures. All chemical reagents and solvents were obtained from 
Sigma Aldrich, Merck, Alfa Aesar, or Fluka and were used without further 
purification. The microwave-assisted reactions were performed using the 
Biotage Initiator microwave synthesizer. Analytical TLC was carried out on 
precoated silica plates (Merck silica gel 60, F254) and visualized with UV light. 
1H NMR and 13C NMR spectra were measured on a Bruker ACF 300 or AMX 
500 Fourier transform spectrometer. Chemical shifts were reported in parts per 
million (δ) relative to the internal standard of tetramethylsilane (TMS). The 
signals observed were described as follows: s (singlet), d (doublet), t (triplet), q 
(quartet), dd (doublet of doublets), m (multiplet). The number of protons (n) 
for a given resonance was indicated as nH. Mass spectra were performed on a 
Finnigan/MAT LCQ mass spectrometer under electron spray ionization (ESI) 
or electron impact (EI) techniques. 
General Procedure for the Synthesis of 4-7a to 4-7l. To a mixture of 
oxalacetic acid (2.6 mmol), aldehyde (2.0 mmol) and urea/thiourea (2.6 mmol) 
in THF (3 mL) was added TFA (0.10 mL). The mixture was heated at 95 °C 
for 15 min using microwave irradiation in a sealed tube. Thereafter, the 
mixture was cooled and the solvent was removed under reduced pressure. The 
residue obtained was washed with Et2O and dried under vacuum to afford the 
final product. 
6-phenyl-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid 4-7a: 
1H NMR (300 MHz, DMSO-d6) δ 9.21 (s, 1H), 8.47 (s, 1H), 7.43-7.27 (m, 5H), 
6.05 (d, J = 4.8 Hz, 1H), 5.18 (dd, J = 2.4, 4.8 Hz, 1H); 13C NMR (75 MHz, 
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DMSO-d6) δ 174.4, 162.3, 142.6, 128.8, 127.9, 126.3, 125.8, 110.8, 54.6; 
HRMS (ESI) [M-H]-: calcd for C11H9N2O2S, 233.0379; found 233.0383. 
6-(4-fluorophenyl)-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic 
acid 4-7b: 1H NMR (500 MHz, DMSO-d6) δ 9.22 (s, 1H), 8.50 (s, 1H), 7.33-
7.30 (m, 2H), 7.26-7.22 (m, 2H), 6.04 (dd, J = 1.3, 3.2 Hz, 1H), 5.20 (dd, J = 
2.5, 5.1 Hz, 1H); 13C NMR (75 MHz, DMSO-d6) δ 174.3, 163.3, 162.3, 160.1, 
138.9, 138.8, 128.5, 128.4, 126.0, 115.8, 115.5, 110.6, 53.9; HRMS (EI): calcd 
for C11H9FN2O2S, 252.0369; found 252.0363. 
6-(2,4-dimethoxyphenyl)-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-
carboxylic acid 4-7c: 1H NMR (500 MHz, DMSO-d6) δ 8.94 (s, 1H), 8.38 (s, 
1H), 7.01 (d, J = 8.2 Hz, 1H), 6.60-6.58 (m, 2H), 5.95-5.94 (m, 1H), 5.29 (dd, 
J = 2.5, 4.4 Hz, 1H), 3.82 (s, 3H), 3.76 (s, 3H); 13C NMR (125 MHz, DMSO-d6) 
δ 174.9, 162.4, 160.4, 156.3, 127.5, 125.6, 122.5, 110.2, 105.1, 98.6, 55.7, 55.3, 
49.6; ; HRMS (ESI) [M+H]+: calcd for C13H15N2O4S, 295.0747; found 
295.0753. 
6-(furan-2-yl)-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid 
4-7d: 1H NMR (500 MHz, DMSO-d6) δ 9.23 (s, 1H), 8.56 (s, 1H), 7.67 (s, 1H), 
6.46 (dd, J = 1.9, 3.2 Hz, 1H), 6.30 (d, J = 3.2 Hz, 1H), 5.97-5.96 (m, 1H), 5.26 
(dd, J = 2.6, 5.1 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 174.5, 162.2, 
153.4, 143.2, 127.3, 110.7, 107.6, 107.2, 48.2; HRMS (EI): calcd for 
C9H8N2O3S, 224.0256; found 224.0250. 
6-(thiophen-2-yl)-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic 
acid 4-7e: 1H NMR (500 MHz, DMSO-d6) δ 9.34 (s, 1H), 8.61 (s, 1H), 7.51 
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(dd, J = 1.9, 3.8 Hz, 1H), 7.03-7.01 (m, 2H) 6.08-6.07 (m, 1H), 5.46 (dd, J = 
2.6, 5.1 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 174.0, 162.2, 146.2, 127.1, 
126.3, 126.2, 125.0, 110.0, 49.8; HRMS (ESI) [M-H]-: calcd for C9H7N2O2S2, 
238.9943; found 238.9944. 
6-(naphthalen-2-yl)-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic 
acid 4-7f: 1H NMR (500 MHz, DMSO-d6) δ 9.34 (s, 1H), 8.56 (s, 1H), 7.97-
7.90 (m, 3H), 7.76 (s, 1H), 7.53-7.47 (m, 3H), 6.14 (d, J = 4.5 Hz, 1H), 5.39 
(dd, J = 2.5, 4.4 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 174.5, 162.3, 
140.0, 132.8, 132.6, 128.8, 127.9, 127.6, 126.6, 126.3, 126.0, 124.9, 124.6, 
110.6, 54.9; HRMS (EI): calcd for C15H12N2O2S, 284.0619; found 284.0612. 
2-oxo-6-phenyl-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid 4-7g. 1H 
NMR (500 MHz, DMSO-d6) δ 7.76 (s, 1H), 7.39-7.28 (m, 5H), 5.79 (d, J = 4.4 
Hz, 1H), 5.16 (dd, J = 1.9, 4.5 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 
163.0, 152.4, 143.8, 128.7, 127.7, 127.6, 126.1, 109.0, 54.7; HRMS (EI): calcd 
for C11H10N2O3, 218.0691; found 218.0696. 
6-(4-fluorophenyl)-2-oxo-1,2,3,6-tetrahydro pyrimidine-4-carboxylic 
acid 4-7h: 1H NMR (500 MHz, DMSO-d6) δ 7.80 (s, 1H), 7.35-7.32 (m, 2H), 
7.22-7.19 (m, 2H), 5.78-5.77 (m, 1H), 5.18 (dd, J = 1.9, 4.4 Hz, 1H); 13C NMR 
(125 MHz, DMSO-d6) δ 162.9, 162.5, 160.6, 152.3, 140.0, 140.0, 128.2, 128.2, 
127.8, 115.5, 115.4, 108.7, 54.0; HRMS (EI): calcd for C11H9FN2O3, 236.0597; 
found 236.0594. 
6-(2,4-dimethoxyphenyl)-2-oxo-1,2,3,6-tetrahydropyrimidine-4-
carboxylic acid 4-7i: 1H NMR (500 MHz, DMSO-d6) δ 7.63 (s, 1H), 7.10 (d, J 
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= 8.2 Hz, 1H), 7.02 (s, 1H), 6.58-6.55 (m, 2H), 5.75 (d, J = 4.4 Hz, 1H), 5.31 
(dd, J = 1.9, 4.4 Hz, 1H), 3.81 (s, 3H), 3.76 (d, J = 5.1 Hz, 3H); 13C NMR (125 
MHz, DMSO-d6) δ 163.0, 160.0, 156.3, 152.9, 127.5, 127.0, 123.4, 108.2, 
104.9, 98.5, 55.6, 55.3, 49.2; HRMS (EI): calcd for C13H14N2O5, 278.0903; 
found 279.0913. 
6-(furan-2-yl)-2-oxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid 4-
7j: 1H NMR (500 MHz, DMSO-d6) δ 7.85 (s, 1H), 7.62, (s, 1H), 7.34 (s, 1H), 
6.42-6.41 (m, 1H), 6.25 (d, J = 3.2 Hz, 1H), 5.75 (dd, J = 1.9, 3.2 Hz, 1H), 5.21 
(dd, J = 2.5, 5.1 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 162.8, 154.7, 
152.3, 142.8, 129.3, 110.5, 106.1, 105.5, 48.5; HRMS (EI): calcd for 
C9H8N2O4, 208.0484; found 208.0479. 
2-oxo-6-(thiophen-2-yl)-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid 
4-7k. 1H NMR (500 MHz, DMSO-d6) δ 7.89 (s, 1H), 7.49 (s, 1H), 7.47-7.46 
(m, 1H), 7.01-6.99 (m, 2H), 5.83-5.82 (m, 1H), 5.46 (dd, J = 2.5, 5.1 Hz, 1H); 
13C NMR (125 MHz, DMSO-d6) δ 162.9, 151.9, 148.0, 128.1, 127.0, 125.5, 
124.0, 108.2, 50.1; HRMS (EI): calcd for C9H8N2O3S, 224.0256; found 
224.0255. 
6-(naphthalen-2-yl)-2-oxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic 
acid 4-7l: 1H NMR (500 MHz, DMSO-d6) δ 7.91-7.90 (m, 3H), 7.80 (s, 1H), 
7.77 (s, 1H), 7.53-7.49 (m, 3H), 7.43 (s, 1H), 5.87 (d, J = 4.4 Hz, 1H), 5.35 (dd, 
J = 1.9, 4.4 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 163.0, 152.5, 141.1, 
132.9, 132.5, 128.6, 128.0, 127.8, 127.6, 126.4, 126.1, 124.7, 124.3, 108.6, 
55.0; HRMS (EI): calcd for C15H12N2O3, 268.0848; found 268.0838. 
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General Procedure for the Synthesis of 4-7m-4-7w. To a mixture of 
oxalacetic acid (2.6 mmol), aldehyde (2.0 mmol) and N-substituted 
urea/thiourea (2.6 mmol) in THF (3 mL) was added TFA (0.10 mL). The 
mixture was heated at 95 °C for 15 min using microwave irradiation in a sealed 
tube. Thereafter, the mixture was cooled and the solvent was removed under 
reduced pressure. 0.5 M NaOH (20 mL) was then added to the residue and the 
resulting solution was extracted with EtOAc (3 x 15 mL). Subsequently, the 
aqueous phase was acidified using conc. HCl and extracted with 10 % iPrOH 
in CH2Cl2 (3 x 15 mL). The combined organic extract was dried over MgSO4 
and concentrated under reduced pressure. The residue was washed with Et2O 
and dried under vacuum to afford the final product. 
3-methyl-6-phenyl-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic 
acid 4-7m: 1H NMR (500 MHz, DMSO-d6) δ 9.19 (s, 1H), 7.41-7.26 (m, 5H), 
6.22 (d, J = 5.7 Hz, 1H), 5.00 (dd, J = 3.2, 6.3 Hz, 1H), 3.39 (s, 3H); 13C NMR 
(125 MHz, DMSO-d6) δ 179.3, 163.5, 141.9, 131.9, 128.8, 127.8, 126.0, 115.5, 
52.6, 38.1; HRMS (EI): calcd for C12H12N2O2S, 248.0619; found 248.0622. 
6-(4-fluorophenyl)-3-methyl-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-
carboxylic acid 4-7n: 1H NMR (500 MHz, DMSO-d6) δ 9.21 (s, 1H), 7.32-
7.39 (m, 2H), 7.24-7.21 (m, 2H), 6.21 (d, J = 5.1 Hz, 1H), 5.02 (dd, J = 3.2, 5.7 
Hz, 1H), 3.39 (s, 3H); 13C NMR (125 MHz, DMSO-d6) δ 179.2, 163.5, 162.7, 
160.7, 138.1, 138.1, 132.1, 128.2, 128.2, 115.7, 115.5, 115.2, 51.9, 38.1; 
HRMS (EI): calcd for C12H11FN2O2S, 266.0525; found 266.0518. 
3-allyl-6-phenyl-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic 
acid 4-7o: 1H NMR (500 MHz, DMSO-d6) δ 8.85 (s, 1H), 6.97-6.94 (m, 2H), 
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6.88-6.62 (m, 3H), 5.78 (dd, J = 1.3, 5.7 Hz, 1H), 5.26-5.18 (m, 1H), 5.07-5.03 
(m, 1H), 4.62-4.60 (m, 2H), 4.54-4.50 (m, 1H), 4.19 (dd, J = 7.0, 16.5 Hz, 1H); 
13C NMR (125 MHz, DMSO-d6) δ 178.9, 163.5, 141.8, 133.8, 130.5, 128.7, 
127.8, 126.0, 117.3, 116.5, 52.6, 49.6; HRMS (EI): calcd for C14H14N2O2S, 
274.0776; found 274.0770. 
3-allyl-6-(3-chlorophenyl)-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-
carboxylic acid 4-7p: 1H NMR (500 MHz, DMSO-d6) δ 13.5 (br, 1H), 9.35 (s, 
1H), 7.46-7.24 (m, 4H), 6.26 (d, J = 5.1 Hz, 1H), 5.66 (dd, J = 5.0, 10.7 Hz, 
1H), 5.49 (d, J = 15.8 Hz, 1H), 5.08-5.06 (m, 2H), 4.96 (d, J = 17.0 Hz, 1H), 
4.64 (dd, J = 5.7, 15.8 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 179.1, 
163.5, 144.2, 133.7, 133.4, 131.1, 130.8, 127.7, 126.0, 124.6, 117.4, 115.8, 
52.0, 49.6; HRMS (EI): calcd for C14H13ClN2O2S, 308.0386; found 308.0372. 
3-allyl-6-(naphthalen-2-yl)-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-
carboxylic acid 4-7q: 1H NMR (500 MHz, DMSO-d6) δ 9.42 (s, 1H), 7.98-
7.87 (m, 3H), 7.74 (s, 1H), 7.54-7.47 (m, 3H), 6.33 (d, J = 5.1 Hz, 1H), 5.76-
5.68 (m, 1H), 5.52 (dd, J = 4.5, 15.8 Hz, 1H), 5.25-5.24 (m, 1H), 5.08-5.00 (m, 
2H), 4.71 (dd, J = 6.3, 15.8 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 179.0, 
163.6, 139.2, 133.8, 132.7, 132.4, 130.8, 128.7, 127.7, 127.6, 126.6, 126.3, 
124.6, 124.3, 117.5, 116.4, 52.9, 49.7; HRMS (EI): calcd for C18H16N2O2S, 
324.0932; found 324.0918. 
3-methyl-2-oxo-6-phenyl-1,2,3,6-tetrahydropyrimidine-4-carboxylic 
acid 4-7r: 1H NMR (500 MHz, DMSO-d6) δ 7.42 (s, 1H), 7.41-7.28 (m, 5H), 
5.89-5.88 (m, 1H), 5.05-5.04 (m, 1H), 3.07 (s, 3H); 13C NMR (125 MHz, 
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DMSO-d6) δ 163.9, 154.2, 143.2, 132.5, 128.7, 127.5, 126.0, 112.3, 53.2, 31.5; 
HRMS (EI): calcd for C12H12N2O3, 232.0848; found 232.0841. 
6-(4-fluorophenyl)-3-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine-4-
carboxylic acid 4-7s: 1H NMR (500 MHz, DMSO-d6) δ 7.44 (s, 1H), 7.35-
7.32 (m, 2H), 7.23-7.19 (m, 2H), 5.88 (d, J = 4.5 Hz, 1H), 5.07 (d, J = 3.2 Hz, 
1H), 3.07 (s, 3H); 13C NMR (125 MHz, DMSO-d6) δ 163.9, 162.5, 160.6, 
154.2, 139.5, 139.4, 132.7, 128.2, 128.1, 115.6, 115.4, 112.0, 52.5, 31.5; 
HRMS (EI): calcd for C12H11FN2O3, 250.0754; found 250.0746. 
6-(2,4-dimethoxyphenyl)-3-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine-
4-carboxylic acid 4-7t: 1H NMR (500 MHz, DMSO-d6) δ 7.10 (s, 1H), 7.06 (d, 
J = 8.2 Hz, 1H), 6.58-6.55 (m, 2H), 5.84 (d, J = 4.4 Hz, 1H), 5.16 (d, J = 3.2 
Hz, 1H), 3.80 (s, 3H), 3.76 (s, 3H), 3.05 (s, 3H); 13C NMR (125 MHz, DMSO-
d6) δ 164.0, 160.1, 156.6, 154.9, 132.5, 126.9, 122.9, 111.9, 104.8, 98.6, 55.6, 
55.3, 48.2, 31.6; HRMS (EI): calcd for C14H16N2O5, 292.1059; found 292.1071. 
3-allyl-2-oxo-6-phenyl-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid 
4-7u: 1H NMR (500 MHz, DMSO-d6) δ 13.2 (s, 1H), 7.52 (s, 1H), 7.41-7.38 
(m, 2H), 7.31-7.28 (m, 3H), 5.91 (d, J = 4.4 Hz, 1H), 5.77-5.69 (m, 1H), 5.10 
(d, J = 5.0 Hz, 1H), 5.06-4.98 (m, 2H), 4.58 (dd, J = 3.8, 16.4 Hz, 1H), 4.33 
(dd, J = 6.3, 16.4 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 163.9, 153.7, 
143.1, 135.2, 131.4, 128.7, 127.6, 126.0, 116.3, 113.2, 53.3, 43.8; HRMS (EI): 
calcd for C14H14N2O3, 258.1004; found 258.0996. 
3-allyl-6-(3,5-dibromophenyl)-2-oxo-1,2,3,6-tetrahydropyrimidine-4-
carboxylic acid 4-7v: 1H NMR (500 MHz, DMSO-d6) δ 13.3 (s, 1H), 7.77 (s, 
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1H), 7.62 (s, 1H), 7.50 (s, 2H), 5.96-5.95 (m, 1H), 5.73-5.67 (m, 1H), 5.14-
5.13 (m, 1H), 5.07-4.96 (m, 2H), 4.56 (dd, J = 2.5, 16.4 Hz, 1H), 4.31 (dd, J = 
5.7, 16.4 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 163.7, 153.5, 147.5, 
134.9, 132.5, 132.3, 128.1, 122.8, 116.4, 111.8, 52.1, 43.8; HRMS (EI): calcd 
for C14H12Br2N2O3, 413.9215; found 413.9201. 
3-allyl-6-(naphthalen-2-yl)-2-oxo-1,2,3,6-tetrahydropyrimidine-4-
carboxylic acid 4-7w: 1H NMR (500 MHz, DMSO-d6) δ 7.96-7.89 (m, 3H), 
7.78 (s, 1H), 7.65 (s, 1H), 7.53-7.50 (m, 3H), 6.00 (dd, J = 1.3, 5.1 Hz, 1H), 
5.82-5.74 (m, 1H), 5.30 (dd, J = 1.9, 5.0 Hz, 1H), 5.08-5.03 (m, 2H), 4.64-4.60 
(m, 1H), 4.39 (dd, J = 5.7, 16.4 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 
163.9, 153.7, 140.5, 135.2, 132.9, 132.5, 131.6, 128.6, 127.8, 127.6, 126.5, 
126.1, 124.5, 124.3, 116.3, 113.0, 53.5, 43.9; HRMS (EI): calcd for 
C18H16N2O3, 308.1161; found 308.1154. 
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X-ray crystal data of 4-7w 
Identification code  yl217 
Empirical formula  C39 H38 N4 O7 
Formula weight  674.73 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 10.7733(11) Å            = 90°. 
 b = 21.947(2) Å                = 110.448(2)°. 
 c = 15.1328(16) Å             = 90°. 
Volume 3352.6(6) Å3 
Z 4 
Density (calculated) 1.337 Mg/m3 
Absorption coefficient 0.093 mm-1 
F(000) 1424 
Crystal size 0.24 x 0.16 x 0.08 mm3 
Theta range for data collection 2.22 to 27.50°. 
Index ranges -6<=h<=13, -28<=k<=28, -19<=l<=19 
Reflections collected 23436 
Independent reflections 7675 [R(int) = 0.0739] 
Completeness to theta = 27.50° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9926 and 0.9781 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7675 / 0 / 463 
Goodness-of-fit on F2 1.010 
Final R indices [I>2sigma(I)] R1 = 0.0631, wR2 = 0.1392 
R indices (all data) R1 = 0.1267, wR2 = 0.1623 
Largest diff. peak and hole 0.566 and -0.265 e.Å-3 
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